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SUMMARY 
The primary aim of this thesis was to develop an experimental model, as close 
to real life as possible, to simulate circadian rhythm disturbances associated with jet 
lag and shift work. This would then serve to investigate treatment strategies using 
exogenous melatonin and bright light. A second aim was to study potential 
mechanisms through which melatonin exerts its effects. However, before developing 
such models and treatment strategies, it was important to validate a circadian rhythm 
marker which gave a reliable assessment of the behaviour of the endogenous body 
clock. 
Many hormones and other blood constituents have been shown to be 
influenced by posture through the influence of gravity. Melatonin in plasma and 
saliva was found to be concentrated by moving from a supine to a standing position, 
and diluted after an opposite change in posture. 
The endogenous body temperature rhythm is more susceptible to masking 
influences than melatonin. A purification method was employed to reduce masking 
effects on the temperature rhythm after a simulated time-zone transition (in 
collaboration with Drs. Waterhouse and Minors, University of Manchester, UK). 
Masking led to overestimates in the rate of adaptation of the body temperature 
rhythm. Such methods may provide a more accurate estimation of the behaviour of 
the endogenous clock in a normal environment. 
A number of non-invasive techniques are employed to measure the melatonin 
rhythm in saliva, and its metabolite, 6-sulphatoxymelatonin (aMT6s), in urine. These 
various methods have not all been compared under phase-shifted conditions. Close 
relationships between the calculated peak times of melatonin in plasma and saliva and 
of aMT6s in urine, together with the plasma melatonin onset time were established. 
In a partially controlled environment, appropriately timed bright light (- 1200 
lux) and darkness (< 1 lux) in combination with a shift in the sleep/wake cycle 
facilitated the adaptation of the endogenous clock and behavioural functions to a 
gradual 9h advance and delay phase-shift in external time cues within 3-5 days. 
Subjects then resumed their baseline sleep/wake schedule in a normal environment, 
thus experiencing a rapid 9h advance or delay phase-shift of local time cues. 
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Adaptation of circadian rhythms and behavioural functions took longer to adapt to 
advance phase-shifts than to delay shifts, underlining the preferred direction of 
reentrainment of the biological clock. 
The administration of melatonin (5mg) near bedtime for 3 days after a rapid 
9h advance phase-shift significantly improved sleep, alertness and performance 
efficiency, even in the presence of bright light (2000 lux) timed to counteract the 
phase-shifting effects of melatonin. Improvements using melatonin treatment were 
observed within one day and before significant adaptation of the biological clock 
occurred. 
In addition to a phase-shifting effect on the endogenous biological clock, 
melatonin can induce acute temperature suppression and sleepiness. A significant 
relationship was determined between melatonin-induced temperature suppression and 
the subsequent phase-shift in the biological clock after administration of 5mg at 
1700h. This relationship was further found to be dose-related, suggesting that acute 
changes in body temperature by melatonin may be a primary event in phase-shifting 
mechanisms. Significant sleepiness was only associated with pharmacological plasma 
melatonin levels. With pharmacological doses, melatonin may exert its beneficial 
effects on circadian rhythm disturbances through a combination of transient sedation, 
temperature suppression and phase-shifting mechanisms. 
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CHAý. ''rER 1 
INTRODUCTION 
1.1 CONSEQUENCES OF BIOLOGICAL RHYTHMICITY 
Most organisms are able to predict and adapt to changes in the environment, 
phenomena that are essential to their survival and well-being in an ever changing and 
often unfriendly environment. From the unicellular flagellate to the higher vertebrate 
this anticipation and response to timed events in the environment is important in 
preparing the organism for a variety of events such as waking and activity throughout 
the day, `winding down' in preparation for sleep at night, reproductive function and 
hibernation at certain times of year. 
These preparations are brought about by various rhythms in physiological and 
behavioural functions. The phase (time) relationship between various rhythms and 
the environment needs to be coordinated so that the correct biological response occurs 
at the right time of day or year. For example, for animals that breed only once a 
year, it is vitally important that heightened reproductive function coincides in both 
males and females so that the offspring may be born at the optimum time of year for 
survival. 
In the absence of all environmental influences, many biological rhythms still 
persist but `free-run' with slightly different periodicities. It is because of this 
endogenous nature of biological rhythms that organisms are considered to have an 
internal rhythm-generating system or a biological clock. Possession of an inherent 
body clock allows the measurement of environmental time so that the body can 
predict regular external changes instead of just reacting to them, allowing an optimum 
response. The most prominent endogenous rhythms are those related to the daily 24 
hour light-dark cycle. In humans, the endogenous biological timing system free-runs 
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with a period of close to 25 hours, hence the term "circadian", from the latin circa - 
about and dies - day (Aschoff, 1965; Wever, 1979,1983,1986; Lewy and 
Newsome, 1983; Kennaway and Van Dorp, 1991). A 25h internal clock is obviously 
an inaccurate forecaster of daily (24h) changes in the environment. Hence, stable 
synchronization of the endogenous biological clock to the environment depends on 
external synchronising factors or time cues, such as temperature, humidity, social 
cues and the light/dark cycle. Many of these rhythms are entrained to 24 hours 
mainly by the daily light/dark cycles. This ability of the circadian system to be 
influenced by external zeitgebers also allows the body to adapt to changes or phase- 
shifts in environmental time. 
Human beings are unique in that they consciously and repeatedly alter their 
daily schedules to suit their own particular lifestyles, overriding the natural 
mechanisms which influence the rhythmicity of the circadian timing system. The 
natural tendency to fall asleep at times of great propensity, which so many organisms 
are powerless against, can be stalled until either the urge to sleep becomes 
overwhelming and sleep becomes inevitable, or the disruption of the sleep pattern 
becomes permanent through continual change and the individual may begin to suffer 
from a sleep disorder. This conscious decision to change the timing of retiring to bed 
and waking up is invaluable to many individuals especially in the modern world 
where they may have to work night shifts or fly to a new time zone. However, there 
is a price to pay. 
Abrupt shifts in local time cues or zeitgebers can result in various rhythmic 
functions becoming out of phase with each other and the external environment. The 
natural tendency of the internal body clock to adapt to such changes is gradual and 
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slow. It may take days or even weeks for some circadian rhythms to resynchronize 
to a large phase-shift. As a consequence, the predictive ability of the body clock 
becomes transiently affected with deleterious effects on human physiology and 
behaviour. For example, humans can become sluggish, cold and sleepy during 
waking hours when starting on a new night shift because the circadian timing system 
has prepared the body for rest and sleep. Subsequent decrements in performance and 
alertness can increase the risk of accidents or errors which may reduce productivity 
and safety. Since shift workers include air-traffic controllers, nuclear submarine and 
power plant operators, emergency doctors and intensive care nurses, it is important 
to understand circadian rhythms in the work place not just from an ergonomic point 
of view but also a safety one. In addition, disturbances in the circadian system have 
been identified in a number of disorders. Treatment strategies to facilitate the 
adaptation or resetting of biological rhythms are therefore of enormous value. 
Light (and darkness) together with the hormone melatonin are closely involved 
with the circadian timing system and have been proposed as potential treatments for 
circadian rhythm disorders. 
This chapter will review current knowledge on the structure, organisation and 
regulation of the circadian timing system, with particular emphasis on the melatonin 
circadian rhythm, and its influences on human physiology and behaviour. 
Disturbances in this pacemaker system will then be discussed, with a review of 
potential treatment strategies concentrating on the use of light and melatonin. There 
are a number of other more immediate effects of light and melatonin on human 
physiology and behaviour, which may or may not be related to their ability to 
influence the circadian timing system, which will also be discussed. Finally, the 
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melatonin secretory rhythm is used as a circadian rhythm marker of the internal 
biological clock and exogenous factors affecting this rhythm will be described. 
1.2 CONTROL OF BIOLOGICAL RHYTHMS 
There is accumulating evidence for a multioscillatory structure of the circadian 
system in rodents and humans coupled through the suprachiasmatic nuclei of the 
hypothalamus (SCN). In everyday conditions all circadian rhythms such as the 
sleep/wake cycle, body temperature and melatonin are synchronized or entrained with 
each other and environmental time. In conditions free from environmental time cues 
and where the sleep/wake cycle is altered, the temperature and sleep/wake rhythms 
may dissociate from one another with different free-running periods of approximately 
24.5h and 33h, respectively (Aschoff, 1965; Wever, 1979). Other physiological 
rhythms can assume a periodicity associated with either the temperature or sleep/wake 
rhythm (Moore-Ede et al, 1983). 
Evidence for the involvement of two subsidiary oscillators controlling the 
circadian timing system has been used by Pittendrigh and Daan (1976) and Illnerovä 
and Vanecek (1982), to describe the response of animals to photoperiodic changes in 
the environments. One oscillator, the morning or "dawn" oscillator is thought to 
regulate the transition between night and day and control the offset of melatonin 
secretion. The other oscillator, the evening or "dusk" oscillator, may trigger the 
onset of melatonin secretion by controlling the transition between day and night, see 
section 1.3.3. In humans there is, however, an indication of a third pacemaker which 
drives endogenous memory performance rhythms with an inherent period of 21 hours 
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(Folkard et al, 1983), thus underlining the complex nature of the system. However, 
the available evidence at present indicates that all circadian rhythms, with the 
exception of visual sensitivity (Terman and Terman, 1985) and activity anticipatory 
to feeding (Krieger et al, 1977; Stephan et al, 1979; Boulos et al, 1980; Clarke and 
Coleman, 1986), are abolished by SCN lesions. 
1.2.1 Location of the body clock 
The SCN, located at the base of the hypothalamus in close proximity to the 
optic chiasm, are thus thought to be the site of the major circadian pacemaker. 
Surgical isolation of SCN cells from other parts of the brain leaves a persistent 
circadian rhythm of neural activity in the SCN which is no longer found in other parts 
of the brain (Inouye and Kawamura, 1979). In vitro, SCN cells generate a 24 hour 
rhythm in neural activity (Green and Gillette, 1982; Groos and Hendriks, 1982). 
Taken together, these studies indicate that if there are no biochemical, neural or 
thermal effects influencing the isolated SCN, then the SCN must have a self-contained 
oscillator (at least in rodents). 
Neural transplantation procedures have provided further support that the 
circadian timing system originates from within the SCN. Circadian rhythmicity 
reappears after foetal SCN tissue is transplanted into rodents with their SCN 
destroyed (Lehman et al, 1987; Sawaki et al, 1984; Drucker-Colin et al, 1984). In 
addition, transplanting SCN tissue from hamster mutants with an endogenous 
circadian period of 20 or 22 hours (instead of the typical 24 hours), into hamsters 
whose own 24 hour clock has been destroyed, will restore rhythmicity that reflects 
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the donor's circadian period (Ralph et al, 1990). 
1.2.2 Neural Projections between the SCN and the eye 
The SCN receive time of day information from the light-dark cycle through 
monosynaptic optical pathways from the retina mainly via the retinohypothalamic tract 
(RHT), but also from the intergeniculate leaflet (IGL) of the lateral geniculate body 
(the geniculohypothalamic tract) (Moore, 1973; Pickard et al, 1987). If these 
connections are destroyed the circadian rhythms lose their entrainment and free-run 
(Rusak, 1977). Potential neurotransmitters thought to be involved in conveying 
light/dark signals via the RHT include glutamate and possibly acetylcholine (Earnest 
and Turek, 1985; Keefe et al, 1987; Meijer et al, 1988). Connections from the IGL 
to SCN consist of mainly gamma-aminobutyric acid fibres and projections which 
contain the neurotransmitter neuropeptide Y (Moore and Speh, 1993). Other 
neurotransmitters such as 5-hydroxytryptamine (5-HT), vasoactive intestinal peptide 
and vasopressin have also been suggested as mediators of photic information 
(Reghunandanan et al, 1993). 
1.2.3 The Pineal Gland 
The end organ of this visual system of photoperiodic time measurement is the 
pineal gland which releases the hormone melatonin (N-acetyl-5-methoxytryptamine), 
during darkness in an entrained individual (Wurtman et al, 1963). There are other 
secretory products of the pineal gland which include other indoles and peptides which 
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Figure 1.1 Schematic Representation of the Neural 
Pathway between Light Perception in the Eye and the 
Pineal Gland. 
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may have biological activity (Pevet, 1983a, 1983b), but their significance is as yet 
unclear. 
1.2.4 Neural projections from the SCN to the pineal gland 
The neural connections which link the SCN to the pineal gland was first 
demonstrated by Berk and Finklestein (1981) and Stephan et al (1981) who identified 
projections from the SCN to the paraventricular nucleus of the hypothalamus (PVN) 
with further projections leading into the sympathetic chain of the spinal cord and 
synapsing in the superior cervical ganglion (SCG), Figure 1.1. Post-ganglionic 
sympathetic nerves from the SCG release noradrenaline (NA) which acts through 
adrenergic receptors on the pineal gland cell (pinealocyte) membrane to stimulate the 
production melatonin. Destruction and stimulation of this pathway has confirmed its 
neural role in melatonin production (Klein et al, 1983; Yanovski et al, 1987). 
1.2.5 Cellular mechanisms of melatonin synthesis 
During the day, light stimulates the activity of the SCN which ultimately 
inhibits the release of noradrenaline (NA) from sympathetic neurons in the pineal 
gland. However, at night this inhibitory influence ceases and NA is released (Wolfe 
et al, 1962; Brownstein and Axelrod, 1974) and interacts with specific adrenergic 
receptors on the pinealocytes to stimulate the production of melatonin, Figure 1.2 
(Parfitt et al, 1976). 
On interaction with the 81-adrenergic receptor, adenylate cyclase is stimulated 
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Figure 1.2 Schematic diagram showing neural pathway from 
light/darkness input to melatonin secretion 
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via a guanine nucleotide-binding regulatory protein, resulting in an increase in the 
intracellular second messenger cyclic 3', 5'-adenosine monophosphate (CAMP, 
Axelrod and Zatz, 1977). Elevated levels of cAMP stimulate the production of N- 
acetyltransferase (NAT) which is usually the rate limiting step in the production of 
melatonin (Klein et at, 1970). There is also activation of an a, -adrenergic receptor 
by NA which increases intracellular Cat+, stimulating protein kinase C. This in turn 
amplifies the activation of cAMP and so augments the production of NAT (Sugden 
et at, 1985a, 1985b; Sugden et at, 1987; Vanacek et at, 1985) through a mechanism 
involving gene transcription and translation. A third adrenergic receptor (a2) has 
been identified recently in the mammalian pineal gland but its involvement is 
uncertain (Simonneaux et at, 1991; Schaad and Klein, 1992). 
Recently, rhythmic circadian control of gene expression has been demonstrated 
in the pineal gland. Stehle et at (1993) have identified a potent regulator of cAMP- 
induced gene transcription known as ICER (inducible cAMP early repressor) which 
shows high levels during the night and low levels in the day. It is suggested that 
ICER may regulate NAT activity by repressing NAT gene expression (Takahashi, 
1993). 
1.2.6 Synthesis of melatonin 
Melatonin is synthesized primarily in the pineal gland although synthesis also 
occurs in the retina (Pang et al, 1977; Vakkuri et al, 1987), the Harderian gland 
(Pang et al, 1977; Menendez-Pelaez et al, 1987) and the gut (Raikhlin et al, 1975; 
Huether et al, 1992; Yaga et al, 1993). However, in mammals the amount of 
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melatonin produced from these non-pineal sources is considered to be small and 
probably used locally since in most studies removal or destruction of the pineal results 
in plasma levels or levels of its metabolite in urine which are undetectable by 
radioimmunoassay (Arendt et at, 1980; Lincoln et at, 1981; Bittman et at, 1983a, b) 
or gas chromatography - mass spectrometry (Markey and Buell, 1982; Tetsuo et at, 
1982; Neuwelt and Lewy, 1983). 
Melatonin is synthesized from its precursor 5-HT which is formed by 
hydroxylation and decarboxylation of the amino acid, tryptophan (Axelrod, 1974), 
Figure 1.3. The rise in NAT activity during the night through sympathetic 
innervation from the SCN then converts serotonin to N-acetylserotonin (NAS, 
Weissbach et at, 1961); NAT catalyses the rate limiting step in the production of 
melatonin (Klein and Weller, 1970; Klein, 1979). Elevated levels of a second 
enzyme, hydroxy-O-methyltransferase (HIOMT), during the night catalyses the 
conversion of NAS to melatonin (Axelrod and Weissbach, 1960). 
Practically every aspect of melatonin's synthesis and release is rhythmic 
(Klein, 1979), even regulation of gene expression of the rate limiting enzyme (Stehle 
et at, 1993). 
1.2.7 Other control mechanisms of melatonin synthesis 
A number of receptor sites have been identified on the pineal gland for 
glutamate, gamma-amino-n-butyric acid (GABA), 5-HT, benzodiazepines, dopamine, 
steroid hormones and prostaglandins but their function remains unknown (Cardinali 
and Vacas, 1978; Cardinali and Ritta, 1983; Ebadi and Govitrapong, 1986). In vivo, 
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Figure 1.3 Synthesis of Melatonin 
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the hormonal modulation of melatonin synthesis appears to have a negligible effect 
(Champney et al, 1985,1986). 
1.2.8 Melatonin secretion 
The melatonin profile in peripheral blood is a good reflection of pineal 
melatonin synthesis at almost the same time (Wilkinson et al, 1977; Illnerovä et al, 
1978), since the pineal gland releases the indole directly and primarily into the blood 
stream rather than the cerebral spinal fluid, with minimal storage (Rollag et al, 1978; 
Pang, 1985). Highly lipophilic in nature, melatonin is readily diffusible and rapidly 
distributed throughout all tissues (Kopin et al, 1961). 
The secretory rhythm of melatonin is characterised by an onset of secretion 
in humans around 2100-2200h, rising to a peak around 0200-0300h and falling to 
daytime levels around 0800-0900h in the morning. The melatonin secretory rhythm 
is a strongly inherent rhythm, persisting in the absence of all environmental time cues 
with endogenous periodicity of close to 25h (Lewy and Newsome, 1983; Arendt et 
al, 1985a; Wever, 1986; Kennaway and Van Dorp, 1991). The timing of the free- 
running rhythm is very precise and the start of its production can sometimes be 
predicted in advance with an accuracy of within 30 minutes (Lewy and Newsome, 
1983). The shape, period and amplitude of the plasma melatonin circadian rhythm 
is highly reproducible in healthy individuals entrained to 24h (Broadway et al, 1987), 
and may therefore provide a reliable indication of the behaviour of the internal 
biological clock. 
A measurable melatonin rhythm may not however be essential for the well- 
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being of an individual. Some people exhibit very low levels of melatonin (< 10 
pg/ml) in the plasma without any apparent detrimental effects on the circadian system 
or health (Arendt et al, 1985). Since probable melatonin receptors have been 
identified in the human hypothalamus pineal melatonin may act locally in much lower 
concentrations in these individuals. 
1.2.9 Melatonin metabolism 
In humans, the metabolism of melatonin occurs predominantly in the liver to 
form 6-hydroxymelatonin and N-acetylserotonin, which are then excreted in the urine 
as conjugates of the glucuronide or sulphate (Jones et al, 1969; Young et al, 1985), 
Figure 1.4. Vakkuri et al (1987) identified a further metabolite, a cyclic isomer of 
2-hydroxymelatonin, which accounted for 5% of the total urinary melatonin 
metabolites after ingestion of 100mg exogenous melatonin. In rabbits, a different 
pathway exists in the central nervous system whereby cleavage of the indole ring 
results in the formation of kynuranamines (Hirata et al, 1974). 
The end products of melatonin metabolism found in urine provide a means of 
measuring a related substance which reflects melatonin output from the pineal in a 
non-invasive and practical way. aMT6s is a good index of plasma melatonin 
secretion in both timing and amplitude (Bojkowski et al, 1987b). 
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Figure 1.4 Major Melatonin Metabolism Pathways in the Liver 
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1.2.10 Target sites and potential circadian effects of melatonin action 
The SCN has been proposed as a site for the actions of melatonin to feedback 
onto the pacemaker and regulate the circadian timing system (e. g. Cassone, 1991). 
In mammals, high affinity melatonin binding sites have been characterised most 
frequently in the SCN of the hypothalamus, the pars tuberalis of the pituitary gland 
and the retina (Dubocovich, 1988; Carlson et al, 1989; Duncan et al, 1989; Morgan 
et al, 1989; Weaver et al, 1989; Cassone, 1991). Human adult and foetal SCN tissue 
are also reported to contain such putative melatonin receptors (Reppert et al, 1988; 
Weaver et al, 1993). The high affinity melatonin binding site is associated with at 
least one signal transduction mechanism involving regulatory G-proteins and therefore 
provides a functional role for this binding site (Carlson et al, 1989; Morgan et al, 
1989a, b; Rivkees et al, 1989; Laitinen and Saavedra, 1990; Stankov et al, 1992). 
High affinity, specific melatonin binding sites comparable to those found in the 
chicken retina have been proposed as ML-1 type receptors (Dubocovich, 1988). 
There are lower affinity sites which are pharmacologically distinct from the ML-1 
type receptor and Dubocovich (1988) has proposed that these sites may be referred 
to as ML-2 sites. However, there is no evidence of separate physiological roles for 
these sites as yet. A daily rhythm for high affinity melatonin receptors in the SCN 
has also been described (Laitinen et al, 1989). 
A possible feedback response of melatonin on the biological clock can be seen 
in vitro. McArthur et al (1991) and later Mason et al (1993) demonstrated that 
exogenous melatonin acts directly within the SCN to phase-shift the circadian 
rhythmicity of neural activity. This feedback system on the SCN may allow 
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melatonin to modulate the phase relationship between the circadian system and the 
environmental light/dark cycle which can alter the duration (and timing) of the 
melatonin signal on a daily basis (see section 1.3). There are also efferent neural 
connections from the SCN into other areas of the brain which provide a means by 
which melatonin can indirectly influence behavioural and physiological functions 
(Watts, 1991). The densest projections from the SCN lead into the adjacent 
paraventricular nucleus (PVN) with a smaller projection to the lateral septal nucleus 
(LSN, Watts et at, 1987). The PVN efferents connect the hippocampus, amygdala 
and nucleus accumbens with the LSN projecting to the hypothalamus. These in turn 
may influence the activity of the medial forebrain bundle which is crucial for many 
aspects of behaviour such as arousal and feeding (Swanson, 1987). 
Exogenous melatonin will entrain the free-running activity rhythms of rats 
(Redman et at, 1983; Cassone et at, 1986). Suitably timed melatonin administration 
to rats after a large shift in the light dark cycle can alter the rate and direction of 
reentrainment of both the activity rhythms and N-acetyltranferase activity (Armstrong 
and Redman, 1985; Redman and Armstrong, 1988; Illnerovä et at, 1989). 
Strong evidence for melatonin's role in reproduction comes from seasonal 
breeders. The duration of the melatonin secretory rhythm provides a direct reflection 
of the length of night in photoperiodic animals (Arendt, 1986), and is able to transmit 
this photoperiodic information to seasonal breeders to time reproductive behaviour 
and function (Tamarkin et at, 1985). Infusion of physiological levels of melatonin 
in animals timed to mimic the secretion pattern in different seasons is able to induce 
the appropriate endocrinological and behavioural response (Bartness et at, 1993). 
However, anatomical evidence demonstrating a relationship between the SCN and the 
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neuroendocrine parts of the hypothalamus is limited. 
There do not seem to be any direct connections from the SCN to the median 
eminence where gonadotrophin-releasing hormone is released to influence the 
secretion of luteinizing hormone from the pituitary gland. However, since high 
affinity melatonin binding sites have been found in the pituitary gland (Morgan and 
Williams, 1989) and projections from some parts of the PVN lead into the preoptic 
area of the hypothalamus where nuclei are closely associated with numerous 
neuroendocrine functions, there is potential for melatonin to influence many aspects 
of neuroendocrinology through indirect and direct mechanisms (see Watts, 1991 for 
review). 
Many structures within the preoptic region of the hypothalamus are intimately 
involved in many aspects of circadian hypothalamic functions such as fluid balance, 
sleep and thermoregulation (Swanson, 1987) and minor projections do lead into this 
area from the SCN (Berk and Finklestein, 1981; Stephan et al, 1981). There are 
however, major pathways which indirectly connect the two sites. For example, the 
primary nucleus for body temperature regulation is the medial preoptic area of the 
hypothalamus (Hellon, 1972; Hensel, 1973; Satinoff, 1978) which is directly 
connected to an area just ventral to the PVN known as the subparaventricular zone 
(sPVHz). This site in turn is directly supplied by dense projections from the SCN 
(Watts et al, 1987). Thus morphological studies support the broad spectrum of SCN- 
dependent effects. 
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1.2.11 Summary - potential physiological Roles for Melatonin 
The presence of high affinity melatonin receptors within the SCN and the 
ability of exogenous melatonin to alter the circadian rhythms of SCN neural activity 
and rodent behaviour, suggest that pineal melatonin plays some role in the circadian 
organisation in mammals. 
Melatonin has a rapid and widespread distribution from the circulatory system 
into all body tissues and fluids indicating that it may have a wide ranging modulatory 
role over a number of different mechanisms within the body. Melatonin easily passes 
through cellular membranes and into the nucleus (Joss, 1981; Menendez-Pelaez and 
Reiter, 1993). The possibility that melatonin could modify the function of many 
tissues and organs even at the nuclear level is therefore reasonable. Recent evidence 
that melatonin is highly effective in neutralising the destructive activity of free- 
radicals (oxidizing agents) suggests a role which does not require a membrane bound 
receptor (Poeggeler et al, 1993; Reiter et al, 1993; Tan et al, 1993). 
In addition, it has been shown that melatonin can modulate the response of the 
immune system in some conditions (Blask et al, 1993; Maestroni, 1993). Circadian 
rhythmicity occurs in number of immune mechanisms (Fernandes et al, 1976,1979; 
Abo et at, 1981; Kawate et al, 1981) and to some extent tumour growth in 
experimental animals can be influenced by photoperiod and melatonin administration 
at different times of day (Bartsch and Bartsch, 1981; Stanberry et al, 1983). Thus 
the pineal gland through its rhythmic circadian release of melatonin can influence the 
immune system and possibly malignant disease (Blask, 1984). 
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1.3 FACTORS AFFECTING MELATONIN SECRETION 
Melatonin is considered to be a reliable circadian rhythm marker and is used 
as such in various physiological and pathological studies. Changes in melatonin 
secretion may indicate a role for melatonin and the circadian timing system. It is 
however, important to exclude disturbing (masking) influences unrelated to the object 
of the study. 
1.3.1 Light suppression of melatonin secretion in humans 
Although the melatonin rhythm is remarkably stable in healthy humans, one 
environmental factor known to greatly influence its production, via suppression, is the 
light/dark cycle. Whether this suppressant effect is related to the phase-shifting or 
entraining property of light is a matter of great interest. 
1.3.1.1 Intensity of light exposure 
Acute exposure to light at night shuts down the synthesis of melatonin rapidly. 
The degree of suppression of nighttime melatonin depends upon the brightness of the 
light. In humans, Lewy et al (1980) originally found suppression of melatonin 
secretion in response to light of 1500 and 2500 lux. Light of 500 lux initially showed 
no suppression although in a later study by Lewy et al (1985) some melatonin 
suppression was found with 500 lux. Further studies have shown that the melatonin 
synthesis is affected by lower intensities of light. Bojkowski et al (1987a) reported 
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partial but significant suppression at 300 lux (30 minutes at 0030h) and McIntyre et 
al (1989a) indicated some suppression with 200 lux (lh at midnight). In all cases 
melatonin levels returned to normal values within 60 minutes after cessation of 
treatment. Waking, and maintaining subjects awake in <1 lux has no effect on 
plasma melatonin levels (Lewy et al, 1980; Bojkowski et al, 1987a). The threshold 
intensity of full spectrum light needed to suppress human melatonin levels has yet to 
be determined but may reveal effective suppression at even lower levels. Using 
monochromatic (green) light, Brainard et al (1988), have observed melatonin 
suppression as low as 5.5 lux in some individuals. Pupil dilation may also be 
important in determining the degree of illuminance falling on the retina and the level 
of light-induced melatonin suppression (Gaddy et al, 1993). Some individuals with 
manic-depressive illness have been found to be supersensitive to light and it has been 
suggested that this may provide an appropriate marker for manic-depressive-illness 
(Lewy et al, 1985). 
1.3.1.2 Timing of Light Exposure 
The response of the pineal gland to light, at least in rats, may be dependent 
on the timing of the light treatment, where NAT activity does not recover to the same 
extent after treatment in the latter half of the night as in the first half (Illnerovä and 
Vanecek, 1984). In man, variations in the ability to detect low light intensities have 
been found over the course of the night suggesting that light-induced suppression of 
melatonin secretion may alter with time (Terman and Terman, 1985; Bassi and 
Powers, 1986). This has been confirmed by Owen and Arendt (1992), who 
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demonstrated in humans living in Antarctica, that suppression by both dim light (m 
300 lux) and bright light (-2200 lux) was more effective in the second half of the 
night and was dependent upon the season (suppression less effective in summer). 
However, in contrast, McIntyre et al (1989b) could find no time-dependent 
differences in the ability of light to suppress melatonin production using 1000 and 
3000 lux. In addition, they and others (Bojkowski et al, 1987a; Lewy et al, 1980) 
found no rebound effect in melatonin levels after light exposure during the early dark 
phase (around the melatonin secretion onset time) unlike Beck-Friis et al (1985) using 
2500 lux treatment. 
1.3.1.3 Duration of light exposure 
A short duration (15 minutes) light pulse of 1500 lux at either 2200h or 2300h 
or even a5 minute pulse of 2500 lux at 0200h can reduce nocturnal melatonin levels 
(Byerley et al, 1989; Petterborg et al, 1991a). All-night exposure to bright light 
(3000 lux) can completely abolish the nighttime melatonin profile (Strassman et al, 
1987), suggesting that this model could be used for studies needing "functional 
pinealectomy" in humans. 
1.3.1.4 Wavelength of light exposure 
The environment in which humans live consists almost exclusively of broad 
spectrum light whether it is natural light or artificial fluorescent and incandescent 
light. In mammals, including humans, the blue/green wavelength of the light 
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spectrum seems to be maximally effective at suppressing melatonin synthesis 
(Brainard et al, 1984,1985). The visual system in humans is most sensitive to green 
light (Riggs, 1965), however, there may be a change in sensitivity to lower 
wavelengths of light during the course of the night (Honma et al, 1992). 
Unfortunately, most of these studies differ in the timing, intensity and duration 
of their light exposure. Further experiments are required to see whether humans have 
the same inverse relationship between intensity and duration as has been found for rat 
NAT suppression (Vanecek and Illnerovä, 1982). In rats, a short pulse of bright light 
has a similar suppressant effect on NAT activity as dim light of longer duration 
(Vanecek and Illnerovä, 1982). Previous lighting history may also prove to be 
important in the response of melatonin suppression in terms of sensitivity to light. 
Many of these studies were conducted under different latitudes with different 
photoperiodic environments of varying natural illuminance. Lynch et al (1981) 
demonstrated that rats on alternating artificial bright light/dim light cycles respond as 
if dim light was natural darkness, and rats on alternating cycles of dim light and 
darkness recognise dim light as natural light. In addition, laboratory-raised and wild- 
captured ground squirrels, exposed to different intensities of light, responded 
differently to light exposure at night (Reiter et al, 1983). 
In summary, the suppressive effects of light on melatonin secretion are 
complex depending on the intensity, timing, duration and wavelength of the light 
treatment together with the photoperiodic history and sensitivity of the individual. 
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1.3.2 Non-visible radiation 
Bright full spectrum light is not the only type of radiation known to affect 
melatonin production. Non-visible radiation in the region of the electromagnetic 
spectrum is reported to influence the production of melatonin (Reiter, 1992a). In 
rats, low frequency (50-60 Hz) or static magnetic field exposure can suppress 
melatonin levels at night (Olcese et al, 1988; Lerchl et al 1991). The pathway 
through which the pineal gland perceives this magnetic information is suggested to 
be via the retina in much the same way as light is recognised, although the exact 
mechanism remains unclear and the function unknown (Olcese et al 1985,1990; Kato 
et al, 1994). 
1.3.3 Changing Daylength (Photoperiod) 
The circadian pacemaker via melatonin secretion provides information to the 
body about the length of day which changes with the time of year. This information 
is used in many species to control seasonal rhythms in physiology and behaviour, 
such as reproductive function and coat growth (Pittendrigh and Daan, 1976). 
In all non-human mammalian species studied, the duration of nocturnal 
melatonin secretion and NAT activity is extended under a shorter "winter" day 
(longer night) and reduced under a longer "summer" day (shorter night), (Review: 
Illnerovä, 1988). It is not known how the body interprets the melatonin signal 
providing information about environmental time and signalling the appropriate 
endocrine and behavioural adjustments to be made. It may be the timing at which the 
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light and/or darkness phases hit the melatonin rhythm or the timing between the 
melatonin rhythm and a rhythm of sensitivity of the receiving organ. A combination 
of the above are likely, depending on the species, together with the direction in which 
the melatonin rhythm alters (Reiter, 1987; Illerovä, 1988). 
In humans studies, the response to seasonal changes in natural photoperiod 
have been variable. Some groups have shown a seasonal variation in melatonin 
plasma concentrations (Arendt et al, 1977,1979; Wirz-Justice and Richter, 1979; 
Touitou et al, 1984), although highest levels were not consistently associated with a 
short photoperiod. Others have found no variation in total aMT6s production with 
the time of year (Beck-Friis et al, 1984; Griffiths et al, 1986; Sack et al, 1986; 
Bojkowski et al, 1988). However, Beck-Friis et al (1985) have found that in winter, 
melatonin levels were raised later in the morning and subsequent studies have shown 
that the melatonin secretion is phase-advanced by up to 2h in the winter compared to 
summer (Illernovä et al, 1985, Arendt and Broadway, 1986; Griffiths et al, 1986; 
Kennaway and Royles, 1986; Bojkowski and Arendt 1988). These studies suggest 
that the changing season affects the timing of the melatonin rhythm more than the 
amplitude. 
More recently it has been demonstrated that humans respond both 
physiologically and behaviourally to changes in artificial photoperiods similar to 
animals (Buresovä et al, 1992; Wehr, 1991; Wehr et al, 1993). The nocturnal 
duration of melatonin secretion along with sleep-phase, cortisol, prolactin and body 
temperature lengthened on exposure to a short "winter" photoperiod (16h darkness: 
8h light) from a longer "summer" one (14h light: 10h darkness). In the winter, 
natural darkness falls in the early evening hours and, in the absence of artificial light, 
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the production of melatonin occurs earlier (phase-advancing). Darkness lifts in the 
later hours of the morning in winter delaying the offset of melatonin secretion until 
dawn appears. Wehr (1991) suggests that the mechanism for this phenomenon could 
employ a two-oscillator system; one which controls the onset of melatonin secretion 
and sleep, and one for the offset. The dual oscillator model has been previously 
demonstrated by Pittendrigh and Daan (1976) using `dawn' and `dusk' oscillators and 
later by Illernovä and Vanecek (1982) with their studies on rodents. Illernovä and 
Vanecek (1982) simulated a dawn and dusk signal using brief 1 minute pulses of 
bright light, giving a so-called `skeleton' photoperiod. 
Further evidence for a dawn and dusk time cue in humans comes from 
Broadway et al (1987) who simulated a 12.5h spring `skeleton' photoperiod well into 
the Antarctic winter, when men live entirely under artificial light (< 500 lux). They 
applied two bright light pulses (of 1 hour duration at 2500 lux), one in the morning 
and one in the evening, and produced a melatonin profile similar to the pattern in 
summer. Dim light was not effective (< 500 lux). After the photoperiodic time cues 
are removed, this response to a change in the light/dark cycle lasts for at least 24h 
(Wehr et al, 1993), or longer if the sleep/wake cycle is fixed (Illnerovä et al, 1993), 
suggesting that the photoperiodic response might be conserved within the human 
circadian timing system. 
These studies indicate that humans can respond to seasonal photoperiod 
variations. However, the intensity of light appears to be important (Broadway et al, 
1987) and may explain why a durational response in nocturnal melatonin was not 
found in some studies since humans in industrialised societies live in artificial lighting 
environments, whether in the home and at work, for most of the year and may not 
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receive bright enough light, or suitably timed photoperiodic signals, for a seasonal 
response to be seen (Illnerovä et al, 1985). 
1.3.4 Puberty 
Puberty is associated with elevated activity of the hypothalamic-pituitary- 
gonadal axis, bringing about sexual maturation. Evidence of a relationship between 
melatonin and puberty has been conflicting, mainly due to methodological differences 
such as day- and night-time sampling, limited number of subjects and single nighttime 
samples (Review: Cavallo, 1993). In extensive studies with frequent nighttime 
sampling in normal healthy children, plasma melatonin levels show little difference 
between sexes and show a fall in the nighttime peak of melatonin secretion with age 
and sexual maturation (Attanasio et al, 1985; Waldhauser et al, 1988; Cavallo, 1992). 
In contrast, some reports show no change in total excretion of the urinary metabolite 
of melatonin aMT6s from childhood to adult (Tetsuo et al, 1982). These results have 
led to the suggestion that any increase in melatonin with age is due to increased body 
mass (Waldhauser et al, 1988), see section 1.3.7. However, Brun et al (1992) have 
found that urinary excretion of 6-sulphatoxymelatonin increases from early to mid 
childhood taking into account body mass. 
Pineal tumours in humans are associated with disturbances in pubertal 
development (Kitay, 1954). However, other factors may be responsible for changes 
in the hypothalamic-pituitary-gonadal axis such as tumour tissue spreading into the 
hypothalamus and elevated secretion of chorionic gonadotropin (Wass et al, 1982; 
Neuwelt and Lewy, 1983). The relationship between the pineal gland and puberty 
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has yet to be fully established. 
1.3.5 Advancing age 
In many species the nocturnal rise in melatonin secretion undergoes a gradual 
decline with age (review: Reiter, 1992b). The fall in amplitude of the nighttime rise 
in melatonin levels has also been shown with age in humans (Iguchi et al, 1982, 
Touitou et al, 1981), together with a shorter nighttime profile (Nair et al, 1986). 
aMT6s excretion follows a similar fall with advancing age (Sack et al, 1986; 
Bojkowski et al, 1990), although Young et al (1988) found no fall in aMT6s 
excretion with age. However, Young et al (1988) grouped subjects into two wide age 
populations (36.5-79.9 years compared to 18-36.49 years) which allows only gross 
comparisons to be made between two variable age groups. Significant changes may 
only occur in later years perhaps only after 60 years as demonstrated by Bojkowski 
et al (1990). 
One theory for the reduction in melatonin secretion involved pineal 
calcification which increases with age (Welsh, 1985). However, the activity of the 
pineal enzymes involved in the synthesis of melatonin is not affected by calcium 
deposits in the pineal gland (Wurtman et al, 1964) and more recent studies have 
confirmed that pineal calcification does not affect melatonin production in young to 
middle-aged adults (Commentz et al, 1986; Bojkowski and Arendt, 1990). 
Another possible mechanism to account for the attenuation of the melatonin 
rhythm with age is the concomitant decline of available B-adrenergic receptor numbers 
on the pinealocyte membrane (Greenberg and Weiss, 1978; Henden et al, 1992) and 
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a, -adrenergic receptors in the SCN (Weiland and Wise, 1990). Food restriction in 
rats can preserve the age-associated fall in these receptor numbers and nighttime 
activity of NAT (Stokkan et al, 1991; Henden et al, 1992). A reduction in the 
neuronal activity of the SCN with age may also contribute to a dampening of the 
melatonin rhythm (Satinoff et al, 1993). 
Administration of exogenous nighttime melatonin or engraftment of pineal 
glands from young to old mice has been found to promote longevity in rats (Pierpaola 
and Regelson, 1994). In addition to changes in melatonin output with age, a 
concomitant fall in the endogenous temperature rhythm amplitude is observed 
(Czeisler et al, 1992), which can be prevented with the melatonin agonist S-20242 in 
rats (Koster-van Hoffen et al, 1993). These studies suggest that melatonin and the 
pineal gland may act as an internal clock mechanism involved in the aging process. 
The alterations in the circadian system with age may affect the individuals' 
ability to be entrained in a normal environment or adapt to changes in a new time 
zone. Recently sleep disorders, which are common in the elderly (Feinberg, 1974) 
have been correlated with disturbances in the melatonin rhythm (Haimov et al, 1994). 
The elderly account for the majority of the population who are diagnosed with 
advance sleep phase syndrome (Moldofsky et al, 1986). 
In aging hamsters the circadian clock either becomes less responsive or 
changes its response to the phase-shifting and synchronising effects of 
benzodiazepines and light/darkness (Zee et al, 1992; Van Reeth et al, 1993). In 
humans, age-related differences in adaptation to shiftwork or a new time zone have 
been attributed to a reduced ability of the internal clock to adjust (Akerstedt and 
Torsvall, 1981; Graeber, 1982). 
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1.3.6 Normal menstrual cycle 
Wetterberg et al (1976) have indicated that melatonin levels showed apparent 
cycling in line with the menstrual cycle, peaking at the time of menstrual bleeding 
and reaching a minimum at ovulation, and suggested a role for melatonin in normal 
menstrual cyclicity. Correlational evidence shows that this menstrual melatonin 
profile is inversely related to the changes in temperature throughout the cycle 
(Nakayama et al, 1992). Amplitude changes and phase-shifts in the luteal phase have 
also been reported by others (Hariharasubramanian and Nair, 1982; Webley and 
Leidenberger, 1986). However, Brzezinski et al (1988) and Fellenberg et al (1982) 
have failed to confirm these findings. Melatonin has been shown to be present in 
human preovulatory follicles (Brzezinski et al, 1987) and nocturnal melatonin levels 
can stimulate the production of progesterone in human granulosa cells (Webley and 
Leidenberger, 1986). The circadian role of melatonin in human ovarian function 
remains to be elucidated although there is evidence for melatonin's role in the 
reproductive function of many mammals (review: Reiter, 1980). 
1.3.7 Body size 
There is contradictory evidence for a relationship between melatonin levels and 
body size. As body weight increases in both men and women, plasma melatonin 
levels have been shown to increase (Arendt et al, 1982; Ferrier et al, 1982). 
However, no correlation has been found for aMT6s (Nair et al, 1986; Sack et al, 
1986; Bojkowski and Arendt, 1990). 
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Height may also influence melatonin levels. Beck-Friis et al (1984) found a 
negative correlation between melatonin and height. However, a similar finding by 
Sack et al (1986) was no longer significant when age was taken into account and 
other studies could not confirm the relationship (Nair et al, 1986; Bojkowski and 
Arendt, 1990). 
Differences in melatonin levels have been observed in the 2 sexes and obesity 
by some workers. Sack et al (1986) found low aMT6s levels in urine with increasing 
weight in women and the opposite for men. Beck-Friis et al (1984) found a negative 
association between obesity and melatonin levels in a mixed population and Arendt 
et al (1982) demonstrated a similar negative correlation in women. However, in 
obese children, Tamarkin et al (1982) have found normal plasma melatonin levels. 
The relationship between melatonin levels and measurements of body size remains 
unclear, but huge individual differences in melatonin secretion (Arendt, 1988) may 
disguise a true effect. 
These studies do suggest that consideration of weight, height and obesity index 
is warranted when measuring melatonin and emphasises the need to use individuals 
as their own controls. 
1.3.8 Exercise/stress 
Stressful stimuli can stimulate the sympathetic nervous system by increasing 
circulating levels of NA (Axelrod and Reisine, 1984). It is therefore conceivable that 
stress could increase the production of melatonin through increased sympathetic 
innervation of the pineal or through direct stimulation of pinealocytes by systemic 
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NA. 
The effects of exercise on melatonin concentrations in humans is conflicting. 
At night a reduction in melatonin production has been observed after physical exercise 
in the dark (Monteleone et at, 1990). However, physical exercise during light- 
induced suppression of melatonin causes no effect (Monteleone et at, 1992). During 
the day Vaughan et at (1979) demonstrated no changes in melatonin levels after a 100 
yard dash. However, more strenuous exercise has been shown to transiently elevate 
melatonin concentrations (Carr et at, 1981; Ronkainen et at, 1986). Similar findings 
have been demonstrated in rats whilst swimming at night (Troiani et at, 1987). 
Stress-related hormones and catecholamines are not involved in this response, since 
removing the adrenal glands and severing sympathetic innervation has no effect on 
this elevation in the rat blood (Wu et at, 1987; Troiani et at, 1988). The active NA 
uptake mechanism of sympathetic nerve endings in the pineal may also provide a 
protective response against acute stress-induced stimulation of the pineal (Parfitt and 
Klein, 1976). No corresponding changes in rat NAT or HIOMT activity are evident 
with the increase in blood melatonin (Troiani et at, 1987). The mechanism of action 
therefore remains unknown. 
1.3.9 Alcohol ingestion 
Alcohol at doses usually ingested socially (0.05-1g/kg wt) can suppress 
melatonin secretion when administered before the melatonin onset time (Ekman et al, 
1993; Röjdmark et al, 1993). The mechanism of action remains unknown but may 
involve inhibition of adrenergic activation of the pinealocytes (Chik et al, 1987, 
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1992). 
In summary, whilst the melatonin circadian rhythm is remarkably stable within 
individuals, there are a number of factors which may disturb the endogenous secretion 
pattern of melatonin leading to inappropriate estimates of circadian parameters. 
Hence, in any studies involving melatonin measurement as a marker of circadian 
time, alcohol and exercise should be restricted and subjects/patients should be drug- 
free wherever possible and matched by age, weight, height and reproductive status. 
1.3.10 Depression and seasonal affective disorder 
Disturbances in the circadian timing system have been associated with 
depression particularly when they are linked to periodic manic episodes. A phase- 
advance theory has been proposed for depressed patients where sleep, temperature 
and cortisol rhythms have been shown to be phase-advanced compared to controls 
(review: Kripke, 1983). The amplitude of nocturnal melatonin secretion may be 
reduced although the evidence is conflicting (e. g. Wetterberg et al, 1978; Claustrat 
et al, 1984; Thompson et al, 1988). 
A number of antidepressant drugs which affect noradrenergic and serotonergic 
function have been shown to stimulate melatonin production in humans. For 
example, desipramine can advance the onset and increase the duration of melatonin 
in humans (Franey et al, 1986; Cowen et al, 1985; Skene et al, 1994), presumably 
by inhibiting the reuptake of NA at the nerve synapses in the pineal gland (Checkley 
et al, 1986). 5-HT uptake inhibitors such as fluvoxamine and melatonin synthesis 
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precursors can elevate melatonin levels (Namboodiri et al, 1983; Demisch et al, 
1986; Skene et al, 1994). In addition, the phosphodiesterase inhibitor rolipram, has 
been shown to increase melatonin (Checkley et al, 1987). All have antidepressant 
activity. These studies underline the importance of noradrenergic, serotonergic and 
cAMP mechanisms in melatonin production but there is little evidence so far to 
suggest a causal effect of melatonin in depression. 
One depression that reappears every autumn and winter, is known as seasonal 
affective disorder (SAD; Rosenthal et al, 1984), and has been linked to a seasonal 
disturbance in the circadian timing system. A delay in the rhythm of melatonin (and 
aMT6s), cortisol and temperature has been observed in SAD patients in various 
studies (Lewy et al, 1987; Terman et al, 1988; Avery et al, 1989; Wirz-Justice et al, 
1990; Wirz-Justice et al, 1993), although this has not been confirmed by others 
(Rosenthal et al, 1990; Checkley et al, 1993; Eastman et al, 1993). 
1.3.11 Circadian rhythm disorders 
There are a number of other situations or pathological states where the timing 
of the endogenous melatonin rhythm is out of phase with environmental zeitgebers 
and apparently with other circadian rhythms. These include jet lag (Arendt et al, 
1987), maladaptation to shift work (Waldhauser et al, 1986; Touitou et al, 1990; 
Sack et al, 1992; Shanahan et al, 1994) and blindness (Lewy and Newsome, 1983) 
and are described in detail in sections 1.5,1.6 and 1.8. 
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1.4 PHASE-SHIFTING RESPONSE OF THE HUMAN CIRCADIAN 
SYSTEM TO BRIGHT LIGHT AND MELATONIN 
1.4.1 Range of entrainment 
There is a limited `length of the day' to which humans can adapt without 
causing circadian rhythms to become misaligned from the environment ("external 
desynchronization"), or from one another ("internal desynchronization"), and continue 
oscillating with their own free-running periods (Wever, 1983). Human physiological 
rhythms can normally entrain to daylengths between 23 and 27h (Wever, 1983, 
1986). Outside this range of entrainment rhythms such as temperature, cortisol and 
melatonin (Lewy and Newsome, 1983) will naturally free-run with a periodicity close 
to 25h (Wever, 1974,1986,1989; Kennaway and Van Dorp, 1991). This free- 
running periodicity is considered to reflect the internal period of the circadian 
pacemaker. However, the range of entrainment also depends upon the strength of the 
zeitgeber (Wever, 1983). Bright light of 3000 lux during the light phase (0.1 lux 
during darkness) has been found to increase the range of entrainment of the 
temperature rhythm (Wever, 1983,1986,1989) by as much as 6h a day from its free- 
running period, i. e. 19-31h. Shorter durations of bright light (2h at 2000-4000 lux) 
exposure administered just before bedtime can also facilitate the entrainment of the 
circadian system to a 26h day (Eastman and Miescke, 1990). 
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1.4.2 Entrainment of the human circadian system to the light/dark cycle 
Originally, the light/dark cycle was not thought to be as effective as social 
time cues in synchronising the human circadian system (Wever, 1979). However, in 
these early studies light was freely available during the dark phase and social cues 
(audible gongs) signalled light/dark transitions. With stricter control of the light/dark 
cycle and social cues, the light/dark cycle was able to entrain the temperature and 
activity rhythms (Czeisler et al, 1981). Many blind subjects do not receive zeitgebers 
of adequate strength to entrain their circadian system indicating that the light/dark 
cycle is an important zeitgeber in man (Orth and Island, 1969; Miles et al, 1977; 
Sack et al, 1987; Arendt et al, 1988; Klein et al, 1993). Brighter intensity light 
(> 3000 lux) throughout the light phase of the light/dark cycle effectively entrains the 
temperature rhythm to a 24h day (Wever et al, 1983; Honma et al, 1987). 
1.4.3 Phase-shifting effects of light 
The ability of circadian timing system to entrain to environmental time cues 
relates to the ability of external zeitgebers to shift the circadian pacemaker in time. 
Suitably timed bright light of sufficient intensity and duration will induce phase-shifts 
in the rhythms of various physiological variables such as core body temperature, 
cortisol and melatonin secretions (Broadway et al, 1987; Shanahan and Czeisler, 
1991). Repeated daily exposure to bright light (2500 lux) in the morning can phase- 
advance the onset of melatonin secretion, whereas evening light treatment can induce 
phase-delays, even when the sleep/wake cycle is held constant (Lewy et al, 1987). 
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Evening exposure to much stronger intensity bright light (> 7000 lux) for one week, 
can phase-delay the endogenous temperature and cortisol rhythms by as much as 6h 
in some individuals, whilst maintaining a constant sleep/wake cycle and regular social 
interactions (Czeisler et al, 1986). In addition, Czeisler et al (1989) demonstrated 
that bright light pulses (> 7000 lux) given on three consecutive days can shift the 
temperature, cortisol and urine output rhythms, advancing them with morning light 
exposure or delaying them with evening light treatment. 
Bright light can also acutely phase-shift the circadian pacemaker after a single 
exposure. Buresovä et al (1991) reported an a 0.6-2.2h advance in the melatonin 
rhythm one day after exposure to bright light (3000 lux) between 0300-0900h. A 
single 3h bright light pulse (5000 lux) administered up to 5h before the temperature 
minimum phase-delayed the melatonin rhythm by an average of 74 minutes (van 
Cauter et al, 1994). Average phase-advances of 28 minutes were evident between 1- 
4h after the temperature minimum. 
In constant routine ('unmasked') conditions, the magnitude and direction of 
shift of the plasma melatonin, plasma thyrotropin, core body temperature, plasma 
cortisol and urine production rhythms are similar (Czeisler et al, 1989; Shanahan and 
Czeisler, 1991; van Cauter et al, 1994). Taken together these studies strongly 
suggest that light has an unique ability to phase-shift the master human circadian 
pacemaker governing a number of physiological circadian rhythms. 
These findings have led to the establishment of a phase response curve (PRC) 
for bright light which predicts the magnitude and direction of shift of the circadian 
pacemaker, in response to light pulses at various times of day (Minors et al, 1991; 
van Cauter et al, 1994), Figure 1.5. A classical PRC using single pulses of bright 
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light has been described by Minors et al (1991) using the core body temperature 
rhythm as a circadian phase marker of the biological clock. Bright light administered 
before the temperature minimum (0400-0500h clock time) caused a phase-delay and 
light given after the temperature minimum phase-advanced the rhythm. Phase- 
responses were obtained under 3 different conditions where 1) subjects were initially 
entrained to a 24h day before being exposed to a 3h pulse of 5000 lux bright light, 
2) subjects were free running before exposure to 3h of bright light at 9000 lux and 
3) subjects were free-running before exposure to 3h of 9000 lux on three consecutive 
days. Larger phase-shifts were obtained with subjects free-running and even more 
so with repeated daily light exposure. A similar phase response effect of bright light 
(5000 lux) has been demonstrated by van Cauter et al (1994) using plasma melatonin 
and thyrotropin as circadian rhythm markers, and Honma and Honma (1988) using 
the free-running sleep/wake rhythm as a circadian phase marker. 
Czeisler et al (1989) have generated a light phase response curve which can 
induce much larger phase-shifts in temporal isolation and under constant routine 
conditions. This is based on repeated daily exposure of bright light in combination 
with darkness. Using 5h of bright light (7000-12000 lux) on 3 consecutive days and 
maintaining regular 8h darkness (sleep) episodes, phase-shifts of up to 12 hours in the 
temperature rhythm were achieved after 3 days. The greatest shifts were obtained 
when light pulses were centred over the temperature minimum with subjects in 
darkness (and sleep) during the day. The time of the temperature minimum is 
considered to be the most sensitive phase of the circadian system where the largest 
phase-shifts can be induced (Czeisler et al, 1989). These results reflect a combination 
of imposed light/dark and sleep/wake cycles. in achieving the shift. 
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Figure 1.5 Human phase-response curves for bright light and 
melatonin 
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Phase-response curves (PRC) for bright light and melatonin showing the magnitude 
and direction of phase-shift in the endogenous biological clock after bright light or 
melatonin treatment at different times of the day. Two light PRCs for single 3h 
bright light pulses are shown and are plotted using the midpoint of light exposure. 
One used the core body temperature rhythm as the circadian phase marker (, 
light intensity = 5000/9000 lux, ----: no estimate made). The second light PRC 
used the endogenous melatonin rhythm as a phase marker (- , 
light intensity = 
5000 lux). Two melatonin PRCs are shown and both have used the endogenous 
melatonin rhythm as the circadian phase marker. One shows a cumulative phase- 
shift reponse after repeated melatonin treatment (0.5mg) for 4 days (-). The 
second shows the response to single 3h melatonin infusions at physiological doses 
only at four different times of day (A), and is plotted using the start of each 
infusion. Adapted from Minors et al, 1991, Lewy et al, 1992, van Cauter et al, 
1994 and Zaidan et al, 1994. 
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Response curves allow the prediction of the effects of light treatment at 
different times of day and therefore could be used therapeutically in conditions where 
there are underlying circadian rhythm disturbances, e. g. jet lag. However, it must 
be noted that the generation of such phase response curves in a free-running state or 
in temporal isolation may not apply to a "normal" environment where the circadian 
system will be influenced by daily zeitgebers which alter rhythm parameters. For 
example, natural ambient bright light exposure can prevent the desired phase-shift 
with artificial bright light if appropriately timed to oppose the desired shift (Eastman 
and Miescke, 1990). Control of ambient light intensity in the normal environment 
is therefore important when treating circadian rhythm disturbance. 
1.4.4 Phase-shifting effects of melatonin 
Under normal conditions, repeated melatonin administration (2mg and 8mg) 
at 1700h or 2200h will phase-advance its own endogenous rhythm (Arendt et al, 
1985a; Wright et al, 1986; Mallo et al, 1988). The cumulative phase-shifting effect 
of repeated melatonin administration has been extended to cover responses at several 
times of day and has led to the establishment of a PRC for melatonin (Lewy et al, 
1992) with almost a reverse phase relationship to the light PRC (Minors et at, 1991; 
van Cauter et al, 1994), Figure 1.5. Using the onset of melatonin secretion in plasma 
as a circadian phase marker, the PRC was determined with reference to the 
individuals melatonin onset time in plasma, which for normal sighted individuals 
occurs at 2100-2200h clocktime (Arendt et al, 1977; Lewy et al, 1992; Deacon and 
Arendt, 1994). Using 2200h as a guide, phase-advances were apparent between 
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1200-2000h and phase-delays were evident between 0400-1000h. A zone of little or 
no response occurred between 2000-0200h, Figure 1.5. 
Recently, the acute phase-shifting effects of single melatonin infusions have 
been described in terms of a phase-response curve (Zaidan et al, 1994). Intravenous 
infusion of physiological levels of melatonin starting at 1600h and 2000h advanced 
the endogenous melatonin rhythm and when administered between 0400-0700h and 
1200-1500h the melatonin profile was delayed, Figure 1.5. In contrast to the PRC 
of Lewy et al, Zaidan and workers reported a larger phase-shift later in the day. 
Such work suggests that melatonin has phase-shifting properties of its own and 
provides a means of resetting the biological clock similar to the ability of bright light, 
where disturbances in biological rhythms exist, for example abnormal sleep phase 
syndromes and shiftwork. 
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1.5 ABRUPT PHASE-SHIFTS IN LOCAL TIME CUES 
Two aspects of modern society where the local time cues are quickly altered, 
time-zone travel and shift work, result in behavioural and physiological problems 
which can interfere with the individuals ability to perform everyday tasks and make 
them more susceptible to having accidents, compromising productivity and safety. 
1.5.1 Jet lag 
Tiredness during the day, difficulty in sleeping at night, poor performance and 
alertness together with digestive problems are common complaints after rapid 
transmeridian flight over many time zones (Siegel et al 1969; Winget et al, 1984; 
Comperatore and Krueger, 1990). Travel weariness and sleep loss are associated 
with time-zone travel, however, the symptoms of jet lag tend to persist longer than 
the time taken to recover from these effects. Underlying circadian rhythm 
disturbances are also associated with the jet lag state (D6sir et al, 1981; F6vre- 
Montange et al, 1981). On arrival at their new destination, jet travellers are exposed 
to a range of social and environmental zeitgebers and imposed routines that are 
shifted in time, although their body clocks are not yet adapted. The jet lag state tends 
to persist whilst the circadian system slowly adapts to new local time cues at a rate 
of 1-1.5h a day (Aschoff et at, 1975; Klein and Wegmann, 1980). The length of 
time for different circadian rhythms to readjust to a new time zone or schedule is 
variable resulting in a temporary internal dissociation between circadian rhythms 
(Elliot et al, 1972; Aschoff, 1978; Klein and Wegmann, 1980; D6sir et at, 1981). 
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Even rhythm parameters (e. g. minimum and maximum) may adapt differently, 
suggesting that different control mechanisms regulate different aspects of rhythmic 
functions (Ddsir et al, 1981). However, masking of endogenous circadian rhythms 
by external factors such as activity and sleep may influence the apparent rate of 
adjustment and should be considered (Folkard et al, 1991; Minors and Waterhouse, 
1992a, 1992b). 
The speed of resynchronization of circadian rhythms depends upon the number 
and direction of time zones crossed together with the strength of the zeitgeber 
(Aschoff et al, 1975; Klein and Wegmann, 1980). Resynchronization takes longer 
after eastward rather than westward flights. To adjust the circadian rhythms to an 
eastward time zone, the circadian timing system needs to be advanced, i. e. moved 
forward in time. In contrast, adjustment to a westward time zone requires the 
circadian timing system to be delayed, i. e. moved backwards in time. This is 
achieved by either temporarily shortening or lengthening the period/cycle of the 
internal clock. For example, in normal everyday life the period of the endogenous 
body clock m 24h. Adopting a longer period, say 25h, gradually delays the timing 
of the circadian system by lh a day until the desired shift is achieved. Then 
environmental and behavioural time cues will reinforce and entrain the biological 
clock to the new 24h cycle. 
67 
1.5.2 Shift work 
The major industrial disasters Chernobyl and Bhopal occurred during the night 
shift when sleepiness related accidents are common (Folkard et al, 1978; Akerstedt, 
1988; Mitler et al, 1988). Often the adaptation of circadian rhythms to the newly 
imposed work schedules is never complete and individuals sleep and work at 
abnormal circadian times even after many years of night shift work (Colquhoun et al, 
1969; Folkard et al, 1978; Akerstedt and Gillberg, 1981; Czeisler et al, 1990; Sack 
et al, 1992). Although night shift workers are deprived of sleep at night they may 
still suffer from disturbed sleep during the day (Akerstedt and Gillberg, 1981; 
Czeisler et al, 1982). Continual adjustment of the circadian system to new work 
schedules is associated with health problems that include sleep disorders, digestive 
problems and a higher risk of cardiovascular disease (Czeisler et al, 1983; Akerstedt 
et al, 1984). 
Adaptation of the circadian system to newly imposed changes in the 
sleep/wake cycle may be hindered, firstly by individuals not maintaining the same 
sleep/wake schedule on days off and secondly, insufficient time to adapt during 
rotating shift schedules. Shift workers are also often exposed to other zeitgebers such 
as the natural light/dark cycle and social contacts which prevent adaptation to new 
schedules (Eastman, 1987). This problem is often compounded by the fact that night 
shift workers are typically exposed to light intensities at work which are much less 
than natural outdoor light, and hence the zeitgeber strength is attenuated. 
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1.5.3 Susceptibility to jet lag and maladaptation to shift work 
Susceptibility to jet lag and problems adjusting to shift work varies with 
different individuals. 
1.5.3.1 Age 
One of the factors affecting the ability to adapt to new time zones and shift 
work is age. A reduced ability to adapt has been associated with increased difficulty 
in sleeping at inappropriate circadian phases (Graeber, 1982; Moline et al, 1992). 
In a simulated jet lag paradigm in which the subjects' day/night routine was advanced 
rapidly by 6h, Moline et al (1992) found that middle-aged men showed no difference 
in the rate of readjustment of the core body temperature rhythm compared to younger 
controls but experienced more disrupted sleep at night and suffered increased 
sleepiness and fatigue during the day. This study indicates that the disruption of the 
pattern or timing mechanism of sleep is more likely to occur after abrupt phase-shifts 
in middle-aged men than in younger individuals. More fatigue, greater disruption of 
the sleep pattern and slower adaptation of the temperature rhythm has also been 
observed in middle-aged men compared younger controls following transmeridian 
flight (Hauty and Adams, 1965; Evans, 1970; Evans et al, 1972). 
1.5.3.2 Circadian rhythm characteristics 
The stability and amplitude of circadian rhythms may also influence the rate 
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of adaptation in individuals (Reinberg et al, 1978; Klein and Wegmann, 1980; 
Graeber, 1982; Winget et al, 1984; Comperatore and Krueger, 1990). Some workers 
suggest that individuals with larger circadian rhythm amplitudes (e. g. body 
temperature) find it harder to adapt to phase-shifts (Reinberg et al, 1978). The 
stability of circadian rhythms is assessed by the standard deviation (SD) over 12 
consecutive days (Colquhoun and Folkard, 1978). A low SD indicates a more stable 
rhythm and is associated with a lower rate of shift. The circadian phase of the 
individual may also predict the rates of adaptation to abrupt phase-shifts. For 
example, after an 8h eastward (advance) time-zone shift, Colquhoun (1979) found that 
individuals with earlier temperature maximums entrained faster. 
1.5.3.3 Personality 
The circadian phase may also be related to certain personality types. A 
number of studies suggest that evening-type individuals adapt to shift work easier than 
morning-types (e. g. Folkard and Monk, 1981; Hildebrandt and Stratmann, 1979). 
Morning-type people are more alert in the morning and show an earlier peak time of 
the body temperature rhythm (Home and Östberg, 1976). Thus when the new time 
zone or shift schedule requires a delay of the circadian system, it is logical that the 
earlier the circadian phase of the individual the longer it will take for them to adapt. 
This is confirmed by field studies showing that the speed of circadian adjustment to 
night work of morning-type people is reduced on delayed shifts (Costa et al, 1989). 
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1.6 BRIGHT LIGHT AND MELATONIN TREATMENT FOR JET LAG 
AND SHIN WORK 
The circadian system cannot adapt fast enough to abrupt changes in local time 
cues because it has a limited range of entrainment. However, by increasing the 
strength of the zeitgeber the circadian system may resychronise itself with the external 
environment faster. 
1.6.1 Bright light treatment for jet lag 
The rate of adaptation may depend upon the time-zone travellers activities (and 
environment) after the flight. In a study by Klein and Wegmann (1974), the rate of 
reentrainment of performance rhythms after a 6h phase-shift were much slower in one 
group of subjects kept indoors compared to another group who enjoyed the freedom 
of outdoor activities. Differences in social zeitgebers were considered to be 
responsible for this effect. However, exposure to brighter intensity light outdoors 
may also have contributed to the faster adaptation through mechanisms of entrainment 
and phase-shifting (Czeisler et al, 1981,1986,1989; Wever et al, 1983; Honma and 
Honma, 1988; Minors et al, 1991; van Cauter et al, 1994). These effects of light 
have led to its use in facilitating the readaptation of circadian rhythms to the new 
local time and alleviating the associated behavioural problems. 
In 1984, Daan and Lewy suggested a light treatment strategy for jet lag using 
exposure to natural daylight, based on animal light phase response curve theory (see 
section 1.4.3). After two subjects travelled east over 9 time zones (9h phase- 
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advance), they exposed themselves to natural daylight for one week either between 
0700-1000h local time, intended to phase-delay, or between 1000-1300h local time, 
intended to phase-advance. The temperature rhythm of the latter reentrained faster 
by one week compared to the former. However, this observation conflicts with 
human light phase response curve theory (Czeisler et al, 1989; Honma and Honma, 
1988; Minors et al, 1991; van Cauter et al, 1994) since light exposure between 1000- 
1300h should have delayed the temperature rhythm, although individual circadian 
phase, differences in daylight intensity and other competing zeitgebers may account 
for the discrepancies. 
The actual intensity of light can alter the rate of reentrainment after an abrupt 
phase-shift. In a laboratory setting, Wever (1985a) observed that the rate of body 
temperature adaptation after a phase-delay of the light dark cycle was faster by 
0.4h/day with indoor light intensities of 2000-5000 lux compared to < 1500 lux, over 
the first few days post-shift, suggesting that the strength of the zeitgeber is important. 
There is also evidence for delayed effects of bright light. In one study, no 
overall differences were observed in the rate of body temperature adaptation 
comparing light treatments of 2500 lux and 300-500 lux administered for 4h on 
waking after a 6h phase-advance (Moline et al, 1989). Both light groups advanced 
at the same rate throughout the treatment period of 4 days, but after the fifth post- 
shift day the bright light group delayed for 2 days. No differences in objective sleep 
measurements were identified. In a similar phase-shift paradigm, Samel et al (1992) 
treated individuals with bright light exposure (3500 lux) at either 0400h or 1300h 
(mid-points of light exposure) for two days. Only on the seventh day after the phase- 
shift did the morning bright light group show an earlier peak time in the temperature 
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rhythm. Another study has shown improvements in polysomnographic sleep 
patterns with morning exposure of bright light (>3000 lux) compared to dim light 
(< 500 lux) for 3 days after an 8h advance time zone shift (Sasaki et al, 1989). Cole 
and Kripke (1989) analysed subjective measurements of sleep after time zone advance 
shifts of 6.5-10h, followed by light treatment upon wakening for 3 days consisting of 
bright white light (2000 lux) or dim red light (< 100 lux). No group mean 
differences between the two light treatments were apparent although on at least one 
of the light treatment days early morning bright light treatment appeared to 
consolidate sleep into a single period at night. 
To date the effects of bright light treatment in alleviating jet lag are 
inconclusive despite successful treatment for maladaptation to shift work. 
1.6.2 Bright fight treatment for shift work 
In laboratory simulations of night shift work, normal adaptation can be 
achieved within a week (Rutenfranz et al, 1981). However, this contrasts markedly 
to field based studies, underlining the importance of the strength and timing of natural 
environmental zeitgebers, in particular the natural light/dark cycle (Akerstedt et al, 
1977; Folkard et al, 1978; Reinberg et al, 1984; Monk, 1986). 
Bright light (<2800 lux) just prior to sleep and light control the following 
morning can facilitate the adaptation to a 26h day (Eastman and Miescke, 1990). By 
maintaining this schedule over a number of days, it provides a method for adjusting 
the circadian system gradually during slowly-rotating shift schedules (i. e. a week or 
more between different shifts, Eastman, 1987). 
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By increasing the strength of the light zeitgeber and adjusting the timing of 
exposure, a few studies have achieved the desired rapid adjustment, without treatment 
prior to the new shift. Controlled exposure to bright light (> 7000 lux for 4 nights) 
during the whole night, and darkness during the day, can induce complete adaptation 
to simulated night shift work, despite the morning commute home in natural light 
(Czeisler et al, 1990). Shorter durations of bright light exposure (> 6000 lux, 2400- 
0400h) during the night shift are also sufficient to significantly improve daytime sleep 
and nocturnal performance (Dawson and Campbell, 1991; Bougrine et al, 1993). 
In addition to an effect on the circadian system, bright light may have direct 
arousing or stimulating effects which can benefit mood and performance during the 
night shift, see section 1.10.2. 
Most of the studies described above have involved young people (< 30 years). 
Although bright light therapy may be effective in facilitating adaptation to shiftwork 
in these people, older individuals have been found to be less responsive to the same 
light treatments (Campbell et al, 1994). This underlines the importance of adapting 
bright light treatment to suit particular individuals. 
1.6.3 Melatonin treatment for jet lag 
Exogenous melatonin (5mg) has been shown to alleviate jet lag symptoms, 
facilitate the reentrainment of the endogenous melatonin and cortisol rhythms and 
resynchronize the melatonin excretion rhythm after simulated or actual time zone 
shifts (Arendt et al, 1987; Samel et al, 1991). Other studies have shown melatonin 
to successfully alleviate subjective feelings of jet lag in field studies (Arendt and 
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Aidhous, 1988; Nickelsen et al, 1991b; Claustrat et al, 1992; Petrie et al, 1989, 
1993). 
In all these studies, melatonin was administered near bedtime after the flight. 
In a few cases, pre-flight treatment of melatonin was used to initiate the phase-shift 
in the circadian system in order to accelerate the resynchronization process (Arendt 
et al, 1987; Petrie et al, 1989; Samel et al, 1991). Melatonin was administered at 
a time when it would be naturally released in the new time zone. In a recent study, 
Petrie et al (1993) compared the efficacy of melatonin in alleviating jet lag in aircrew 
with and without pre-flight treatment for 2 days. Post-flight treatment alone 
demonstrated faster alleviation of jet lag symptoms, suggesting that pre-flight 
treatment was not necessary. Pre-flight melatonin treatment was timed assuming that 
every individual was entrained to local time before the flight. However, 
administering melatonin treatment to aircrews at the correct circadian time pre-flight 
for every individual is complicated by their frequent time-zone travel. 
1.6.4 Melatonin treatment for shift work 
During rotating shift work, Armstrong et al (1986) showed that melatonin 
administration (5mg) favoured the reentrainment of the body temperature rhythm to 
the new schedules. During night shift work, melatonin administered at the desired 
bedtime improved the quality and duration of sleep (Folkard et al, 1993). One 
performance parameter showed deleterious effects but others were unchanged or 
slightly improved (Folkard et al, 1993). 
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1.7 Bright light and melatonin treatment for SAD 
In early studies, the effectiveness of morning bright light exposure as opposed 
to evening therapy in treating this disorder was thought to be a result of the circadian 
phase-shifting effects of light (Lewy et al, 1987). The phase-shift theory suggests 
that circadian rhythms are delayed with respect to the external clock time and 
subjects' sleep times. Thus advancing rhythms with morning light treatment, resets 
the circadian system. However, the circadian timing of light therapy is no longer 
thought to be critical since improvements are now seen with light treatment no matter 
what time of day treatment is given (James et al, 1985; Wehr et al, 1986; Jacobsen 
et al, 1987; Wirz-Justice and Anderson, 1990; Wirz-Justice et al, 1993), and 
improvements in SAD patients have been noted whether they were initially phase- 
delayed or not (Wirz-Justice et al, 1993). 
Another theory to explain the antidepressant effects of phototherapy is the 
melatonin hypothesis. Here the reduction of the duration of melatonin secretion in 
SAD patients by simulating a summer photoperiod, was thought to alleviate the 
depression (Rosenthal et al, 1984). However, since light treatment in the middle of 
the day improves the symptoms without affecting the melatonin rhythm, other factors 
are thought to be involved (Wehr et al, 1986). Use of the B-adrenergic antagonist 
atenolol, which causes suppression of melatonin secretion, shows no remission in the 
disorder, and therefore disproves the hypothesis (e. g. Rosenthal et al, 1988). 
Light therapy remains the "choice" treatment for SAD, but these 
biological/psychological effects of light do not appear necessarily to involve the 
melatonin rhythm and the circadian timing system. 
76 
1.8 EFFECTS OF EXOGENOUS MELATONIN ON OTHER SLEEP/WAKE 
DISORDERS 
1.8.1 Blindness 
Many blind people keep regular schedules and report few sleep problems. 
However, others suffer from periodic insomnia and daytime fatigue which relates to 
the inappropriate phase position of endogenous rhythms as a function the desired sleep 
times (Miles et al, 1977; Lewy and Newsome, 1983; Klein et al, 1993). 
Exogenous melatonin (0.5-5mg) administered close to the desired bedtime can 
synchronise the sleep/wake cycle in blind subjects to a 24h day and improve the 
quality of life (Arendt et al, 1988; Folkard et al, 1990; Sack et al, 1991; Jan et al, 
1994). Similar findings were described after administering 0.5mg earlier in the 
evening at 1800h (Palm et al, 1991). However, the timing of administration seems 
to be more important for some blind subjects. Tzischinsky et al (1992b) reported 
successful treatment of sleep disturbances with melatonin administration at 2000h but 
not between 2200-2300h. 
1.8.2 Sleep phase syndrome disorders 
Difficulties in initiating sleep at night and problems with waking in the 
mornings are characteristic features of a type of insomnia known as delayed sleep 
phase syndrome. Despite their "sleep onset insomnia" patients generally have no 
difficulty in maintaining sleep once initiated with the onset and offset of sleep 
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occurring nearly at the same clock times each day (Weitzman et al, 1981). 
Individuals often have difficulties in maintaining a normal working life since morning 
starts will inevitably curtail sleep and result in daytime fatigue (Alvarez et al, 1992). 
There is therefore an inappropriate relationship between the circadian sleep/wake 
rhythm and environmental time cues. 
Entrainment to the environment can be facilitated with exogenous melatonin. 
Late evening melatonin treatment has been shown to advance sleep/wake cycles 
towards normal time with an overall improvement in the quality of life (Dahlitz et al, 
1991; Alvarez et al, 1992; Tzischinsky et al, 1993). 
1.8.3 Insomnia 
Supraphysiological levels of melatonin (75mg oral dose) administered in the 
late evening improved subjective measurements of total sleep time and daytime 
alertness in chronic insomniacs (MacFarlane et al, 1991), although changes in sleep 
structure with polygrahic recordings were less clear in a similar group of patients 
after 1mg and 5mg of melatonin at 2100h (James et al, 1987). In artificially induced 
insomnia, Waldhauser et al (1990) demonstrated significant improvements in sleep 
disruption and onset after 80mg melatonin given at 2100h and suggested that these 
changes were similar to the effects of hypnotics. Beneficial effects of far lower doses 
of melatonin (0.5-5mg) have been observed on disturbed sleep/wake patterns and 
overall behaviour in children with chronic neurological disabilities and behavioural 
problems, where other sleep management techniques including sedatives, strict 
scheduling of the sleep/wake cycle and psychological procedures, had proven 
78 
unsuccessful (Jan et al, 1994). 
In conditions where the nighttime melatonin profile has been abolished after 
destruction of the pineal gland, the lack of endogenous melatonin may prove to be 
detrimental. Petterborg et al (1991b) reported on a subject whose pineal gland had 
been destroyed through radiation therapy for a pineal astrocytoma and as a 
consequence suffered from insomnia and daytime sleepiness. Daily melatonin 
treatment during the late evening improved subjective sleep and daily mood and led 
to the synchronisation of growth hormone and prolactin secretory rhythms (melatonin 
and temperature were not measured). 
1.9 ADVERSE EFFECTS OF MELATONIN 
The successful alleviation of behavioural problems by melatonin, with the 
realignment of at least the sleep/wake rhythm with the local time cues in a number 
of these circadian rhythm disorders, indicates a wide therapeutic spectrum for this 
compound. However, the effects of exogenous melatonin on other physiological and 
behavioural parameters under a range of doses and under long term treatment must 
first be established. Melatonin, even in very high doses has extremely low toxicity 
in rodents (Sugden, 1983). In humans, no serious adverse reactions have been 
reported to date with short-term or long term use of low doses. Somnolence may 
occur, but this may be an important physiological effect of the hormone and not a 
pharmacological side-effect, see section 1.10.1. 
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1.9.1 Endocrinological effects 
Low milligram doses of melatonin have little acute or delayed effects on the 
levels of a number of endocrine variables including growth hormone, luteinizing 
hormone (LH), testosterone, cortisol, follicular stimulating hormone and thyroxine 
even after repeated daily administration for up to one month (Lissoni et al, 1986; 
Wright et al, 1986; Waldhauser et al, 1987; Mallo et al, 1988; Petterborg et al, 
1991; Terzolo et al, 1993), although in one report melatonin acutely amplified LH 
pulses in women when given in the morning (Cagnacci et al, 1991). Slight changes 
in prolactin levels may occur but only at certain times of day (Lissoni et al, 1986; 
Wright et al, 1986; Waldhauser et al, 1987; Mallo et al, 1988; Terzolo et al, 
1993). In much higher doses over longer periods (300mg/day for 4 months), 
melatonin has been shown to reduce levels of luteinizing hormone in women. This 
preparation in combination with a progestin is undergoing clinical trials as a 
contraceptive (Voordouw et al, 1992). 
Cortisol and melatonin secretion are thought to be inversely correlated 
(Wetterberg et al, 1982). The masked rhythms are, however, readily dissociated 
under phase-shifted conditions (Fevre-Montange et al, 1981). Although melatonin 
administration to humans may facilitate the reentrainment of cortisol rhythms after a 
time zone change (Arendt et al, 1987), in other situations exogenous melatonin will 
shift the phase of its own rhythm but not the cortisol rhythm (Wright et al, 1986; 
Mallo et al, 1988; Zaidan et al, 1994). It is not surprising that circadian rhythms 
show a close correlation to each other under entrained conditions. However, a causal 
effect is not supported. 
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1.10 ACUTE EFFECTS OF MELATONIN AND BRIGHT LIGHT 
1.10.1 Sedative effects of melatonin 
Reports of the `hypnotic' effects of melatonin in humans have been 
inconsistent. Daytime administration of melatonin given orally, intravenously or 
intranasally in doses of 0.3mg to 240mg has been shown to increase drowsiness, 
reduce performance and advance sleep onset time (Cramer et al, 1974; Vollrath et al, 
1981; Arendt et al, 1984; Lieberman et al, 1984; Waldhauser et al, 1990; Dollins et 
al, 1993,1994). Using objective measurements of sleep (polysomnography), Anton- 
Tay (1974) reported significant changes in sleep structure with increased REM density 
and stage 2 sleep after morning administration of lg melatonin for 6 days. Nickelsen 
et al (1989) reported increased drowsiness in the morning (0900h) but not in the 
evening (1900h), after an oral dose of 50mg, whereas Arendt et al (1984,1985a) 
demonstrated that subjective evening fatigue only increased significantly after 4 days 
with 2mg melatonin daily at 1700h. James et al (1987) after late evening (2300h) 
treatment of lmg and 5mg melatonin found an increased REM latency with 5mg only, 
but the sleep onset and duration were not affected by either treatment. No changes 
in sleep structure were identified after 50mg of intravenous melatonin administered 
just before bedtime even though psychomotor activity was reduced and latency to 
sleep shortened (Cramer et al, 1974). 
In summary, there are no clear effects of supra-physiological levels of 
melatonin on human sleep architecture when measured objectively. It is only in 
conditions of circadian rhythm disturbance that melatonin seems to consistently 
81 
improve sleep quality and adjust the sleep/wake cycle when administered close to the 
desired bedtime, see sections 1.7 and 1.8. Whether this improvement in sleep by 
melatonin is via sleep inducing/initiating processes and/or circadian mechanisms is 
still unclear. It is interesting to note that giving melatonin in doses sufficient to 
entrain the motor activity rhythms in the rat, no changes in sleep EEG measurements 
have been observed (Tobler et al, 1994). 
1.10.2 Arousal/stimulating effects of bright light 
In addition to an effect on the circadian system, bright light (z 1000 lux) can 
directly and acutely enhance alertness and performance during the night (Campbell 
and Dawson, 1990; Czeisler et at, 1990; Badia et at, 1991; Dawson and Campbell, 
1991; Hannon et at, 1992) and in the early morning (Clodore et at, 1990), although 
it must be noted that in one study, Dollins et at (1993) reported no stimulatory effect 
on alertness and performance with light exposure at night. True physiological arousal 
with bright light exposure at night has been associated with changes in waking EEG, 
but only during the treatment. Badia et at (1991) demonstrated increased beta activity 
associated with increased light intensity which was considered to be a reflection of 
the stimulating effects of bright light. 
The effects of bright light exposure on normal nocturnal sleep are less clear. 
In some cases, bright light had no effect on sleep latency (Drennan et at, 1989; 
Bunnell et at, 1992), whereas one study demonstrated increased difficulties in 
initiating sleep after bright light (Dijk et at, 1991). In the latter study, longer sleep 
latencies were associated with elevated body temperature rather than alterations in 
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brain electrical activity. 
The mechanism of action of the acute effects of bright light remains unknown. 
However, it has been suggested that the arousal effects may be mediated via 
melatonin and its thermoregulatory effect on temperature (Badia et al, 1993). 
1.10.3 Stimulating effect of bright light on body temperature 
Further evidence of true physiological arousal with bright light exposure has 
been demonstrated with increases in body temperature. It has been shown that, under 
sleep deprivation conditions, nighttime administration of bright light of z 2500 lux 
versus dim light of <_ 50 lux increased tympanic temperature (Badia et al, 1990a, 
1990b, 1991; Murphy et al, 1991; Myers and Badia, 1991); administration of bright 
light versus dim light during the day showed no difference (Murphy et al, 1991; 
French et al, 1990). In addition, Dijk et al (1991) showed that after a single 3h 
exposure of bright and dim light (- 2500 lux) before bedtime, core body temperature 
was elevated and remained raised for the initial 4h of sleep after the bright light 
treatment. A dose-response curve for the effects of light intensity on tympanic 
temperature has been established by Myers and Badia (1993). Body temperature 
increases were associated with increasing light intensity but this effect was only 
apparent after 2100h, which is the approximate time of the onset of melatonin 
secretion in plasma (Lewy et al, 1989). 
These acute effects of bright light on temperature are only clear during the 
nighttime or darkness hours when bright light has a suppressive effect on melatonin, 
suggesting that melatonin may mediate this temperature elevating effect. 
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1.10.4 Acute effects of exogenous melatonin on temperature 
There is a consistent inverse relationship between the endogenous melatonin 
and core body temperature rhythms under normal (Cagnacci et al, 1992), free-running 
and non-24h environments (Wever, 1989) which is independent of the sleep/wake 
cycle (Akerstedt et al, 1979, Cagnacci et al, 1992). 
Melatonin's acute hypothermic properties have been reported in a number of 
studies (Carman et al, 1976; Cagnacci et al, 1992; Dawson and Encel, 1993; Dollins 
et al, 1994). Suppression of endogenous melatonin levels with the B-adrenergic 
antagonist atenolol, attenuated the night time fall in body temperature and reduced the 
amplitude by about 40%, suggesting that endogenous melatonin is directly responsible 
for at least 40% of the body temperature rhythm (Cagnacci et al, 1992). In addition, 
a divided dose of 1.75mg oral melatonin given in the evening completely inhibited 
the stimulatory effect of late evening light treatment on body temperature (Cagnacci 
et al, 1993). 
Strassman et al (1991) have confirmed melatonin's role in the bright light 
stimulation of body temperature using a melatonin infusion paradigm (Strassman et 
al, 1987) during bright light suppression of endogenous melatonin. Exogenous 
melatonin, infused to reproduce an approximate physiological profile, reversed the 
bright light-induced elevation of body temperature. 
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1.11 POTENTIAL PHARMACOLOGIC AND BEHAVIOURAL TREATMENT 
STRATEGIES FOR CIRCADIAN RHYTHM DISTURBANCES 
1.11.1 Manipulation of the sleep/wake cycle 
One way of speeding up the readaptation of the circadian system to large 
phase-shifts could simply involve manipulating the sleep/wake cycle. The principal 
is to split the phase-shift over a number of days (Samel et al, 1994). For example, 
to achieve a 9h advance phase-shift, the sleep/wake schedule can be advanced by 5 
hours one day and then a further 4 hours the following day. This system prevents the 
"antidromic" effect where subjects adapt to the new local time cues by delaying 
instead of advancing, thereby shortening the time taken to adjust completely (Samel 
et al, 1994). 
1.11.2 Melatonin agonists and antagonists 
New melatonin analogues have recently been developed. Hopefully these will 
help to elucidate the function and mechanisms through which melatonin exerts its 
effects on body physiology and in particular the circadian system. 
In vitro studies have shown that Luzindole (2-benzyl-N-acetyltryptamine) 
inhibits the activation of melatonin receptors and may provide a appropriate 
pharmacological melatonin antagonist for studying the physiological role of melatonin 
(Dubocovich, 1988). Kennaway et al (1989) demonstrated that the melatonin agonist, 
6-chloromelatonin, promoted the synchronization of the urinary 6-sulphatoxymelatonin 
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rhythm after an 8h shift of the light/dark cycle. Recently the amino acid sequence 
of the melatonin receptor has been determined thus enabling the development of 
melatonin agonists and antagonists with specific structural relationship to the 
melatonin receptor (Ebisawa et al, 1994). Development of newer analogues has 
resulted in the formation of napthalene bioisosteres with high affinity and specific 
binding to melatonin receptor sites in the pars tuberalis (Yous et al, 1992; Howell et 
al, 1991). 
One such compound, S-20098 (N [2-(7-methoxy-l-naphthyl) ethyl] amide), has 
been shown to facilitate the reentrainment of rat locomotor activity rhythms when 
free-running or after an 8h advance shift of the light/dark cycle (Bonnefond et al, 
1993; Redman and Guardiola-Lemaitre, 1993). In a rat model for delayed sleep- 
phase syndrome, S20098 proved effective in advancing delayed activity rhythms, 
resetting to them to darkness onset (Armstrong et al, 1993). In vivo studies have 
shown S-20098 to mimic the effects of melatonin in phase-shifting the rhythm of 
neural activity of the rat SCN (Mason et al, 1993). Another related melatonin agonist 
S-20242 can prevent the age-associated reduction in temperature rhythm amplitude 
and stability in rats (Koster-van Hoffen et al, 1993). 
In humans, doses of up to 800mg of S-20098 have been well tolerated with 
one subject experiencing tachycardia and slight hypotension at 1200 mg (Van Reeth 
et al, 1994). Morning administration of S-20098 has shown similar hypothermic 
effects to melatonin but at higher doses (Van Reeth et al, 1994). 
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1.11.3 Physical activity and hypnotics 
In the normal environment, multiple zeitgebers probably act to entrain the 
circadian system and when suitably timed may prove useful in resetting the circadian 
system after an abrupt shift, or in clinical disorders. In animals, arousal and activity 
act as strong zeitgebers. Periods of physical activity and arousal have been shown 
to entrain and phase-shift rodent activity rhythms (Mrosovsky and Salmon, 1987; 
Reebs and Mrosovsky, 1989; Wickland and Turek, 1991; Hastings et al, 1992). 
Recently, the acute phase-shifting effects of single timed pulses of physical activity 
at night on the human circadian system have been reported (Van Reeth et al, 1994). 
A 3h pulse of exercise prior to the temperature minimum phase-delayed the melatonin 
rhythm by 1-2h one day after exercise exposure. Smaller delays were induced after 
the temperature minimum. 
Benzodiazepines used in the treatment of insomnia, anxiety and other stress- 
related problems can induce phase-shifts in rodent activity rhythms (Turek and Losee- 
Olsen, 1986). However, this ability is associated with an increase in activity after 
administration since restraining hamsters can prevent triazolam-induced phase-shifts 
(Van Reeth and Turek, 1989). How increased arousal transducer information into 
phase-shifting signals is unknown but is thought to involve the intergeniculate leaflet 
of the hypothalamus (Johnson et al, 1988). Connections from here to the SCN 
contain the neurotransmitter neuropeptide Y (Moore and Speh, 1993) which has been 
shown to phase-shift the neuronal activity in the rat SCN (Medanic and Gillette, 
1992). There is also serotonergic input from the raphe nuclei to the IGL and the 
SCN which may modulate the phase-shifting response of non-photic zeitgebers 
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(Prosser et al, 1990; Smale et al, 1990). 5-HT agonists can phase-shift the clock in 
vitro and in vivo similar to those shown by triazolam and other non-photic stimuli 
(Prosser et al, 1990; Tominaga et al, 1992). 
In humans, benzodiazepines facilitate sleep adaptation after transmeridian 
flight, but not the rate of adjustment of the endogenous body clock (Nicholson et al, 
1985; Donaldson and Kennaway, 1991). Hypnotics are commonly used to facilitate 
sleep and in shift work studies they facilitate sleep during the day and may improve 
alertness and performance during the night shift in some people (Bonnet et al, 1988; 
Walsh et al, 1991). They may indirectly affect the circadian pacemaker by imposing 
a more regimented sleep/wake and therefore light/dark cycle. 
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1.12 RESEARCH PROPOSAL AND AIMS OF THESIS 
Field studies on jet lag are expensive and difficult to control with the 
collection of biochemical data an obvious problem. Laboratory simulations provide 
a more controlled setting with which to study these disorders in detail. However, 
previous simulations have involved complete isolation from the subjects normal 
environment. The primary aim of this work was to develop an experimental model 
to simulate circadian rhythm disorders such as jet lag and maladaptation to shift work 
without complete environmental isolation and to study melatonin and bright light as 
potential treatment strategies. 
However, in developing such models, it is important to use a physiological or 
behavioural rhythm marker that gives an accurate reflection of the behaviour of the 
endogenous biological clock. Overt (measured) circadian rhythms are subject to 
behavioural and environmental masking influences such as light, sleep, activity, stress 
and meals, and can result in the unreliable estimation of the circadian time of the 
internal biological clock. Compared to other circadian rhythm markers melatonin is 
less susceptible to exogenous masking influences other than light, and is extensively 
used to assess circadian rhythm status. Thus any factors influencing its concentration 
other than endogenous rhythmicity must be assessed. Changing posture influences 
the levels of a number components in the blood. If melatonin appears to be 
influenced by a change in posture then it must be controlled for when designing 
studies. The effects of changing posture on melatonin concentrations in plasma and 
saliva were therefore assessed. 
One method of separating these masking effects from the endogenous profile 
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of the temperature rhythm is a mathetical "purification" procedure developed by 
Minors and Waterhouse (1988,1992). This procedure was used to "purify" the 
temperature data after a simulated rapid time zone (in collaboration with Drs. 
Waterhouse and Minors, University of Manchester, UK) to give a more reliable 
estimation of the endogenous behaviour of the body clock. The problem of masking 
and the usefulness and assumptions of such a procedure are discussed with reference 
to the experiment. 
Due to the difficulties in measuring the melatonin secretory rhythm in the 
blood, non-invasive techniques have been employed to measure the melatonin rhythm 
in saliva and its urinary metabolite rhythm in the urine. However, the relationship 
between melatonin in the blood, melatonin in saliva and its urinary metabolite under 
different conditions must be firmly established. Since most of the following 
experiments involve a phase-shift, the relationship between melatonin rhythm 
parameters in different mediums were evaluated under normal and phase-shifted 
conditions. 
Light and melatonin therapy to treat jet lag can be timed to induce phase- 
advances or phase-delays, and their respective PRCs mirror each other to some 
extent, i. e. they act in opposite directions. Combined treatments have not yet been 
studied. In real life, natural light exposure may occur at inappropriate times for the 
most expeditious reentrainment of circadian rhythms and oppose the effects of 
melatonin treatment. So, after an abrupt phase-shift in local time cues, the beneficial 
effects of suitably timed melatonin treatment were studied in the presence of bright 
light exposure timed to oppose the phase-shifting effects of melatonin. 
Finally, a group of studies were carried out to elucidate the mechanisms 
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through which melatonin may exert its beneficial effects on jet lag and other circadian 
rhythm disorders. 
Experimental treatment for jet lag has commonly involved repeated daily 
administration of melatonin at the same time of day to facilitate the reentrainment of 
circadian rhythms, but little is known about the phase-shifting effects of single 
melatonin treatments. In addition to these circadian effects, melatonin also causes 
immediate effects on body temperature and behaviour after acute administration. It 
is possible that these effects of melatonin are related. In an attempt to study any 
relationship between these phenomena, the effectiveness of a single 5mg melatonin 
treatment -a dose commonly used to treat circadian rhythm disorders - to phase-shift 
the endogenous clock was compared to its acute effects on temperature and behaviour. 
It has been demonstrated that zeitgeber strength - at least with regards to light 
- is important in entraining and phase-shifting circadian rhythms. A human dose- 
response phase-shifting effect of melatonin has not been demonstrated but would help 
to determine optimum doses of melatonin needed to treat jet lag and other circadian 
rhythm disorders. The phase-shifting effects of single, low oral doses of melatonin 
were studied and compared to their immediate effects on body temperature and 
behaviour. 
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CHAPTER 2 
CLINICAL CONSIDERATIONS PRIOR TO STUDIES. 
PHYSIOLOGICAL AND BEHAVIOURAL MEASUREMENTS 
AND ANALYSIS 
Clinical considerations prior to studies. 
Physiological and behavioural measurements and analysis 
2.1 CLINICAL TRIALS: general conditions 
2.1.1 Subject criteria 
The subjects for these trials were healthy volunteers under no medication 
except for minor analgesics and oral contraceptives, except for the studies described 
in Chapters 9 and 10. In the latter studies, aspirin-based analgesics and females 
taking oral contraceptives were excluded because of their possible influence on body 
temperature. Ingestion of any drug throughout the trials was noted. 
Further exclusion criteria were as follows: 
1) Subjects who had either undertaken a transmeridian flight or night shift work 
within one month of the commencement of the trial. 
2) Subjects who normally consumed more than two units of alcohol per day. 
3) Knowledge or suspicion of pregnancy. 
4) Familial or personal history of psychiatric disorders, migraine, epilepsy, sleep 
disorders or food allergies. 
5) Heavy smokers (> 10 per day). 
6) Subjects who had donated blood within the preceding 3 months. 
All subjects gave informed consent and the study protocols were approved by 
the Advisory Committee on Ethics of the University of Surrey. In addition, in studies 
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where blood sampling was necessary, subjects read and signed the University of 
Surrey's consent form for the donation of blood for teaching or research. 
2.1.2 Details of the melatonin preparation 
The melatonin used in all studies is licensed by the FDA for experimental use 
in normal human volunteers (M5250 FD). A clinical trials exemption certificate is 
held by Prof. J. Arendt (University of Surrey, UK) under who's supervision these 
trials were conducted. It is chemically synthesised and supplied by Sigma Chemicals 
Co. Ltd. (Poole, Dorset, UK., product no. W 5318-3). It is used either as a gelatine- 
lactose capsule, prepared by Penn Pharmaceuticals Ltd. (Gwent, Wales), with quality 
control at the University of Surrey, or as specified in the relevant chapters. 
Possible side-effects of melatonin 
Melatonin has been administered orally (2-10mg) in a number of studies with 
minimal side-effects (Arendt et al, 1987; Arendt and Aldhous, 1988, Wright et al, 
1986, Samel et al, 1991; Jan et al, 1994). Table 2.1 shows the percentage number 
of people who suffered from a particular side-effect as a result of taking melatonin 
(5mg) for the alleviation of jet lag in field studies carried out by Prof. J. Arendt 
(University of Surrey, UK). 
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Table 2.1 Percent side effects reported more than once after taking 5mg melatonin 
to alleviate jet lag (from 1984 to Nov. 1994) 
Side-effect Placebo (n = 112) Melatonin (n=484) 
Sleepiness 1.78 8.3 
Headache 2.7 1.65 
Nausea 0.9 0.8 
Dizziness 0 1.4 
2.1.3 Health and safety effects of light 
Moderately bright, full spectrum light up to a maximum of 2000 lux at eye 
level was used in these experiments. The source of light consisted of a light box with 
6-8 light tubes made by True-Lite, Duro-Test Corporation, Fairfield, NJ, USA, 
obtained through Full Spectrum Lighting, High Wycombe, Buckinghamshire, UK. 
The intensities of light used were much less than that experienced on a bright sunny 
day (up to 100 000 lux, Thorington, 1985). Normal artificial room intensity lighting 
at eye level ranges from 50-600 lux. Full spectrum light (2500 lux for up to 6 hours) 
is used clinically to treat seasonal affective disorder (Terman et al, 1990; Terman and 
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Terman, 1990). To date, no problems have been reported even'the use of relatively 
high intensity light (10 000 lux) full spectrum light (Terman and Terman, 1990; 
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Goodwin, 1992). 
The levels of UV light from conventional fluorescent lamps and the light boxes 
used are extremely low and not thought to be detrimental to health (Whillock et al, 
1988). The trend towards the use of brighter high efficiency sources suggests that 
phototherapy lamps are unlikely to have any adverse effects on health and may even 
be advantageous. 
2.2 COLLECTION AND STORAGE OF SAMPLES 
Plasma: Blood samples were collected into lithium heparin tubes and centrifuged 
for 15 minutes at 3000g. The plasma was separated carefully within 25 minutes of 
collection, and stored at -20°C until analysis. 
Saliva: Saliva samples were collected into plastic vials. In some studies saliva 
was collected with stimulation by chewing for 2 minutes on parafilm. The method 
of collection was constant within each study. There is a possibility that stimulation 
may affect salivary melatonin levels through altering salivary flow rates. However, 
no significant differences in the ratio between melatonin levels in plasma and saliva 
have been observed with and without stimulation of flow rate by chewing gum or 
parafilm (McIntyre et al, 1987; Miles, 1989). 
Caffeine and smoking were excluded during saliva sampling due to 
interference with the assay. All samples were checked for the presence of blood and 
food which may have contributed to high salivary melatonin levels in other studies 
(McIntyre et at, 1987; Miles, 1989). Samples were stored at -20°C until analysis. 
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After thawing, if any samples contained visible particulate matter they were 
centrifuged before assay. 
Urine: Urine volumes were recorded on collection and a 5m1 aliquot placed 
in a plastic vial and stored at -20°C until analysis. aMT6s has been found to be very 
stable in urine for up to 5 days at room temperature or 4°C and for up to 2 years at - 
20°C either with or without preservative (Bojkowski, 1988). 
2.3 RADIOIMMUNOASSAY OF MELATONIN AND aMT6s 
2.3.1 Basic principle and summary of procedure 
The sample is incubated with a fixed amount of antiserum specific to the 
melatonin/aMT6s (antigen) together with trace amounts of radioactive 
melatonin/aMT6s (labelled antigen) which competes with the non-radioactive antigen 
for the limited number of antibody binding sites. Since the number of antibody 
binding sites and the amount of radioactive melatonin/aMT6s is constant, the amount 
of radioactivity associated with the antibody is dependent upon the concentration of 
melatonin/aMT6s (antigen) in the sample. When equilibrium is established, the free 
and antibody-bound fractions of melatonin/aMT6s are separated either by charcoal 
adsorption of free antigen or with a second precipitating antibody system. 
The melatonin/aMT6s concentration in unknown samples can be determined 
by comparing the amount of radioactivity measured in either the bound or the free 
fraction to that obtained with a set standards of known concentration. 
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2.3.2 RIA of melatonin in human plasma 
Plasma melatonin levels were determined by direct RIA using the method 
described by Fraser et al (1983) which is used routinely in our laboratory. 
Materials: Antiserum (product no. AB/S/02 or AB/S/021) and melatonin-free 
plasma (product no. LMHP1), were obtained from Stockgrand Ltd., University of 
Surrey, UK. 3H-melatonin (product no. TRK-798) was purchased from Amersham 
International (Amersham, Buckinghamshire, UK). 2,5-diphenyloxazole (PPO) and 
1,4-bis-[2-(5-phenyloxazolyl)]benzene (POPOP, low sulphur grade) were obtained 
from Fisons (UK). All other chemicals including melatonin (product no. M-5250) 
were obtained from Sigma Chemical Co. Ltd. (Poole, Dorset, UK). 
Reagents 
Buffer. All dilutions were made in buffer made freshly every week. This 
consisted of tricine (0.1 mol/1), 0.9% NaCl and 0.1% gelatin made up in double- 
glass-distilled water (DGDW) to give a stock solution at pH 5.5. In order to dissolve 
the gelatin, the buffer was heated to 50°C for 30 minutes. 
Antiserum: The antiserum was supplied freeze-dried and was reconstituted with 
2m1 of DGDW to provide an intermediate dilution of 1: 10. It was then divided into 
50µ1 aliquots and stored frozen at -20°C. Diluting one 501A1 aliquot to 20m1 with 
tricine buffer provides enough antiserum for 100 tubes with a dilution of 1: 4000. 
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Dextran-coated charcoal: Norit activated charcoal (2 %) was suspended in tricine 
buffer for 5 minutes. After centrifugation at 4°C at 1000rpm, the supernatant and any 
fines around the sides of the vessel were discarded. The charcoal was resuspended 
in the original volume of tricine buffer and then stirred with 0.02 % Dextran T70 for 
at least lh at 4°C, before storing at 4°C. The suspension was freshly made each 
week. 
Radiolabel: An intermediate dilution of the stock 3H-melatonin was prepared by 
diluting 20µl to 2m1 in absolute ethanol and storing at -20°C. A working solution was 
freshly prepared by further diluting with tricine buffer to give approximately 5000cpm 
in 1O0µ1. 
Scintillation fluid: The toluene-based scintillant was prepared by adding 12.5g PPO 
and 0.75g POPOP to 2.5 litres of toluene. 
Melatonin standards: A stock melatonin standard was prepared every 3 months 
by dissolving 10mg melatonin in 0.5m1 absolute ethanol. This was made up to lOml 
with DGDW to give a concentration of 1 mg/ml and stored at 4°C. The working 
standard was freshly made for each assay from this stock solution as follows: 
100µ1 of 1mg/ml solution to 100ml in DGDW to give 1µg/ml 
500141 of 1µg/ml solution to 50m1 in DGDW to give lOng/ml 
125µl of lOng/ml solution to 2.5m1 in melatonin-free plasma to give 0.5ng/ml. 
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Standards covering the range 2.5 to 250 pg/ml for the standard curve were prepared 
with further dilutions in melatonin-free plasma as follows: 
Melatonin standard Melatonin-free Melatonin conc. 
0.5ng/ml (µ1) plasma (µl) pg/0.5m1 
500 0 
5 495 2.5 
10 490 5.0 
25 475 12.5 
50 450 25.0 
100 400 50.0 
200 300 100 
500 - 250 
Duplicate tubes were prepared for all samples, standards, non-specific binding tubes, 
quality control samples. Total counts tubes were prepared in quadruplicate. 
Procedure 
Plasma samples, melatonin standards and quality control samples in 500µ1 
aliquots were mixed with 200µ1 antiserum then incubated for 30 minutes at room 
temperature. 100µl 3H-melatonin were then added, mixed again and the assay 
incubated for 18h at 4°C. The antibody-bound melatonin was separated from the free 
fraction by mixing with 5001A1 of dextran-coated charcoal then incubating for 15 
minutes at 4°C. The charcoal was continuously stirred for 30 minutes prior to 
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addition to make sure it was suspended properly in the buffer. Rapid addition of the 
charcoal to all assay tubes was necessary to reduce intra-assay variation. After 15 
minutes, the assay tubes were centrifuged at 1500g for 15 minutes at 4°C. 7O0µ1 of 
the supernatant were transferred into vials containing 4m1 of scintillation fluid. The 
vials were then shaken for lh in order to extract all the 3H-melatonin into the organic 
phase to provide an appropriate medium for radioactivity detection without quenching. 
Radioactivity in the tubes were counted in a suitable B-counter and the sample 
concentrations calculated using a'RIAcalc' program. 
The RIAcalc program automatically determines the percentage of total counts 
bound or free, and then plots them as a function of the known concentrations of 
melatonin standards. A curve is fitted through the standard points based on the 
smoothing spline calculation method. This fits a continuous curve to each pair of 
standard points using the conventional method of least squares, but in addition, it 
calculates the best-fitting curve with the minimum number of turning points and is as 
smooth as possible. The concentration of the unknown samples are then determined 
from this curve. 
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2.3.3 RIA of melatonin in human saliva 
Salivary melatonin levels were determined using a modification (English et al, 
1993) of the direct RIA using the method described by Fraser et al (1983), and used 
routinely in our laboratory. 
Materials: Antiserum (product no. AB/R/03) was obtained from Stockgrand Ltd., 
University of Surrey, UK. The separation system SAC-CEL (a solid-phase, second 
antibody [donkey anti-rabbit] coated cellulose suspension) was purchased from IDS, 
Bolden, Tyne & Wear, UK). 125I-2-iodomelatonin was purchased from Amersham 
International (Amersham, Buckinghamshire, UK). All other chemicals including 
melatonin (product no. M-5250) were obtained from Sigma Chemical Co. Ltd. 
(Poole, Dorset, UK). 
Reagents 
Bq er: as described in 2.1.1 except that 0.2 % gelatine was used and the buffer was 
adjusted to pH 8 with 1M NaOH. 
Antiserum: The antiserum was supplied freeze-dried (133µl of a 1: 10 dilution) and 
was reconstituted with 2m1 DGDW to provide an intermediate dilution of 1: 150.5O1&1 
aliquots were stored at -20°C. Diluting one 501A1 aliquot to lOml with tricine buffer 
provided enough antiserum for 100 tubes with a dilution of 1: 30 000. 
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Separation system: A solid phase second antibody coated cellulose suspension, 
SAC-CEL, was used as supplied. 
Radiolabel: "I-2-iodomelatonin was diluted in buffer to give approximately 10 000 
cpm in l00µ1. 
Melatonin standards: The stock solution was prepared as described in section 2.1.2. 
The working solution was freshly prepared as follows: 
10011 of lmg/ml melatonin solution to 100ml in DGDW to give 1µg/ml 
5O01A1 of 1µg/ml melatonin solution to 50m1 in DGDW to give lOng/ml 
5O1A1 of long/ml melatonin solution to 2.5m1 in buffer to give 0.2ng/ml 
Standards covering the range 2 to 200 pg/ml for the standard curve were prepared 
with further dilutions in buffer as follows: 
Melatonin standard Assay buffer Melatonin conc. 
0.2ng/ml (µl) (µl) pg/ml 
500 0 
5 495 2 
10 490 4 
25 475 10 
50 450 20 
125 375 50 
250 250 100 
500 - 200 
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Duplicate tubes were prepared for all samples, standards, non-specific binding 
tubes, quality control samples. Total counts tubes were prepared in quadruplicate. 
Procedure 
Saliva samples, quality controls and standards in 500141 aliquots were incubated 
with 100141 antiserum at room temperature for 30 minutes. 100µl of '25 I-2- 
iodomelatonin were added and the assay was incubated at room temperature for 4h. 
The antibody-bound melatonin and free fractions were separated using 100/41 of SAC- 
CEL. After addition, the assay was intermittently mixed for lh at room temperature, 
centrifuged at 1500g for 10 minutes at 20°C and the suspension discarded. 
Radioactivity of the remaining pellet was measured in a gamma counter and the 
sample concentrations read from the standard curve using a `RIACa1c' program. 
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2.3.4 RIA of 6-sulphatoxymelatonin in human urine 
6-sulphatoxymelatonin (aMT6s) levels were determined using the method 
described by Aldhous and Arendt et al (1988), and used routinely in our laboratory. 
Materials 
Antiserum (product no. AB/S/04), 'I-aMT6s, charcoal-stripped (aMT6s-free) 
urine and aMT6s standard were obtained from Stockgrand Ltd., University of Surrey, 
UK. All other chemicals were obtained from Sigma Chemical Co. Ltd. (Poole, 
Dorset, UK). 
Reagents 
Buffer. - as described in 2.1.1 . 
Dextran-coated charcoal: as described in 2.1.1 
Antiserum: The antiserum was supplied freeze-dried and was reconstituted with 
1ml DGDW and 9m1 of buffer added to provide an intermediate dilution of 1: 100. 
100µl aliquots were stored at -20°C. Diluting one 50µl aliquot to 20m1 with tricine 
buffer provided enough antiserum for 100 tubes with a dilution of 1: 20 000. 
Radiolabel: `I-aMT6s was diluted in buffer to give approximately 8000 to 10 000 
cpm per l00µ1. 
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Charcoal-stripped urine: This was supplied freeze-dried (1O01A1 per vial) and was 
reconstituted with 25m1 buffer to give a dilution of 1: 250. 
aMT6s standards: The stock was supplied as 200pg/ml diluted in 1: 250 with charcoal- 
stripped plasma. Standards covering the range 2 to 50 ng/ml for the standard curve 
were prepared with further dilutions in buffer as follows: 
aMT6s standard aMT6s-free urine aMT6s conc. 
200pg/ml(µ1) 1: 250 dilution (µl) ng/ml 
500 0 
5 495 0.5 
10 490 1 
20 480 2 
40 460 4 
70 430 7 
100 400 10 
200 300 20 
500 - 50 
Duplicate tubes were prepared for all samples, standards, non-specific binding 
tubes, quality control samples. Total counts tubes were prepared in quadruplicate. 
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Procedure 
Urine samples were diluted 1: 250 with buffer prior to the assay. Urine 
samples, quality controls and standards in 500141 aliquots were incubated with 200µ1 
antiserum at room temperature for 30 minutes. 100µ1 of ' I-aMT6s were then added, 
mixed again and the assay incubated for 15-18h at 4°C. The antibody-bound aMT6s 
was separated from the free fraction by mixing with l00141 of dextran-coated charcoal 
then incubating for 15 minutes at 4°C. The charcoal was continuously stirred for 30 
minutes prior to addition to make sure it was suspended properly in the buffer. Rapid 
addition of the charcoal to all assay tubes was necessary to reduce intra-assay 
variation. After 15 minutes, the assay tubes were centrifuged at 3500g for 15 
minutes at 4°C and the supernatant immediately discarded. Radioactivity of the non- 
antibody-bound fraction in the charcoal pellet was counted in a suitable gamma 
counter and the sample concentrations calculated using a' RlAcalc' program. 
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2.4 LIGHT INTENSITY MEASUREMENT 
Light intensity was measured using a handheld digital light meter obtained 
from Full Spectrum Lighting, High Wycombe, Buckinghamshire, UK. Measurements 
were taken at eye level directly in front of the eyes towards the light source and other 
fields of view likely to be used by the subjects (i. e. towards computer screen, 
television, etc. ). 
2.5 CORE BODY TEMPERATURE 
Core body temperature was recorded every 6 minutes using rectal probes and 
Squirrel Minilogger recording devices (Grant Instruments, Cambridge, UK). Subjects 
wore rectal probes and recording devices continuously except during 
defecation/showering/bathing when necessary. Perception of the probe decreased 
after one day. 
2.6 ACTIVITY DIARIES 
Subjects were required to record their activity in a diary during each day of 
the study (certain experiments only). The day was divided into half-hourly intervals 
and subjects ticked the appropriate box if they: 
1) consumed any food/drink (identifying a meal as opposed to a snack) 
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2) exercised (anything more intensive than walking) 
3) relaxed (rested) 
4) were stressed 
5) any drug ingestion and alcohol 
6) removed the temperature probe 
7) were sedentary whilst working 
8) were showering 
within the half-hour. 
These diaries were necessary to determine reasons for missing or erroneous 
values in the raw data and to assess subject conformity. In addition, they enabled 
exogenous influences (e. g. exercise and stress) which affect body temperature to be 
mathematically removed to give a more accurate profile of the endogenous 
temperature rhythm, see Chapter 7. 
2.7 BEHAVIOURAL MEASUREMENTS 
All behavioural assessments were performed using handheld computers, Psion 
Organisers (Psion UK, Greenford, UK). Programs for the Psions were written and 
kindly provided by Dr P. Totterdell (University of Sheffield, UK) and Professor S. 
Folkard (University of Swansea, UK) who have used this method of recording 
behavioural parameters extensively (Totterdell and Folkard, 1992). 
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2.7.1 Mood and sleep quality ratings 
Subjective alertness was rated on a visual analogue scale as follows: 
Very drowsy Very alert 
The extreme right end of the line represented the most alert a subject ever felt, and 
the extreme left end of the scale the most drowsy that they ever felt. In a similar 
fashion subjective cheerfulness (Very sad ý--- Very happy), calmness (Very calm 
ý----º Very tense) and sleep quality (Very poor ý--ý Very good) were rated. 
Since these ratings were purely subjective and depended to a great degree on 
how individuals interpreted these scales, subjects were used as their own controls. 
2.7.2. Sleep logs 
Subjects completed sleep logs daily on waking and recorded: 
1) time of retiring to bed, 2) time of trying to sleep, 3) how long it took to fall 
asleep, 4) number of night awakenings, 5) the total duration of night awakenings, 
6) time of waking and 7) time of getting up. Sleep quality was rated on a VAS as 
described above. The sleep logs and sleep quality scales used were originally 
developed by Prof. A. Borb6ly (University of Zurich, Switzerland). 
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2.7.3 Performance measurements: Search and memory (SAM) tests 
Subjects were required to memorise either one (SAM-1) or five (SAM-5) 
letters of the alphabet after which they were shown two lines of alphabetic characters. 
Every time a memorised letter was recognised they pressed a key on the computer. 
Subjects performed these tasks as quickly as possible whilst keeping their performance 
as accurate as possible. For example, when required to identify the letters RKTL 
Z in the following sequence of letters: 
GHjJVSYPRVBMFGBHJM 
FGDWZXCFWGLVQWQZQWYJH 
the response key would be pressed 8 times (the target letters have been highlighted 
and underlined as an example). 
The performance parameters of accuracy, response time and efficiency were 
determined from the data and were defined as the percentage of correct responses, 
time taken to complete the task and accuracy/square root response time. Since 
performance variables are highly dependent upon the individual, for example some 
people are naturally slow but accurate, others are naturally quick but inaccurate, 
subjects were used as their own controls. Where grouped comparisons were 
necessary all values were taken as a percentage of the individuals own baseline before 
grouping. 
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2.8 COSINOR ANALYSIS 
Circadian rhythms are not only characterized by the period (i. e. the rhythm 
repeats itself about every 24h) but also the shape, amplitude and mean level. The 
studies described in this thesis were concerned with the phase (time) relationship 
between endogenous circadian rhythms and the environmental zeitgebers after induced 
phase-shifts together with the amplitude of the rhythm. The rhythmic parameters can 
be determined using various curve-fitting programs or just through visual inspection 
of the data. However, interpreting the phase or amplitude of the rhythm from a set 
of data can often lead to unreliable estimates, especially where there are difficulties 
in the collection of data. For example, comparing the maximum/minimum values 
from infrequent data points in a 24h profile to identify phase differences from day to 
day can lead to problems associated with using a single possible aberrant value and 
which may not be the actual maximum or minimum point of the rhythm. The 
frequency of sampling is therefore of considerable importance when trying to identify 
the true parameters. In some cases, e. g. urine collection, frequent sampling is 
impractical and integrated samples are obtained over a period of time after 
accumulation in the bladder. This obviously leads to a loss of definition of the 
circadian profile since each sample represents a average of values over the whole 
collection period. However, urine sampling is convenient and practical and provides 
accurate estimates of total 24h excretion. 
One method of estimating the parameters of a rhythm based on all the 
collected sample points is to fit a curve which "best fits" the data. This can provide 
a powerful means of calculating rhythmic parameters with irregular and infrequent 
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sampling points. 
One curve-fitting method known as "cosinor analysis" provides measures of 
all parameters except for the shape of the rhythm which it assumes to be sinusoidal 
in shape (Nelson et al, 1979; Minors and Waterhouse, 1988). The best-fitting cosine 
curve is fitted to the data by the conventional method of least squares. Estimates of 
the amplitude (variation in concentration over time), acrophase (peak time) and mesor 
(mean concentration over time) of the rhythm are provided from the "best-fitting" 
cosine curve. Figure 2.1 illustrates the terms used to describe these circadian rhythm 
parameters. 
Acrophase 
(time of peak) 
Nadir 
(time of minimum) 
Figure 2.1 Parameters of a circadian rhythm 
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A major assumption of cosinor analysis is that the rhythm fits a cosine curve 
even though many rhythmic circadian functions clearly do not. There may also be 
instances where the shape of the rhythm changes such as after time-zone travel or 
workers on alternating night/day shifts. In order to check whether the cosinor- 
derived parameters are valid, two estimates of the "goodness of fit" are determined. 
Firstly, cosinor analysis identifies whether the data are more likely to fit a straight 
line as opposed to a cosine curve. A "significant fit" is set at p<0.05 such that the 
probability that the data will fit a straight line is !. 5%. Secondly, the percentage 
variability in the data accounted for by the cosine curve (% rhythm) is given. A 
100% rhythm would indicate a perfect fit. 
In order to use this method of cosinor analysis, the period of the rhythm must 
be known or assumed. Under entrained conditions where the subject is exposed to 
the normal 24h zeitgebers, the period of the rhythm is expected to be 24h. However, 
by stating a range of periods for the cosinor analysis program, it is possible to 
identify the probable period of the rhythm by identifying the period with the best % 
rhythm and lowest probability of a straight line fit. 
In the following studies, cosinor analysis was used to identify whether a 
particular 24h data set reliably fitted a 24h cosine curve during the baseline or control 
days under normal entrained conditions. Repeated measures ANOVA was used to 
confirm a significant time of day (rhythmic) effect. If significant rhythmicity was 
established by these two measures, all subsequent comparisons were made with 
respect to the control values. An estimate of reentrainment (and reestablishment of 
24h cosinor rhythmicity) were provided by the two estimates of "goodness of fit" 
described above. Comparisons with raw data profiles and ANOVA performed on the 
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raw data were used to confirm the results from cosinor analysis. 
Since for some performance and mood parameters, the number of data points 
collected in one day was small and only obtained during wakefulness, several days' 
data were combined to achieve a more reliable estimate of rhythmic parameters using 
cosinor analysis (Arbogast et al, 1983). 
There are other methods of determining rhythm parameters (see Klemfuss and 
Clompton, 1993 and Refinetti, 1993 for comparison of methods), but few allow the 
phase of the rhythm to be estimated. Cosinor analysis provides an appropriate 
method of determining the phase and amplitude of circadian rhythms (Minors and 
Waterhouse, 1988) and was therefore employed in the studies described in this thesis. 
However, comparison of the cosinor-derived values with raw data were used to 
confirm the results. The cosinor analysis program used was written and kindly 
provided by Dr D. S. Minors (University of Manchester, UK). 
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CHAPTER 3 
INFLUENCE OF POSTURE ON MELATONIN 
CONCENTRATIONS IN PLASMA AND SALIVA 
Influence of Posture on Melatonin Concentrations in Plasma and Saliva 
3.1 INTRODUCTION 
The force of gravity causes significant changes in the human circulatory 
system and with the continual changing of posture in everyday life the influence of 
gravity on various blood parameters becomes apparent. In healthy subjects, when an 
upright position is adopted after lying recumbent (supine), the plasma volume is 
reduced and the concentration of various plasma components, especially that of the 
proteins and of the constituents bound to them, increases. This rise in plasma 
constituent concentration is in the order of 10-20% and the effect is reversible on 
reversing the postural position (Stoker and Wynn, 1966; Husdan et al, 1973; Tan et 
al, 1973; Hagan et al, 1978). 
The pineal hormone melatonin is secreted into the blood in a highly stable and 
reproducible pattern within individuals (Broadway et al, 1987). An important feature 
of its secretion is that, with the exception of light (Lewy et al, 1980; Bojkowski et 
al, 1987a; McIntyre et al, 1989a), it is less susceptible to behavioural and 
environmental masking (disturbing) influences, than other overt (measured) circadian 
rhythms such as core body temperature and cortisol secretion. These latter rhythms 
are masked by factors including sleep, waking, meals and stress (Czeilser et al, 1976; 
English et al, 1982; Chapter 7) and can lead to inaccurate estimates of the circadian 
time of the internal biological clock. For this reason the melatonin circadian rhythm 
is thought to provide an appropriate and reliable marker of the endogenous biological 
horologue under normal conditions, as well as in constant routine and in other 
117 
isolated environments. 
Although melatonin, a lipophilic molecule, easily filters through capillary 
membranes, up to 70% of melatonin may be weakly bound to albumin (Cardinali et 
al, 1972) which is not readily diffusible, and albumin-bound hormones do not pass 
into the surrounding tissues (Riad-Fahmy et al, 1982); the ratio of albumin in plasma 
to saliva is 10,000: 1 (Vining and McGinley, 1984). It is therefore possible that a 
shift in posture may cause a change in plasma melatonin levels. 
Salivary melatonin is thought to reflect closely the changes in plasma 
melatonin levels (Vakkuri, 1985; Miles et al, 1987; McIntyre et al, 1987; Nowak et 
al, 1987), and since saliva is becoming a routine method of determining melatonin 
secretion it is important to consider the effects of posture on salivary melatonin levels 
as well. It is the purpose of this investigation to study the possible masking influence 
of posture on melatonin levels. 
3.2 SUBJECTS and METHODS 
3.2.1 Subjects 
7 healthy volunteers (3M: 4F), aged 24-35 years (26.3 ±4 years, mean f 
SD), one of whom was a smoker, refrained from heavy exercise and drinking 
alcoholic beverages or those containing caffeine for 12 hours prior to and during each 
stage of the study. On each day of the study, the subjects moderated their fluid 
intake to no more than 1.5L daily. 
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3.2.2 Design 
The 4-day study was divided into two periods (stages 1 and 2) of 2 days, 1 
week apart, and was performed in October during the rising phase of the melatonin 
rhythm, between 2100h and 0130h. On all 4 days subjects remained in a sitting 
position from 2100-2400h and under domestic lighting (150-300 lux) from 2100- 
2300h. From 2300-0130h, subjects remained awake under dim light (< 10 lux). 
After this baseline period the treatments were applied within each stage as a 
randomised crossover design. From 2400h the subjects assumed a different postural 
position as follows: 
Stage la: 2400h - standing, 0030h - supine, 0100h - standing, 
Stage lb: 2400h -supine, 0030h - standing, 0100h - supine, 
Stage 2a: 2400-0130h - supine, 
Stage 2b: 2400-0130h - standing. 
Brief, minimal and slow movement was allowed throughout each stage. 
3.2.3 Sampling 
Blood samples (5 mis, collected by dim red torch light, < 10 lux, after 
2300h) and saliva samples (after chewing on parafilm) were taken hourly via an 
indwelling forearm cannula, from 2100-2400h and then every 10 minutes from 2400h 
until 0130h. Only limited water was allowed immediately after saliva sampling, to 
reduce any possible interference with salivary melatonin estimation. Urine was 
collected to determine any differences in aMT6s excretion due to changes in posture. 
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After completely voiding the bladder at 2400h, urine was collected at the end of 90 
minutes in the supine (stage 2a) and standing (stage 2b) positions. 
Samples were collected, stored and analysed as described in section 2.2. The 
interassay coefficients of variation for the plasma assay were 12.4%, 9% and 7.3% 
at 19.4,36.8 and 191 pg/ml (n =10). The interassay coefficients of variation for the 
saliva assay were 16%, 10%, 9% and 6% at 8.7,20,36 and 58 pg/ml (n=8). For 
aMT6s, the interassay coefficients of variation were 16.8%, 11.6% and 5.8% at 2.4, 
14.7 and 31 ng/ml. The minimum level of detection for each assay was 3.8 ± 0.24 
pg/ml, 1.9 ± 0.15 pg/ml and 0.3 ± 0.05 ng/ml (mean ± SEM), respectively. 
3.2.4 Statistical analysis 
All plasma and salivary melatonin values were calculated as a percentage 
change in melatonin levels from the initial point of assuming a different postural 
position. Each subject was used as their own control, in view of the large inter- 
individual differences in melatonin levels (see section 1.3). Since each stage was of 
a random crossover design, any differences between standing and supine positions 
were compared between stage la and b and between stage 2a and b. Area under the 
curve (AUC) analysis followed by Student's paired t-tests (two-tailed) were used to 
identify significant differences between postures. Paired comparisons were also made 
at each 10 minute sampling point between standing and supine using Student's paired 
t-tests (two-tailed). Correlations between plasma and salivary melatonin levels were 
carried out using Pearson's correlation. All values lower than the detection limit of 
the assay were excluded from the calculations. This corresponded to 5% of the 
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plasma melatonin data and 6% of the salivary melatonin data. All values are quoted 
as mean ± SD unless stated otherwise. 
3.3 RESULTS 
All subjects completed stage 1. Four subjects completed stage 2 and one 
further subject completed stage 2a and 60 minutes of stage 2b. No subject reported 
any oral lesion and no blood contamination was observed in the saliva samples. 
However, salivary melatonin was unmeasurable in the one subject who smoked, 
through contamination or interference in the assay, and was discarded from the 
analysis of salivary melatonin. 
Figure 3.1 shows the percentage change in melatonin levels within 30 minute 
periods in alternate postural positions from 2400h. Changing from standing to supine 
and back to standing (stage la), and vice versa when the positions were reversed 
(stage lb), caused marked differences in percentage change of both plasma and 
salivary melatonin levels. AUC analysis identified significant differences between 
standing and supine positions with greater increases associated with the standing 
position (Figure 3.1). Significant changes between postures were observed within 10 
minutes in all three time periods for plasma melatonin, Figure 3.1 A. Differences 
in salivary melatonin levels between standing and supine positions were less 
significant than with plasma, Figure 3.1 B. Table 3.1 shows the mean difference in 
% change between the two postures. 
Figure 3.2 shows the individual profiles for the percentage change in plasma 
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melatonin levels over a 90 minute period between stages 2a and b. Differences 
between standing and supine positions were significant for plasma melatonin only 
(p<0.01) with AUC analysis. The changes in salivary melatonin levels were more 
variable and proved not to be significant, Figure 3.3. 
Good correlation between plasma and salivary melatonin concentrations was 
obtained during hourly sampling (r=0.83, p<0.0001, y= 0.59 [± 0.01]x -2 [± 
1.2]) from 2100-2400h. Although still highly significant, the correlation between the 
two melatonin mediums was not as good during short term sampling (r=0.555, 
p<0.0001, y= 0.23 [± 0.02]x + 5.7 [± 0.9]). Salivary melatonin levels were 
estimated to represent 46.2 ± 18.1 % and 40.4 ± 18.7% during hourly and 10 minute 
sampling, respectively, of the corresponding plasma levels. 
There were no significant differences in aMT6s levels between standing and 
supine positions. After 90 minutes in the standing position, aMT6s levels were 
calculated to be 103 ± 17% of the levels found after an equivalent period lying 
recumbent. 
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Figure 3.1 Immediate effect of posture on plasma and salivary 
melatonin levels in alternate postural positions 
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Percentage change in A. plasma melatonin and B. salivary melatonin levels within 
30 minutes in alternate postural positions from 2400h. Mean +/- SD, plasma: 
n=7, saliva: n=6. * p<0.05, ** p<0.01, *** p<0.001: significant differences 
between standing and supine positions (Stage la (S) versus stage lb (p), paired 
t-test, two-tailed). 
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Table 3.1 Mean (± SD) difference and range in % change in melatonin levels 
between standing and supine positions. 
Plasma 
Stage 1 
2400-0030h 
0030-0100h 
0100-0130h 
35.2 ± 21.3 (n=7)' 
range -7.5 to 78 
33.5 ± 16.2 (n=7)" 
range 5.6 to 85 
36.7 ± 17.5 (n=7)" 
range 7.8 to 71 
Saliva 
42 ± 27 (n=6)** 
range -16.9-81 
30.9 ± 34.4 (n=6) 
range -23 to 113 
31.9 ± 44.8 (n=6) 
range -21 to 88 
Stage 2 
2400-0130h 
2400-0100h 
18.6 ± 14.8 (n=4)" 
range -13 to 59 
34.1 ± 41.7 (n=5) 
range -13 to 132 
25.7 ± 46.3 (n=4) 
range -41.8 to 93.1 
28.6 ± 43.9 (n=5) 
range -41 to 93 
'p<0.05, "p<0.01: significance determined from AUC analysis followed by paired 
t-test. 
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Figure 3.2 Long term effects of posture on plasma melatonin levels 
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Individual profiles showing the percentage change in plasma melatonin levels 
after adopting a supine (0, stage 2a) or a standing (0, stage 2b) position for 
90 minutes from 2400h. Significant difference (p<0.01) over 90 minutes 
between supine and standing positions (n=4, excluding subject five, AUC 
analysis, paired t-test). The changes in plasma melatonin levels reached 
significance (p<0.05, paired t-test, n=4) at 20,40,50,60 and 70 minutes 
between stages 2a and 2b. 
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Figure 3.3 Long term effects of posture on salivary melatonin levels 
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3.4 DISCUSSION 
When moving from a supine position to a standing position, blood volume 
becomes redistributed from the central pool within the chest, to the lower limbs 
where small molecules pass through the capillary membranes into the interstitial space 
by diffusion due to the increased fluid pressure in the plasma. The plasma volume 
is reduced, thus increasing the concentration of nonfilterable blood constituents such 
as red cells, and proteins together with their bound components (Stoker and Wynn, 
1966; Husdan et al, 1973; Tan et al, 1973; Hagan et al, 1978), including albumin- 
bound hormones (Riad-Fahmy et al, 1982). 
The results from this study indicate that changing from the standing to the 
supine position caused a marked fall in plasma and salivary melatonin levels which 
was reversed on returning to the standing position once again. When these positions 
were reversed over the same period of time an opposite effect of similar magnitude 
was seen. These differences were significant for plasma melatonin within 10 minutes 
as calculated between stages la and lb and within 20 minutes comparing stages 2a 
and 2b. These changes showed no reliable (p > 0.1) progressive change with time 
indicating that the changes in plasma melatonin levels associated with the effects of 
posture were rapid and remained constant after approximately 20 minutes. This 
agrees well with other posture-related studies affecting various blood constituents 
where little change occurred after 20 minutes (Hagan et al, 1978; Tan et ao. 
The effects on salivary melatonin levels were more variable. This may be 
associated with frequent and forced sampling (every 10 minutes) which probably 
changes salivary composition and secretory mechanisms of the gland (Dawes, 1972), 
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modifying the true melatonin concentration in saliva. A high degree of correlation 
between plasma and salivary melatonin levels was observed throughout hourly 
sampling similar to that shown previously by other studies (Vakkuri, 1985; McIntyre 
et al, 1987; Nowak et al, 1987; Miles et al, 1985,1987). Although the overall 
proportion of melatonin levels in saliva to plasma, throughout hourly and 10 minute 
sampling, remained comparable, the correlation fell considerably throughout 10 
minute sampling. Only the linear relationship throughout hourly sampling 
corresponded well with previous studies. For example, McIntyre et al (1987) 
demonstrated a correlation of r=0.90 and the regression relationship as: 
y (salivary melatonin) = 0.55 [± 0.05] x (plasma melatonin) - 2.6 [± 2.1] 
(f SEM). 
Differences in urinary aMT6s output associated with alterations in posture 
might be expected to be delayed due to liver metabolism and renal excretion 
processes. Therefore changes were likely to become apparent after 90 minutes. 
However, there were no differences in urinary aMT6s output between standing and 
supine positions, suggesting that the changes in melatonin concentrations observed in 
plasma and saliva were likely to be fluid distribution effects rather than a change in 
total melatonin output. 
Abalan et al (1992) recently noted a difference of 32.6% ± 34.3 (mean f 
SD, range: -20% to 91 %) in total plasma cortisol - another circadian phase marker - 
on standing for 40 minutes compared to remaining supine, during the rising phase 
of the cortisol rhythm. A similar difference in plasma and salivary melatonin levels 
was observed in this study even though sampling was more frequent and over 
different periods of time. 
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Although considerable interindividual variation was evident, these results 
indicate that posture has a masking effect on plasma and salivary melatonin levels. 
Changes due to posture may prove to be important when interpreting data from 
subjects in different postural positions, for example, comparing bedridden patients and 
healthy controls, and may have implications in situations where the body is exposed 
to other environments where body fluid shifts are also experienced, such as 
spaceflights, water immersion and exercise. Changes in melatonin and cortisol levels 
due to posture may alter circadian parameters such as daily means and amplitudes and 
influence acrophase values. Samel et al (1993) studied the effects on the circadian 
system of 7 days of bed rest with a constant sleep/wake cycle and a regular 
photoperiod. Although neither melatonin or cortisol were measured, small changes 
in rhythm acrophases were evident for noradrenaline, adrenalin, potassium, heart rate 
and urine volume and significant changes in rhythm amplitudes were observed. These 
changes may be attributable to inactivity and posture. 
This study indicates the necessity for standardising the timing of blood 
sampling and indeed saliva sampling with prior knowledge of the postural position 
and the time in that position. Care should also be taken in the interpretation of 
results from high frequency saliva sampling. 
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CHAPTER 4 
INDUCING CIRCADIAN RHYTHM DISTURBANCES IN 
PARTIAL ENVIRONMENTAL ISOLATION: AN INITIAL 
STUDY. 
COMPARISON OF THE MELATONIN RHYTHM IN 
PLASMA, URINE AND SALIVA BEFORE AND AFTER A 
FORCED PHASE SHIFT 
Inducing circadian rhythm disturbances in partial environmental isolation: an 
initial study 
- Comparison of the melatonin rhythm in plasma, urine and saliva before and 
after a forced phase-shift 
4.1 INTRODUCTION 
Rapid time-zone change and shift work can lead to conflict between the new 
external time cues (zeitgebers) and the internal biological horologue with consequent 
physiological disturbances and deleterious effects on, for example, sleep and 
performance (Seigel et al, 1969; Fevre-Montange et al, 1981; Winget et al, 1984; 
Touitou et al, 1990). One treatment strategy for facilitating the adaptation of circadian 
rhythms to rapid shifts in external time cues and alleviating the associated behavioural 
problems, is the use of bright light (Daan and Lewy, 1984; Czeisler et al, 1990; 
Eastman, 1992). 
When suitably timed, bright light of sufficient intensity and duration will 
induce phase-shifts in physiological variables such as core body temperature, cortisol 
and melatonin secretion (Czeisler et al, 1986; Broadway et al, 1986,1987; Dijk et 
al, 1987,1989; Lewy et al, 1987; Minors et al, 1991; Shanahan and Czeisler, 1991; 
van Cauter et al, 1994), even when other zeitgebers, such as the sleep/wake cycle and 
social cues, are kept constant (Czeisler et al, 1986; Lewy et al, 1987). When a light 
pulse is used in combination with a shift in the sleep/wake schedule, far greater 
phase-shifts can be achieved (Czeisler et al, 1989; Shanahan and Czeisler, 1991). 
The magnitude and direction of the shift in melatonin and core body temperature 
rhythms are similar when measured under constant routine (`unmasked') conditions 
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suggesting a common control mechanism (Shanahan and Czeisler, 1991). 
The establishment of a phase-response curve for light has allowed predictions 
of the magnitude and direction of the shift based upon the timing of the light pulse. 
Exposure to bright light in the evening can delay circadian rhythms and morning light 
exposure will produce advance shifts, with the greatest shifts achieved with light 
exposure close to the temperature minimum (Minors et al, 1991, Czeisler et al, 1989, 
section 1.4). Such a phase-response curve for light may be applied to treat circadian 
rhythm disorders such as jet lag and maladaptation to shift work (Daan and Lewy, 
1984; Czeisler et al 1990; Eastman, 1992). It may also provide a means of 
simulating such disorders in a laboratory. 
Field studies of shift workers and jet travellers are expensive and difficult to 
control. One primary aim of this study was to devise a simple, rapid and inexpensive 
method to study the adaptation of circadian rhythms, sleep, mood and performance, 
during and after a phase-shift without complete environmental isolation. In this initial 
study a combination of moderately bright light and subsequent imposed darkness (and 
sleep) was used to induce a gradual and slow phase-shift of the circadian system in 
the laboratory. Subjects then resumed their baseline sleep/wake cycle, in their normal 
environment, inducing a rapid shift of external time cues similar to that experienced 
by jet travellers or shift workers. The subsequent readaptation of the subjects in their 
normal environment was then studied. 
Under normal environmental conditions melatonin is less susceptible to 
masking (disturbing) influences by external factors, other than light (Lewy et al, 
1980), compared to other circadian rhythms such as core body temperature and 
cortisol secretion. Melatonin was therefore employed as an appropriate tool for 
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measuring the phase of the internal body clock. The usefulness of self-rated alertness 
as a behavioural circadian rhythm marker was assessed. 
Melatonin has been variously measured and compared in plasma, saliva, and 
its metabolite aMT6s in urine under normal environmental conditions (Arendt et al, 
1985b; Markey et al, 1985; Vakkuri, 1985; Bojkowski et al, 1987b; McIntyre et al, 
1987; Nowak et al, 1987). The onset of its secretion in dim light has been 
extensively used by Lewy and co-workers as a circadian phase marker (for example, 
Lewy and Sack, 1989). A second aim of this study was to assess the relative validity 
of these various approaches in determining the circadian phase position under normal 
and phase-shifted conditions. 
4.2 SUBJECTS and METHODS 
4.2.1 Subjects 
6 healthy volunteers (3M: 3F), aged 22-26, under no medication and all non- 
smokers, refrained from heavy exercise and caffeine-containing drinks for 12 hours 
before sampling of body fluids and restricted their alcohol consumption (maximum 
2 units per day) throughout the experiment. Using the Home and Osterberg 
Morningness/Eveningness questionnaire (1976), four subjects were classified as 
"moderately morning" types, one as an "intermediate" type and one as a "moderate 
evening" type. 
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4.2.2 Study design 
The study was performed in early December 1991. Figure 4.1 shows a 
diagrammatic representation of the study. 
DAYS (D) 
-7 -6 -5 -4 -3 -2 -1 01234567 
Baseline 
Regular sleep/wake cycle 
and normal environment 
Slow, forced Post-treatment: 
6h delay Readaptation to a normal 
phase-shift environment with baseline 
sleep/wake cycle. 
Rapid 6h advance 
phase-shift 
Figure 4.1 Diagrammatic design of the study. 
Baseline: For one week prior to light treatment (days (D) -7 to 0), the subjects 
were required to maintain a regular sleep/wake schedule, retiring to bed at 2330h and 
waking at 0800h, remaining in the dark (< 1 lux) between these times. 
Light/Dark Treatment: Immediately following the baseline week, the subjects 
were exposed to a 6h pulse of moderately bright, full spectrum light (average 1200 
lux at eye level) at progressively later times over 3 consecutive days. The light 
treatment occurred during the following periods: 
DI: 2000-0200h, D2: 2200-0400h, D3: 2400-0600h . 
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Each period of light treatment was followed by 8 hours of imposed darkness 
(< 1 lux). During the remaining hours of each day strict light control was not 
imposed until dusk (1630h), but the subjects were asked to refrain from periods of 
exposure to bright sunlight. From dusk until the light treatment period, subjects 
remained in domestic intensity light (150-300 lux at eye level). Throughout the light 
treatment (D1-3) meal-times were shifted progressively by 2 hours each day in line 
with the imposed light/dark and sleep/wake cycle. Subjects were allowed to choose 
their activity (e. g. reading, writing, watching videos) as long as they glanced 
periodically (at least every 5 minutes) at the light source. They were continuously 
supervised throughout these periods. 
Post-Light/Dark Treatment: Immediately following the last light/dark treatment (i. e 
after 1400h on D4), subjects were required to assume the baseline sleep/wake 
schedule, i. e. retiring to bed at 2330h and waking at 0800h for 4 days (D4-8). The 
subsequent readaptation of the subjects in their normal environment was then 
observed. Subjects were only allowed to sleep during the periods of darkness 
throughout this study. Naps were not allowed. In addition, subjects were asked to 
avoid bright sunlight. 
4.2.3 Sampling 
Blood, urine and saliva samples were taken on the last baseline day (DO), the 
first post-light treatment day (D4) and the fourth post-treatment day (D7). All blood 
samples obtained throughout the dark-phase were taken in the recumbent position and 
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daytime blood and saliva samples after sitting for at least 10 minutes. On all 
sampling days subjects remained in the clinical investigation unit and during waking 
hours the light intensity ranged from 100 to 300 lux. 
Blood: An indwelling cannula was inserted into the forearm of each subject, 
under local anaesthetic, between 1630h and 1700h. Blood samples (5 ml) were 
obtained hourly from 1700h for 24 hours on each sampling day. Sampling during 
darkness was performed in dim red light (< 1 lux). A total of 396 ml of blood was 
removed from each person. 
Saliva: Samples (2-3ml) were obtained hourly from 1700h for 24 hours 
(following 2 minutes of chewing on parafilm), except during sleep, on the sampling 
days. Meals and drinks were taken just after saliva sampling and a thorough 
mouthwash taken afterwards to reduce any possible interference with salivary 
melatonin estimation. 
Urine: Sequential 4-hourly urine samples (8-hourly when asleep) were 
collected from 1600h throughout 24 hours on DO, 4 and 7. Each subject voided at 
1600h on each sampling day. All urine was then collected throughout each four hour 
period and the bladder completely emptied at the end of that collection period. The 
volume of each sample was noted and a5 ml aliquot from each sample collected. 
For information on preparation and storage of the samples, see section 2.2. 
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4.2.4 Behavioural Measurements 
During waking hours throughout the entire experimental period, subjective 
alertness was rated and performance tasks were carried out every 2 hours. Subjective 
alertness was rated on a 10cm visual analogue scale (VAS, " Drowsy a-. Alert ") and 
high and low memory capacity performance tasks were used (1- and 5-letter search 
and memory [SAM] tasks, respectively). Subjects were required to practice the tests 
for at least three days before the study. In addition, daily sleep logs were kept. 
Section 2.7 describes these behavioural measurements in detail. 
4.2.5 Hormone assays 
Methods of measuring melatonin and aMT6s are described in section 2.3. The 
interassay coefficients of variation for the various assays were as follows: 
Plasma melatonin: 10.4%, 15.2% and 9% at 22,40 and 210 pg/ml (n=10). 
Salivary melatonin: 15.3 %, 11.7 % and 5.5 % at 24,40 and 67 pg/ml (n =6). 
Urinary aMT6s: 16.8%, 11.6% and 5.8% at 2.4,14.7 and 31 ng/ml (n=6). 
The minimum level of detection for each assay was 6 pg/ml, 3.2 pg/ml and 0.3 
ng/ml, respectively. 
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4.3 STATISTICAL ANALYSIS 
4.3.1 Hormonal and alertness rhythms 
The raw hormonal and alertness data were analysed by two-factor ANOVA 
for repeated measures (day of study and time as factors). Subsequently, a cosinor 
analysis program was used to derive the rhythm characteristics of both the alertness 
and hormonal data (see section 2.8). ANOVA followed by Duncan's Multiple Range 
Test, were applied to the cosinor-derived parameters of acrophase and amplitude. All 
data below the limit of detection of the assay were excluded from the analysis, except 
for the purposes of the cosinor program where values lower than this limit were 
assigned a value of half the minimum detection limit of the assay. 
The onset and offset of plasma melatonin secretion were defined as twice the 
minimum detection limit of the assay when two consecutive values either exceeded 
or were below this amount, respectively. The relationships between concentrations 
of melatonin in saliva and plasma, and aMT6s in urine, and between their respective 
acrophases and plasma melatonin onset time were determined by linear regression 
analysis and Pearson's Correlation. 
4.3.2 Sleep data, and daily means for performance and alertness 
Daily means for alertness and performance (accuracy, response time and 
efficiency) were determined for each individual and calculated as a percentage of 
individuals' own mean baseline. One factor ANOVA (day of study) followed by 
Duncan's multiple range test were applied to the sleep data and the daily means for 
alertness and performance (accuracy, response time and efficiency). Performance 
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accuracy, response time and efficiency were defined as described in section 2.7.3. 
Values quoted are mean ± SEM unless stated otherwise. 
4.4 RESULTS 
No subjects reported any oral lesion or discomfort throughout the study and 
no saliva sample appeared to be contaminated with blood. On 4 of the baseline days 
(D-6 to -3) one subject suffered from flu-like symptoms which subsequently resulted 
in reduced alertness and performance, and disrupted his sleep pattern. The data 
obtained on these days were excluded from the analysis. 
4.4.1 Melatonin 
The profiles of plasma melatonin, salivary melatonin and urinary aMT6s are 
shown in Figures 4.2 to 4.4, respectively. 
Inspection of the aMT6s data indicated a marked phase delay on the first post- 
treatment day (D4) in 5 out of 6 subjects. One subject showed a 3-fold increase in 
the amplitude of aMT6s on D4 with no phase change and, in contrast to all the other 
subjects, a poor correlation with plasma and salivary melatonin. This subject was 
consequently excluded from the analysis of aMT6s. 
A significant time-dependent effect of treatment (ANOVA: phase-delay) was 
shown by aMT6s (p < 0.01) and plasma melatonin (p < 0.05) only, on the first post- 
treatment day (D4), which was no longer present on the fourth post-treatment day 
(D7) (p>0.1). 
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Cosinor analysis gave most significant fits for plasma melatonin (17 out of 18 
profiles at p<0.001), followed by salivary melatonin (14 out of 18 at p<0.05) and 
urinary aMT6s (10 out of 15 at p<0.1) reflecting the missing data during sleep for 
both salivary melatonin and aMT6s. However, the percentage of the variance 
accounted for by a cosine curve was greater than 81 % in the aMT6s profiles. 
Using the acrophase data derived from the cosinor programme, a significant 
phase delay (ANOVA) was present in all measures of melatonin secretion on the first 
post-treatment day. The mean peak time was shifted by 2.67 ± 0.3h (n=5) for 
aMT6s (p < 0.001), 2.35 ± 0.29h (n = 6) for plasma melatonin (p < 0.001) and 1.97 
± 0.32h (n=6) for salivary melatonin (p<0.01), 1 day post-treatment, Figure 4.5. 
Plasma melatonin onset also showed a significant delay on D4 (3.12 ± 0.74h, n =6, 
p<0.001). These shifts did not significantly differ from each other (p>0.1). The 
acrophase estimates and melatonin onset time for the fourth post-treatment day (D7) 
were not significantly different from baseline (p>0.1, ANOVA), but were 
significantly different from D4 (p < 0.05, ANOVA), indicating reentrainment by D7. 
The plasma melatonin offset time shifted to a lesser degree (1.33 ± 0.35h, n=6) 
compared to its onset time. 
Table 4.1 shows the correlation of acrophases between plasma and salivary 
melatonin and urinary aMT6s, together with plasma melatonin onset times. 
There was a direct correlation between plasma and salivary melatonin in 
samples taken simultaneously (r=0.758, p<0.001) before the light treatment, 
immediately after the phase-shift (r=0.792, p<0.001) and on D7 (r=0.576, 
p<0.01). The difference between plasma and salivary melatonin levels remained 
constant throughout the study. Salivary melatonin levels were estimated to represent 
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a mean ± SD of 40 ± 6.9 % of the corresponding plasma levels throughout the 
baseline day (DO), 44.1 ± 4.9% over the first post-treatment day and 37.4 ± 4.6% 
on the fourth post-treatment day, to give an overall mean ± SD value of 40.4 f 
5.3%. 
The amplitude of the individual urinary aMT6s rhythms correlated well with 
the amplitude of the plasma melatonin rhythm (r=0.73, p<0.001). In addition, the 
total output of urinary aMT6s in 24h significantly correlated with the total 24h 
melatonin concentration in plasma, as assessed by area under the curve analysis 
(r=0.71, p<0.001). 
The degree of shift for aMT6s on D4 was inversely correlated (P<0.05) to 
the pre-treatment amplitude of the aMT6s rhythm, such that the greater the amplitude 
the smaller the phase-shift. No such correlations were found to be statistically 
reliable with plasma or salivary melatonin rhythms. No significant change in the 
rhythm amplitude was apparent after the phase-shift with any of the measures of 
melatonin secretion. 
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Figure 4.2 Circadian plasma melatonin profiles before and after a 
forced phase-shift 
IIIIIIIIIIIIIIIIIIIIII 
1800 2200 0200 0600 1000 1400 
Time (hour of day) 
I 
Circadian profiles for plasma melatonin showing (a) phase-delay on the first 
post-treatment day (D4,  ) compared to baseline (DO, O) and (b) readaptation by the 
fourth post-treatment day (D7, A ); no significant difference from baseline (DO). 
Darkness from 2330 to 0800h. Phase-delay indicated by significant time-dependent 
treatment effect (* p<0.05; two-way ANOVA for repeated measures). Values 
represent mean +/- SEM (n=6). 
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Figure 4.3 Urinary aMT6s circadian profile before and after a 
forced phase-shift 
1600- 
2000 
2000- 2330- 0800- 1200- 
2330 0800 1200 1600 
Time (hour of day) 
Circadian profiles for urinary aMT6s showing (a) phase-delay on the first post-treatment 
day (D4,  ) compared to baseline (DO, Q) and (b) readaptation by the fourth 
post-treatment day (D7,0) - no difference from baseline (DO). Darkness from 2330 to 
0800h. Phase-delay indicated by significant time-dependent treatment effect (** p<0.01; 
two-factor ANOVA for repeated measures). Values represent mean +/- SEM (n=5). 
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Figure 4.4 Circadian melatonin profile in saliva before and 
after a forced phase-shift 
a) 
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Circadian profiles for salivary melatonin, without night-time sampling, 
showing (a) phase-delay in the offset of secretion on the first 
post-treatment day (D4,  ) compared to baseline (DO, D) and (b) 
readaptation by the fourth post-treatment day (D7, f). Darkness from 
2330 to 0800h. Values represent mean +/- SEM (n=6). 
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Figure 4.5 Relationship between acrophase estimates for melatonin, 
aMT6s, alertness and melatonin onset time 
I T 
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Acrophase estimates for urinary aMT6s (0), plasma MT (o), salivary MT (A), 
plasma MT onset (  ) and alertness (4) on baseline (day 0), one day 
post-treatment (day 4) and four days post-treatment (day 7). Mean +/- SEM 
(n=5 for aMT6s, n=6 for other variables). ** p<0.01, *** p<0.001: 
significant difference from baseline (ANOVA). D7 was significantly different 
from D4 (p<0.05) but not from DO for all variables (Duncan's multiple range). 
0200 ý 
2400 ý 
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Table 4.1 Correlation and linear regression analysis of acrophase estimates between 
plasma melatonin, salivary melatonin and urinary aMT6s, together with the time of 
plasma melatonin onset. y= mean (± SEM) x+ mean (± SEM). 
Urinary aMT6s acrophase = 0.82 (± 0.18) plasma melatonin 
acrophase + 1.45 (± 0.93) 
r=0.754, p<0.001, n=15 
Plasma melatonin acrophase = 0.60 (t 0.2) salivary melatonin 
acrophase + 2.35 (t 0.93) 
r=0.6, p<0.01, n=18 
Urinary aMT6s acrophase = 0.78 (± 0.19) salivary melatonin 
acrophase + 2.09 (± 0.78) 
r=0.718, p<0.001, n=18 
Plasma melatonin acrophase = 0.62 (f 0.1) plasma melatonin onset 
time + 5.06 (t 0.23) 
r=0.849, p<0.001, n=18 
Urinary aMT6s acrophase = 0.7 (± 0.14) plasma melatonin onset 
time + 5.6 (± 0.23) 
r=0.69, p<0.01, n=15 
Salivary melatonin acrophase = 0.39 (f 0.15) plasma melatonin onset time + 
4.55 (f 0.24) 
r=0.53, p<0.05, n=18 
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4.4.2 Alertness 
Using the cosinor-derived acrophase parameters (83% significant fits at 
p<0.05), no significant difference in the timing of the alertness acrophase was 
observed throughout the baseline days (mean acrophase 14.84 ± 0.28h), Figure 4.6. 
A maximum delay phase-shift of 6.33 ± 1.3h (p<0.01) was evident on the last 
treatment day (D3). By D4, there was still a clear phase delay in the rhythm (shift: 
3.08 ± 0.67h, p<0.01, n=6, ANOVA; 1 day post-treatment compared to DO). This 
effect is shown in Figure 4.6 and 4.7. A phase delay was also indicated with 
ANOVA on the raw data (p<0.01), figure 4.7. The alertness rhythm reentrained by 
the second post-treatment day (D5, Figure 4.6). No reliable difference in amplitude 
was apparent although the daily mean alertness fell significantly during the first day 
of the light treatment (p<0.01, Duncan's Multiple Range). The degree of shift in 
the alertness rhythm on D4 (compared to DO) was not significantly different from the 
shift in urinary aMT6s, plasma melatonin, salivary melatonin and the plasma 
melatonin onset time (p>0.1), Figure 4.5. 
4.4.3 Performance 
No change in performance was observed over the week prior to the treatment 
(p > 0.1), but a deterioration was observed during and after treatment, Figure 4.8. 
SAM-5 accuracy scores fell earlier than SAM-1 (first [D1] versus third [D3] 
treatment days, respectively) and returned to baseline values earlier than SAM-1 (D6 
versus D7, respectively, after returning to the normal environment). Response times 
were not significantly affected although a slight decrease was apparent over the 
treatment period. Efficiency only suffered significantly for both tasks on the first day 
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after the rapid advance of external time cues (D5; p<0.01). 
4.4.4 Sleep 
No significant changes in any sleep parameters were apparent over the week 
prior to treatment, Figure 4.9. The quality of sleep deteriorated on the first night (by 
30%, p<0.05) and third night (by - 40%, p<0.01) of the treatment period. 
Sleep duration decreased (by : lh, p<0.05), sleep latency increased (by - 50 
minutes, p<0.05) and sleep quality fell significantly (by = 60%, p<0.05) on the 
first post-treatment night (N4, i. e. first night after the rapid 6h advance shift of 
external time cues), Figure 4.9. 
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Figure 4.6 Alertness daily means and acrophase estimates 
before, during and after a forced phase-shift 
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Alertness (a) acrophase estimates and (b) daily means throughout an 8-day 
baseline (D-7 to DO), a 3-day delay phase-shift period (D1-3) and after 
returning to normal baseline sleep/wake cycle and environment on D4. A 
significant delay phase-shift was apparent on D3 and D4 with reentrainment by 
D5. Daily mean alertness was only significantly affected on D1. * p<0.05, ** 
p<0.01: significant difference from baseline values (Duncan's multiple range 
test). Values represent mean +/- SEM , n=6 
(D-6 to D-3, n=5). 4 Blood 
sampling days. 
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Figure 4.7 Subjective alertness profiles before and after a 
forced phase-shift 
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Subjective alertness profiles showing (a) phase-delay on the first post-treatment 
day (D4,  ) compared to baseline (DO, Q) and (b) readaptation by the fourth post- 
treatment day (D7, A); no significant difference from baseline. Darkness from 
2330h to 0800h on DO and D7 (M) and 0600 tol400h and 2330 to 0800h on 
D4 (EM). Phase-delay indicated by significant time-dependent treatment effect 
(* * p<0.01, two-way ANOVA for repeated measures). Values represent mean 
+/- SEM (n=6). 
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Figure 4.8 Performance measures before, during and after a forced 
phase-shift 
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Daily mean performance measures for (a) accuracy and (b) efficiency showing 
high- and low-memory load capacity tasks (SAM-5,  , and SAM-1, ", 
respectively). No significant variation over the 8-day pre-treatment period (D- 
7 to DO), significant fall in SAM-5 accuracy over the slow delay phase-shift 
(D1-3), and significant decrements in all performance parameters on the first 
day after returning to normal baseline sleep/wake schedule (D5). * p<0.05: 
significant difference from baseline (Duncan's multiple range test). 
+ 
Blood 
sampling days. Values represent mean +/- SEM, n=6 (D-6 to D-3, n=5). 
151 
Figure 4.9 Subjective sleep parameters before, during and 
after a forced phase-shift 
130 H 
110 
90 
`.. 
70 ** 
v, 
50 ** 
ý 
30 
-8 -6 -4 -2 0246 
100] 
b) 
y 
80 
60 
a) 
40 -1 
20 ý 
Llý 
_8 
ý J, J- ý 
0 
9.5 H 
8.5 H 
7.5 ý 
6.5 -1 
5.5 
C) 
0 ýrl lll -4 -2 02 
III III 
46 
-8 -6 -4 -2 0246 
Night of study 
Subjective measures of sleep for (a) sleep quality (b) sleep latency and (c) sleep duration 
showing no significant variation over the 9-night baseline period (N-8 to NO), fall in sleep 
quality over a slow delay forced phase-shift (N 1-3), and significant deterioration on the first 
night (N4) after the rapid advance phase-shift on D4 for all parameters. * p<0.05, ** p<0.01: 
significant difference from baseline (Duncan's multiple range test). 4 Blood sampling nights. 
Values represent mean +/- SEM, n=6 (D-6 to D-3, n=5). 
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4.5 DISCUSSION 
One objective of this study was to assess the usefulness of non-invasive 
methods of determining melatonin secretion in the form of salivary melatonin and 
urinary aMT6s before and after a phase-shift. The close relationship between plasma 
melatonin onset as a phase marker, and the calculated peak times of melatonin in 
plasma and saliva, and aMT6s in urine, suggests that all these approaches give valid 
information. A high degree of correlation between the onset time and acrophase for 
melatonin in plasma has also been determined in a recent study using shift workers 
and blind subjects (Blood et al, 1994). During the light treatment it was not possible 
to assess correctly the phase position of circadian rhythms due to the direct, acute 
effects ("masking") of light. For example, with sufficiently bright light melatonin is 
suppressed and core body temperature is increased (Lewy et al, 1980; Badia et al, 
1993; Myers and Badia, 1993). For this reason, the immediate post-light treatment 
period provides the nearest estimate to the actual phase-shift induced. During this 
period (D4), during the baseline (DO), and after readaptation (D7) the melatonin onset 
and mean peak values occurred in conditions of dim light or darkness. In such 
conditions, it is assumed that the measured phase position of melatonin represented 
the actual phase position on those days, and that the magnitude of the actual induced 
shift was greater than or equal to the measured shift on D4. 
In order to minimise sleep disturbance which may have compromised 
behavioural measurements, saliva and urine sampling were avoided during the sleep- 
phase. This resulted in the loss of definition in the circadian profiles, particularly for 
salivary melatonin. Certainly the estimates of the melatonin rhythm amplitude in 
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saliva would not be reliable. In spite of this problem a comparable phase-shift in the 
salivary melatonin rhythm was obtained. Clearly, however, the saliva data would 
greatly have been enhanced by night-time sampling. The salivary melatonin onset 
time was not a useful index of the rhythm in this study since a high proportion (67%) 
of onset times occurred during the sleep phase after the phase-shift. 
In this present study the ratio of salivary melatonin levels to plasma melatonin 
levels remained constant (approximately 40%) and the correlation remained highly 
significant even immediately after the rapid phase-shift. Even though the number of 
samples with detectable melatonin levels in saliva were reduced through no night-time 
sampling, the ratio agrees well with other reports where samples were obtained 
throughout 24h in a normal environment. In these studies, the ratio of melatonin in 
saliva to plasma was found to represent 32% (Nowak et al, 1987), 30-60% (Vakkuri, 
1985), 27-32% (Miles et al, 1987), and an estimated 55% (McIntyre et al, 1987). 
McIntyre et al (1987) also showed a good correlation (r=0.92, p<0.005) when 
plasma melatonin and salivary melatonin levels were suppressed with one hour of 
bright light between 2400h and 0100h. Nickelson et al (1991a) suggested that the 
relationship between salivary melatonin and urinary aMT6s concentrations may 
change following a9 hour forced phase-shift. There is no evidence for this 
phenomenon in this present study. However, the induced shift was much smaller, 
and more frequent saliva collections were made, at least during waking hours. 
A high degree of correlation (r=0.73) was observed between the rhythm 
amplitudes for plasma melatonin and urinary aMT6s and agrees well with Bojkowski 
et al (1987b) who demonstrated a correlation of r=0.70. In addition, a significant 
relationship between the individual total 24h plasma melatonin and urinary aMT6s 
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concentrations was observed (r=0.71), which has been established by previous studies 
under normal conditions (r=0.76: Markey et al, 1985; r=0.75: Bojkowski et al, 
1987b; r=0.72: Nowak et al, 1987), suggesting that urinary aMT6s is a reliable 
index of plasma melatonin levels even after an imposed shift in the circadian system. 
The practical advantage of urinary aMT6s is that it provides an integrated 
measure for melatonin production over the night-time period and allows repeated and 
longitudinal studies in the same individual to be performed. However, it is not 
possible to measure subtle changes in the rhythms due to limited frequency of 
sampling. The delayed aMT6s acrophase compared to that of plasma melatonin is 
presumably due to the delay in hepatic metabolism of melatonin and the time taken 
for the passage and diffusion of the metabolite through the kidney before appearing 
in the urine. 
A clear phase-delay in the alertness rhythm was evident, although alertness 
was clearly influenced by the sleep/wake cycle, since it was only rated during 
wakefulness. However, it is clear from the alertness data on D4 that the fall of the 
rhythm occurred significantly later in the evening compared to baseline suggesting a 
delay in the endogenous alertness rhythm. In addition, the degree of shift was 
comparable to that of melatonin which is not affected by the sleep/wake state (Folkard 
et al, 1984; Morris et al, 1990). This may imply a causal relationship as suitably 
timed melatonin administration can modify alertness (Arendt et al, 1987, see chapters 
9 and 10) and advance the timing of the self-rated fatigue and the closely associated 
sleep propensity rhythm (Arendt er al, 1984; Tzischinsky et al, 1992a). However, 
in this study it is more likely that the treatment induced a shift in central rhythm 
generating mechanisms common to both variables. 
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A significant decline in daily mean alertness was apparent only on the first 
treatment day. It is likely that this was due to blood sampling the previous night and 
during the day. Subjective sleep quality and SAM-5 accuracy did fall during this 
night and day but not significantly. However, disturbances in sleep, alertness and 
performance were not associated with all blood sampling periods, hence it is difficult 
to attribute changes in behaviour to blood sampling. Perhaps the novelty of 
cannulation and sleep in a new environment compromised behaviour on this day. 
Disturbances in sleep quality over the treatment period (during the slow delay 
phase-shift) were observed. There were also important and significant decrements in 
performance accuracy during this period with time-dependent differences in high and 
low memory capacity tasks. These observations suggest that even a brief shift in the 
sleep/wake cycle may compromise sleep and performance. 
The light/dark treatment schedule was chosen to enhance the natural tendency 
of circadian rhythms in the majority of people to delay. Since humans have a free- 
running period of about 25h, the natural tendency is to delay by approximately 
lh/day. Wever et al (1983), Wever (1986) and Aschoff and Wever (1981) have 
demonstrated that physiological rhythms can entrain to a 26h day even without bright 
light treatment. However, bright light can enhance the entrainment to longer days 
(Wever et al, 1983; Wever, 1989). In the present study, using a 26h sleep/wake 
schedule over 3 days, with bedtime and wake time 2h later each day, the evening 
light treatment was aimed to hit the delay portion of the phase-response curve each 
day. It is possible that the light treatment was not of sufficient intensity or duration 
or the light suitably timed to promote the adaptation of sleep and performance to the 
new sleep/wake cycle. However, sleep quality and performance accuracy were the 
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only sleep and performance parameters to be adversely affected. Eastman and 
Miescke (1990) found that in a similar 26h sleep/wake schedule, bright light (1770- 
2800 lux) administered for 2h before bedtime facilitated the entrainment of the 
temperature rhythm in 74% of the subjects and promoted better sleep. However, 
shielding from natural bright light for 6h after sleep was necessary for this effect. 
Only 17% of the subjects entrained with natural light exposure at any time of day. 
Strict light control was not imposed until dusk in the present study and may help to 
explain the disturbances in sleep and performance over the imposed 26h sleep/wake 
schedule due to the effect of inappropriate light exposure on the circadian system. 
These behavioural disturbances may also have been confounded by the effects of 
blood sampling and the novel sleep environment. 
Individual differences may also account for the behavioural disturbances 
following adaptation to an extended day. The majority of subjects in this study were 
moderately "morning types". There is a suggestion that "evening type" individuals 
adapt quicker to imposed shifts in the sleep/wake cycle (Folkard and Monk, 1981; 
Hildebrandt and Stratmann, 1979). 
The major and consistent deleterious effects on sleep and performance 
occurred when the subjects were rapidly returned to their normal baseline sleep/wake 
cycle and environment on D4. A transient increase in latency, fall in quality and 
duration were observed on the first night after the rapid advance phase-shift, together 
with decrements in performance accuracy and efficiency the following day. The 
disturbances in sleep and performance (possibly as a consequence of disrupted sleep) 
can be attributed to the inappropriate phase relationship between the endogenous sleep 
propensity rhythm and the imposed sleep/wake cycle (Dijk and Czeisler, 1994), i. e. 
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the subjects were trying to sleep at a time when the circadian pacemaker was 
promoting wakefulness. As a result sleep deprivation probably made it even more 
difficult to perform well the following day (Carskadon and Dement, 1979,1981). 
In this initial study, the use of a three-cycle stimulus of moderate intensity 
bright light (1200 lux), suitably timed and coupled with periods of imposed darkness 
(< 1 lux) and sleep, clearly induces significant phase-shifts in a major endogenous 
hormonal circadian rhythm (melatonin) and a major behavioural rhythm (self-rated 
alertness). The subsequent readaptation of the subjects in their normal environment 
produced transient but major behavioural disturbances. It should therefore be possible 
to simulate circadian rhythm disorders and related problems such as jet lag and 
shiftwork, similar to those seen in field studies, in an inexpensive and controlled 
environment where the subjects are left in their normal environment for most of the 
time. Clearly since the induced phase-shift was small and the behavioural problems 
transient on readaptation, larger phase-shifts are necessary in order to study the 
efficacy of treatment strategies in treating circadian rhythm disorders. 
158 
CHAPTER 5 
INDUCING CIRCADIAN DISTURBANCES IN PARTIAL 
ENVIRONMENTAL ISOLATION: A RAPID 9h ADVANCE 
PHASE-SH HFT AFTER A GRADUAL 9h DELAY SHIN 
Inducing Circadian Rhythm Disturbances in Partial Environmental Isolation: 
A Rapid 9h Advance Phase-shift After a Gradual 9h Delay Shift. 
5.1 INTRODUCTION 
Field studies on phase-shifting and other strategies to alleviate the problems 
associated with jet lag and shift work are expensive and difficult to control. 
Laboratory simulations provide a more controlled environment with which to study 
these circadian rhythm disorders in detail. However, one disadvantage of laboratory 
simulations is that the subjects are completely isolated from a normal environment, 
whereas field studies allow the subject to be exposed to a whole range of time cues 
which may be important in the normal adaptation process in everyday life. In order 
to simulate conditions as true to life as possible, an experimental model was 
developed without complete environmental isolation allowing subjects to adapt to 
rapid shifts in local time in their normal environment. 
This experiment was a crossover study which investigated the effects of bright 
light and melatonin in facilitating the readaptation of the circadian system and 
alleviating the associated behavioural problems after a rapid 9h advance shift in local 
time. Comparison of these treatment strategies will be discussed in Chapter 6. It is 
the purpose of this chapter to describe in detail an experimental model which 
gradually forces a 9h delay phase-shift in the circadian system under controlled 
environmental conditions and allows a rapid 9h advance shift of external time cues 
to be induced when the subjects resume their baseline sleep/wake schedule. The 
readaptation of the subjects to their normal environment will be described (under 
placebo treatment). A combination of exposure to bright light and darkness was 
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timed to gradually delay circadian rhythms over a number of days in a similar way 
to that described in Chapter 4. 
5.2 SUBJECTS and METHODS 
5.2.1 Subjects 
8 healthy volunteers (4M: 4F), aged 22-26, under no medication and all non- 
smokers were recruited from research students of the University of Surrey who 
followed similar sleep/wake schedules and lifestyles. Using the Horne and Östherg 
questionnaire (1976) to determine morning or evening type individuals, no definite 
morning or evening types were detected (scores > 70 or < 31). However, two 
subjects were more of the morning type (scores of 63 and 64) and three were rather 
of the evening type (scores of 36,41 and 41) 
The subjects refrained from heavy exercise and restricted their alcohol 
consumption (maximum 2 units per day) throughout the experiment. 
5.2.2 Study Design 
This experiment was a double-blind, placebo-controlled crossover study with 
four different treatments administered after the rapid 9h advance phase-shift. The 4- 
stage study was performed from November 1992 and April 1993. At least two weeks 
separated the start of each stage. Each stage began on the same day of the week and 
spanned the first two weeks of the month. 
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Each stage comprised the following: 
DAYS (D) 
-2 -1 0123456789 10 11 
(Changing ; Stable 
Baseline Slow, forced 
Regular sleep/wake 9h delay 
cycle and normal phase-shift 
environment T 
Readaptation in normal 
environment with baseline 
sleep/wake cycle. 
Rapid 9h advance 
phase-shift 
Baseline: For 3 days prior to the phase-shift (days (D) -2 to 0), the subjects were 
required to maintain a regular sleep/wake schedule, retiring to bed at approximately 
2330h and waking at 0800h, remaining in the dark (< 1 lux) between these times. 
Gradual 9h delay phase-shift: Immediately following the baseline days, the 
subjects were exposed to 9h pulses of moderately bright (average 1200 lux at eye 
level), full spectrum light at progressively 3h later times over the first three days (D1- 
3) and then at the same times on D4-5 as for D3. The periods of light exposure were 
as follows: 
D 1: 1800-0300h, D2: 2100-0600h, D3,4,5: 2400-0900h. 
Each period of light treatment was followed by 8 hours of imposed darkness 
(< 1 lux) when they slept. During the remaining hours of each day subjects were 
in dim light (< 300 lux, indoors) or moderately bright light (< 1000 lux, outdoors 
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with sunglasses) until dusk (1630/1700h). From dusk until the light treatment period, 
subjects remained in domestic intensity light (50-300 lux at eye level). Throughout 
the phase-shift (D1-5) meal-times were shifted progressively by 3 hours on days 1-3 
and then maintained at the same times on D4-5 as for D3, in line with the imposed 
light/dark and sleep/wake cycles. Subjects were allowed to choose their activity (e. g. 
reading, writing, watching videos) as long as they glanced regularly (at least every 
5 minutes) at the light source. The subjects were continuously supervised throughout 
these periods. The patterns of exposure to bright light, natural ambient light and 
darkness are summarized in Figure 5.1. 
9h rapid advance phase-shift: Immediately following the last light/dark 
treatment on day 6, subjects were required to assume the baseline sleep/wake 
schedule in their normal environment, inducing a rapid 9h advance phase-shift in 
external time cues, i. e. retiring to bed at 2330h and waking at 0800h for 6 days (D6- 
11). The subsequent readaptation of the subjects in their normal environment was 
then observed. Subjects took a placebo pill (lactose-gelatin capsule) just before the 
desired bedtime at 2300h on D6-8. In addition, from 0800-1200h on D7 and D8 
subjects were exposed to controlled lighting of between 50-300 lux. Subjects were 
asked to avoid bright sunlight and wore sunglasses when outdoors (filtering out 
>90% of the light). At dusk, they were required to remain in ordinary domestic 
lighting (50-300 lux) until bedtime (and darkness). Each subjects ambient lighting at 
work and home was monitored using a digital light meter (see section 2.4). 
Subjects were only allowed to sleep during the periods of darkness throughout 
this study. Naps were forbidden. 
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Figure 5.1 Diagrammatic design of the study 
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Diagrammatic design of the study showing patterns of exposure to bright light 
(O 
,- 1200 
lux), darkness/sleep (m) and natural ambient light (0). 
After a3 day baseline (D-2 to DO), a gradual 9h delay phase-shift was induced 
over 3 days (D 1-3) and then the 9h shift was maintained for the following 2 
days (D4-5). On day 6, subjects resumed their baseline sleep/wake schedule 
in a normal environment, thus experiencing a rapid 9h advance phase-shift of 
local time cues. 
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5.2.3 Sampling 
Urine: Sequential 4-hourly urine samples (8-hourly when asleep) were collected 
throughout the study. All urine was collected throughout each four hour period and 
the bladder completely emptied at the end of that collection period. See section 2.2 
for sample collection and storage. 
Temperature: Rectal temperature was recorded continuously every 6 minutes 
throughout the trial (see section 2.5). 
5.2.4 Behavioural Measurements 
Every 2h throughout the whole trial during waking hours, mood parameters 
(alertness, cheerfulness and calmness) were rated on 10cm visual analogue scales 
(VAS: Drowsy *-º Alert, Depressed Happy and Tense*--, - Calm, respectively) 
and performance tasks (low- and high-load search and memory tests: SAM-1 and 
SAM-5, respectively) were carried out every. In addition, daily sleep logs and 
activity diaries were kept. For 3-4 days prior to the trial subjects practised the 
performance tests regularly. Behavioural measurements were recorded using Psion 
organisers. Sections 2.7 describes these behavioural measurements in detail. 
5.2.5 aMT6s assays 
For methods of analysis of urinary aMT6s, see section 2.3.4. The interassay 
coefficients of variation were 7,4 and 3.3% at 2.9,22.3 and 42.7 ng/ml (n=37). 
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The minimum level of detection was 0.4 ± 0.22 ng/ml (n=37). 
5.3 STATISTICAL ANALYSIS 
The 4 legs of the trial involved 4 different treatments administered after the 
rapid 9h advance phase-shift. During the baseline and gradual 9h delay phase-shift, 
these legs will be referred to as the pre-treatment groups. 
5.3.1 Temperature and aMT6s rhythms 
Repeated measures ANOVA (factors: pre-treatment group, day of study and 
time of day) followed by post-hoc analysis (Duncan's Multiple Range Test) were 
applied to raw aMT6s and temperature data, and the cosinor-derived parameters of 
acrophase and amplitude for 24h temperature and aMT6s profiles over the baseline, 
gradual phase-delay shift and readaptation periods (under placebo treatment). For 
analysis by ANOVA, the temperature data were averaged over each hour. Degrees 
of shift were determined by comparison with the individual's mean baseline. 
5.3.2 Mood and performance rhythms 
24h profiles for each mood and performance parameter were analysed by 
cosinor analysis over 3-day windows for more reliable estimates of acrophase and 
amplitude (baseline: D-2 to DO, changing phase-shift: D1-3, stable phase-shift: D3-5, 
readaptation period: D7-9 and D9-11) followed by ANOVA (for repeated measures). 
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An estimate of entrainment to the 24h day (and establishment of cosinor rhythmicity 
with a period of 24h) is provided by (1) the percentage number of subjects with 
significant 24h cosine fits and (2) the percentage variance accounted for by a cosine 
curve, see section 2.8. Where the mood and performance parameters exhibited 
significant cosinor rhythmicity over the baseline period, all comparisons are made 
with respect to individuals baseline values. Repeated measures ANOVA was also 
used to establish a time of day effect over the baseline period. 
5.3.3 Sleep data and daily means for mood and performance 
All sleep, mood and performance data were calculated as a percentage of or 
difference from individuals own baseline. Daily means for every mood and 
performance parameter were then determined. The performance parameters accuracy, 
response time and efficiency were defined as the percentage of correct responses, time 
taken to complete the task and accuracy/response time, respectively. Response time 
data were normalised by square root determination. 
5.4 RESULTS 
One subject did not conform to the protocol and was therefore excluded from 
all analysis. 
Cosinor analysis gave most significant fits for 24h temperature data (100% 
at p<0.005) followed by urinary aMT6s (84% at p<0.05). However, the percentage 
variance accounted for by a cosine curve was > 80% in the 24h aMT6s profiles. 
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5.4.1 Ambient light monitoring 
At home in the evening, light intensity did not exceed 180 lux (average 110 
lux). Maximum natural bright light exposure (up to 10 000 lux) commonly occurred 
around 0800-0900h, 1200-1400h and 0500-0700h corresponding to travel to work, 
lunch and travel home, respectively. However, the light intensity always remained 
less than < 1000 lux with sunglasses when outside and more commonly <500 lux. 
In the work environment, the general light intensity was approximately 490 lux (range 
55-1000 lux). However, whilst working at the laboratory bench or at the computers, 
the average light intensity was reduced to 170 lux (range 55-500 lux). 
5.4.2 Baseline 
No baseline differences for any sleep, mood, aMT6s or temperature 
parameters were evident. Of the performance variables, a small but significant fall 
in SAM-1 accuracy was found (p<0.05, as 1% fall, D-2 to DO). A significant time 
of day effect was established by ANOVA (repeated measures) for aMT6s, 
temperature, alertness (Figures 5.2,5.3 and 5.4, respectively) and performance 
response time (p<0.0001). One subject did not exhibit any significant cosine rhythm 
or time of day effect as determined by cosinor analysis and repeated measures 
ANOVA. This subject was discarded from the analysis of SAM-5 performance 
variables. 
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Figure 5.3 Temperature profiles before and during a gradual 9h 
delay phase-shift 
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Circadian profiles for core body temperature over a3 day baseline (D-2 to DO) and a gradual 
9h delay phase-shift (D 1-5) for one of the four trial legs. There were no differences between 
the four legs. A significant phase-delay was indicated by ANOVA for repeated measures 
(time of day by day of study interaction, D5 versus baseline, p<0.001). A decline in 
amplitude was observed over the phase-shift with return to baseline values on D5. Bars 
show patterns of exposure to bright light (1200 lux, =), darkness (< 1 lux, ý) and natural 
ambient light (®). Temperature was recorded continously every 6 minutes then averaged 
and plotted every hour as the mean of 7 subjects (+ SEM). 
170 
Figure 5.4 Alertness profiles before and during a gradual 9h delay 
phase-shift 
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Daily profiles for self-rated alertness over a3 day baseline (D-2 to DO) and a gradual 
9h delay phase-shift (D 1-5) for one of the four trial legs. There were no differences 
between the four legs. Using cosinor acrophase estimates, over 3-day windows, 
there was a significant phase-delay of 10.62 +/- 0.96h (mean +/- SD, D3-5 compared 
to D-2 to DO, p<0.0001, ANOVA). =Bright light exposure (1200 lux), 
m darkness (< 1 lux), ® normal ambient light. Values represent mean (+ 
SEM, n=7) alertness rated every 2h during wakefulness. 
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5.4.3 Gradual, forced 9h delay phase-shift 
Using moderately bright light combined with darkness (sleep) it was possible 
to force a progressively larger delay phase-shift in the temperature and aMT6s 
rhythms (max. degree of shift, D5 compared to mean baseline: 9.13 ± 0.83h and 
9.09 ± 1.06h, respectively), Figure 5.5. A comparable shift in the alertness and 
performance response time rhythms was also evident, Figures 5.6-5.8 (degree of 
shift, D3-5 compared to baseline: 10.62 ± 0.96h, 10.51 ± 1.33h [SAM-1] and 9.24 
± 1.88h [SAM-5], respectively). A delay phase-shift was also indicated with 
ANOVA on the raw aMT6s and temperature data, Figures 5.2 and 5.3 (time of day 
by day of study interaction, p<0.0001). Significant suppression of the temperature 
and aMT6s rhythm amplitudes was observed over the forced phase-shift (ANOVA, 
p<0.0001) with return to baseline values on D4-5 for aMT6s and D5 for 
temperature, Figures 5.2 and 5.3. 
No important detrimental effects on mood or sleep were evident, Figures 5.4, 
5.9 and 5.10. However, a small but significant increase in sleep latency (p=0.025) 
and corresponding fall in sleep duration (p=0.0017) was observed during the phase- 
shift (mean ± SD: 8.1 ± 13.1 minutes, increase in sleep latency). This was mainly 
attributable to the first two nights of the phase-shift. Daily mean alertness and 
calmness significantly increased by 3.0 ± 1.0% and 7.4 ± 2.1%, respectively, 
during the shift (D1-5) with the greatest improvement associated with the latter end 
of the shift. 
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Figure 5.5 Acrophases of aMT6s and temperature rhythms during a 
gradual 9h delay phase-shift 
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Acrophase estimates for (a) aMT6s and (b) core body temperature ('masked') over a 
three day baseline (D-2 to DO) and during a slow 9h delay phase-shift (D1-5) for the 4 
pre-treatment legs of the trial (Bright light,  , Placebo, o, Melatonin + Bright light, " 
and Melatonin, £ ). A highly significant phase-delay was indicated by ANOVA (for 
repeated measures, p<0.0001). Degree of shift (D5 compared to mean baseline) for 
aMT6s was 9.13 +/- 0.83h, and for temperature was 9.09 +/- 1.06h (mean +/- SD). 
Values represent mean +/- SEM, n=7. 
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Figure 5.6 Adaptation of the alertness rhythm during a gradual 
delay phase-shift 
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a) Cosinor-derived alertness acrophase estimates using 3-day windows during 
baseline (D-2 to DO) and a gradual 9h delay phase-shift (D 1-5) for the 4 pre- 
treatment legs of the trial (Bright light,  , Placebo, 0, Melatonin + Bright fight, 
" and Melatonin, A ). An estimate of entrainment (to a 24h cosine rhythm) is 
provided by (b) % number of subjects with significant cosine fits (set at p<0.05) and 
(c) % variance accounted for by a cosine curve. A significant phase-delay of 10.62 
+/- 0.96h (mean +/- SD) was obtained during the forced delay shift (p<0.0001, 
ANOVA, D3-5 compared to baseline). Values for Figs. (a) and (c) represent mean 
+/- SEM (n=7). 
174 
Figure 5.7 Adaptation of the SAM-1 response time performance rhythm 
during a gradual delay phase-shift 
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a) Cosinor-derived SAM-1 response time acrophase estimates using 3-day windows 
during baseline (D-2 to DO) and a gradual 9h delay phase-shift (D1-5) for the 4 pre- 
treatment legs of the trial (Bright light, U, Placebo, 13, Melatonin + Bright light, " 
and Melatonin, A ). An estimate of entrainment (to a 24h cosine rhythm) is provided 
by (b) % number of subjects with significant cosine fits (set at p<0.05) and (c) % 
variance accounted for by a cosine curve. A significant phase-delay of 10.51 +/- 
1.33h (mean +/- SD) was obtained during the forced delay shift (p<0.0001, ANOVA, 
D3-5 compared to baseline). Values for Figs. (a) and (c) represent mean +/- SEM 
(n=7). 
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Figure 5.8 Adaptation of the SAM-5 response time performance rhythm 
during a gradual delay phase-shift 
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a) Cosinor-derived SAM-5 response time acrophase estimates using 3-day windows 
during baseline (D-2 to DO) and a gradual 9h delay phase-shift (D1-5) for the 4 pre- 
treatment legs of the trial (Bright light,  , Placebo, Q, Melatonin + Bright light, 
" and Melatonin, A ). An estimate of entrainment (to a 24h cosine rhythm) is 
provided by (b) % number of subjects with significant cosine fits (set at p<0.05) and 
(c) % variance accounted for by a cosine curve. A significant phase-delay of 9.24 +/- 
1.88h (mean +/- SD) was obtained during the forced delay shift (p<0.0001, 
ANOVA, D3-5 compared to baseline). Values for Figs. (a) and (c) represent mean 
+/- SEM (n=7). 
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Figure 5.9 Daily means for mood before and during a gradual 9h 
delay phase-shift 
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phase- shift (p<0.0001 and p<0.05, respectively, ANOVA). Values represent 
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Figure 5.10 Subjective sleep measures during a gradual forced 9h 
delay phase-shift 
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Figure 5.11 Daily means for SAM-1 performance measures 
before and during a gradual forced 9h delay phase-shift 
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[], Melatonin + Bright 
light, " and Melatonin, f ). Significant fall in accuracy, and increase in response 
time and efficiency during the phase-shift (p<0.001, ANOVA). Values 
represent mean +/- SEM, n=7. 
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Figure 5.12 Daily means for SAM-5 performance measures 
before and during a gradual forced 9h delay phase-shift 
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Daily means for SAM-5 (a) efficiency (b) accuracy and (c) response time over a 
three day baseline (D-2 to DO) and during a gradual 9h delay phase-shift (D1-5) 
for the 4 pre-treatment groups (Bright light,  , Placebo, 0, Melatonin + Bright 
light, " and Melatonin, " ). Significant fall in accuracy, and increase in response 
time during the phase-shift (p<0.001, ANOVA). Values represent mean +/- 
SEM, n=6. 
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SAM-1 and SAM-5 response time quickened significantly (3.7 ± 1.2% and 
2.8 ± 1.5%, p<0.0001) although at the expense of accuracy which fell (SAM-1: 
2.35 ± 0.38%, p=0.028; SAM-5: 4±1.7%, p=0.0002). Overall performance 
efficiency improved for SAM-1 (2.9 ± 0.3%, p=0.0007) and remained unchanged 
for SAM-5, Figures 5.11 and 5.12, respectively. The fall in performance accuracy 
improved towards the latter end of the shift. 
5.4.4 Adaptation to a rapid 9h advance phase-shift (placebo treatment) 
After the rapid 9h advance shift of external time cues on day 6a large and 
highly significant (p<0.0001) reduction in sleep duration (4 1.6 ± 0.36h), quality 
(1 24 ±5%, Figure 5.13) and increase in the duration of night awakenings (t 52.6 
± 14.7 minutes, Figure 5.13) was apparent, nights 6-11. Sleep latency and the 
number of night awakenings remained virtually unchanged, nights 6-11. 
The daily means for cheerfulness and calmness deteriorated (7.5 ± 3% and 
6.1 ± 3%, respectively, D7-11) but the major deleterious effects were evident with 
alertness (p<0.001,11.5 ± 2.7%), Figure 5.14. 
Significant decrements in daily mean performance accuracy (SAM-1: 4.0 f 
0.58%, SAM-5: 11.12 ± 1.55%) and efficiency (SAM-1: 4.2 ± 1.17%, SAM-5: 
11.12 ± 1.2%) were evident (p5 0.0003, D7-11), Figure 5.15. Slower reaction 
times (SAM-1: t 0.45 ± 0.97 minutes, SAM-5: t 0.76 ± 1.07 minutes, D7-11) 
were also apparent. The performance response time and alertness rhythms did not 
reestablish a normal baseline pattern by day 11 (see Figures 6.8,6.11 and 6.12). 
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Figure 5.13 Adaptation of sleep to a rapid 9h advance phase-shift 
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11 compared to baseline) with no significant effect on sleep latency. Values represent 
mean +/- SEM, n=7. 
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Figure 5.14 Adaptation of mood to a rapid 9h advance phase-shift 
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Figure 5.15 Adaptation to a rapid 9h advance phase-shift : 
daily mean performance 
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Significant decrements in efficiency and accuracy were evident (p<0.001, 
ANOVA for repeated measures, D7-11 compared to baseline). Values 
represent mean +/- SEM (SAM-1: n=7; SAM-5: n=6). 
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Figure 5.16 Adaptation of aMT6s and temperature rhythms to a rapid 9h 
advance phase-shift 
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repeated measures ANOVA) whilst the 'masked' temperature rhythm 
apparently reentrained by D7. Values represent mean +/- SEM, n=7. 
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Figure 5.17 Adaptation of the temperature rhythm to a rapid 9h 
advance phase-shift 
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Clock time / Day of study 
12: 00 
Baseline 
(D-1) 
Adaptation of the circadian rhythm for core body temperature after a rapid 9h 
advance phase-shift (on day [D] 6) in a normal environment (placebo stage). 
Although the calculated peak of the rhythm indicates reentrainment by D7 (see 
Figure 5.16), the rhythm amplitude remained significantly reduced (p<0.0001, D7- 
11 compared to baseline, ANOVA). Normal baseline patterns are not established 
until at least D 10. Bars show patterns of exposure to darkness (< 1 lux, M), 
natural ambient light (= ) and bright light (1200 lux, o ). Temperature was 
recorded continously every 6 minutes then averaged and plotted every hour as the 
mean of 7 subjects (+ SEM). 
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Figure 5.18 Direction of reentrainment of individual aMT6s 
rhythms after a rapid 9h advance phase-shift 
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Acrophase estimates for individual circadian aMT6s profiles showing the 
direction of reentrainment after a rapid 9h advance phase-shift (on day 6) in 
a normal environment (placebo treatment). At least two subjects show an 
antidromic effect where they reentrain to a 9h advance shift by delay. 
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Temperature acrophase was delayed significantly from baseline on D6 only 
(p<0.01, Figure 5.16) although the rhythm amplitude remained significantly lower 
on D6-10 (p < 0.05), Figure 5.17. aMT6s acrophase remained significantly delayed 
from baseline (p<0.01) on days 6-11. This was also indicated with ANOVA on the 
raw aMT6s data where a time of day by day of study interaction was still significant 
on D II compared to DO (p<0.0001), Figure 5.16. 
The direction of the subjects natural entrainment of the aMT6s rhythm varied. 
At least 2 subjects reentrained by phase-delay and at least 2 subjects phase-advanced, 
Figure 5.18. 
5.5 DISCUSSION 
5.5.1 Gradual 9h delay phase-shift 
Using a controlled environment, an approximate 9h delay phase-shift was 
induced in the core body temperature and urinary aMT6s rhythms, two commonly 
used physiological rhythm markers of the biological clock. A similar degree of shift 
was also identified with the behavioural rhythms of self-rated alertness and 
performance response time. The contemporary shift in the sleep/wake cycle clearly 
influenced the calculated estimates of acrophase for mood and performance rhythms 
since this data was only collected during wakefulness. In addition, exogenous 
influences may have modified cosinor estimates of the temperature rhythm. 
However, comparable shifts were seen with the aMT6s rhythm which is minimally 
influenced by exogenous factors apart from the acute suppressant effects of bright 
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light, see section 1.3. 
The maximum degree of shift induced (approx. 9h) was assessed on the last 
day of the gradual delay phase-shift under bright light conditions (D5). However, the 
aMT6s rhythm had reestablished the normal baseline amplitude and shape on D4-5 
and visual inspection of the aMT6s raw data confirms the magnitude of the maximum 
shift. A mean delay shift of 7.5h (± 1.5h, mean ± SD) was obtained on day 6, 
when subjects returned to the normal environment in conditions of darkness and dim 
light with no masking influences. This provides a reliable estimate of the shift 
induced allowing for the natural adaptation of the circadian system after one day. 
The gradual delay shift in environmental and social (e. g. meals) time cues, 
together with the suitably timed bright light/darkness were effective in promoting the 
adaptation of sleep, mood and performance efficiency to the 9h delay shift. No 
important detrimental effects on sleep and mood were apparent. Small (2-4%) but 
significant deleterious effects on performance accuracy were observed, mainly over 
the changing shift period (D1-3), which stabilised when the 9h delay shift was 
maintained for another two days. The accelerated response time seen over this period 
was unlikely to be a practice effect since tests were performed regularly before each 
stage of the trial and no observable trend was seen over the baseline. Overall, 
performance efficiency remained either unchanged or slightly improved. In addition 
to the effects of bright light on the circadian system, bright light exposure may have 
directly enhanced mood and performance (Campbell and Dawson, 1990; French et 
al, 1990; Myers and Badia, 1993). 
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5.5.2 Rapid 9h advance phase-shift 
The major and significant deleterious effects on behaviour occurred after 
subjects resumed their baseline sleep pattern in their normal environment. This rapid 
9h advance shift of external time cues can be related to a 9h eastward transmeridian 
flight. Using this direct analogy, a flight at 2300h from Los Angeles to Paris after 
a 9h flight crossing 9 time zones (forward in time) would arrive in Paris at 1700h 
local time or 0800h Los Angeles time. Having adopted local time, travellers would 
retire to bed at approximately 2300-2400h (1700-1800h Los Angeles time) to try and 
get sufficient sleep before rising the following morning for work at 0900h. This 
schedule was simulated in the present experiment. Trying to sleep at inappropriate 
circadian phases inevitably resulted in some sleep disruption or loss because the body 
was not prepared to sleep until 0500-0600h local time, corresponding to 2300-2400h 
Los Angeles time. Travel fatigue and sleep loss whilst flying may have compound 
these problems in real life. 
Sleep patterns, mood and performance variables and the endogenous aMT6s 
rhythm took at least 5 days to reestablish normal baseline patterns in agreement with 
field based studies (Klein and Wegmann, 1980; Fbvre-Montange et al, 1981, 
Wegmann et al, 1983; Arendt et al, 1987) and laboratory simulations (Samel et al, 
1991). The temperature rhythm apparently took two days reentrain. However, 
environmental and behavioural masking were likely to be responsible for this effect. 
Since the natural reentrainment of circadian rhythms after rapid and large phase-shifts 
can take many days or weeks (Aschoff et al, 1975; Klein and Wegmann, 1980; 
Wegmann et al, 1983), and since the zeitgeber strength of natural light exposure was 
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controlled, it was unlikely that in every individual the rhythm shifted by 9h in one 
day. The significant reduction in rhythm amplitude suggests that the rhythmic 
functions of core body temperature had not reentrained properly even after 5 days. 
One potential way of eliminating the masking effects on the endogenous circadian 
component of the temperature rhythm is a mathematical procedure (Minors and 
Waterhouse, 1992). This method has been used to "purify" the temperature profiles 
and will be discussed in Chapter 7. 
Usually, the circadian system reentrains in the direction of the induced shift 
and environmental zeitgebers (Klein and Wegmann, 1980; Wegmann et al, 1983). 
However, the direction of shift in the urinary aMT6s rhythm to the rapid 9h advance 
change of external time cues varied in different individuals even with similar 
environmental zeitgebers. Unfortunately, it was not possible to assess properly the 
direction of entrainment for some subjects and the time taken for complete 
reentrainment to occur due to the limited number of days studied. However, some 
individuals showed a definite tendency to reentrain to the rapid 9h advance shift by 
delay, a so-called antidromic effect (Klein and Wegman, 1980) where individuals 
delay the circadian system by 15h to complete the 24h cycle of entrainment. This 
effect has been observed in field studies over 8-10 time zones flying east (advancing 
time) (Mills et al, 1978; Colquhoun, 1979; Klein and Wegmann, 1980; Gander et al, 
1989; Spencer et al, 1994) and in laboratory based studies after phase-advances of 6h 
(Wever, 1980; Moline et al, 1992). 
The natural tendency for circadian rhythms to delay may explain the fact that 
some individuals apparently reentrained by phase-delay after a rapid and large phase- 
advance. Reasons for the antidromic effect remain unknown. Individual differences 
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in urinary aMT6s acrophase or "morning/evening" type personality scores did not 
correlate with the direction of natural reentrainment. However, the small sample size 
precludes the determination of any reliable relationship. 
The advantage of field studies on travellers and shift workers is the exposure 
to a whole range of external time cues and psychological influences. However, there 
are important disadvantages. Susceptibility to jet lag is highly individual therefore 
crossover experiments afford the best design. However, field studies are expensive 
and difficult to control since standardising social and environmental stimuli over each 
stage is virtually impossible. There are also difficulties in the collection of 
biochemical data. Laboratory studies provide a means of measuring a whole range 
of physiological and behavioural variables in detail and in a controlled environment. 
But the laboratory environment may not give a true reflection of the normal 
readaptation process in real life. For example, Wegmann et al (1986) described how 
sleep quality improved in the quieter isolated environment of the laboratory in 
comparison to real life. Allowing subjects to readapt in a normal environment 
overcomes this problem. This experimental model therefore acts as a compromise 
between field studies and studies in complete environmental isolation. 
Using a controlled environment it was possible to force a progressively larger 
delay phase-shift in circadian rhythms with no significant detrimental effect on sleep 
and mood and only minimal effects on performance. There were no differences 
between the four pre-treatment stages suggesting that this design is effective for 
crossover experiments. The subsequent and rapid 9h advance shift of external time 
cues induced major and significant problems related to behaviour and physiology. 
This model provides an appropriate method to study adaptation strategies after rapid 
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shifts in local time. The following Chapter describes the effects of melatonin and 
bright light on adaptation to a rapid 9h advance phase-shift in the second half of this 
experiment. 
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CHAPTER 6 
INFLUENCE OF MELATONIN ON ADAPTATION TO A 
LARGE RAPID ADVANCE PHASE-SHIFT IN THE 
PRESENCE OF CONFLICTING BRIGHT LIGHT 
Influence of Melatonin on Adaptation to a large Rapid Advance Phase-shift 
in the Presence of Conflicting Bright Light 
6.1 INTRODUCTION 
When exogenous melatonin is administered to humans, at appropriate times 
and in entrained conditions, it will phase-shift its own endogenous circadian rhythm 
(Arendt et at, 1985a; Lewy et at, 1992; Zaidan et at, 1994) and the alertness/fatigue 
rhythm (Arendt et at, 1984). These properties together with its somnolent and sleep 
inducing capabilities (Cramer et at, 1974; Vollrath et at, 1981; Waldhauser et at, 
1990; Dollins et at, 1993,1994) suggest that melatonin may provide a means of 
expediting the adaptation of circadian rhythms following time-zone transitions or 
shiftwork similar to the ability of bright light (Czeisler et at, 1990; Eastman, 1991) 
and help improve sleep, performance and mood at the appropriate times. 
In both field studies and a laboratory simulation melatonin has been shown to 
relieve subjective feelings of jet lag and facilitate the reentrainment of endogenous 
circadian rhythms (Arendt et at, 1987; Arendt and Aldhous, 1988; Claustrat et at, 
1992; Nickelsen et at, 1991b; Petrie et at, 1989,1993 and Samel et at, 1991). 
Additionally, during rotating shift schedules melatonin administration favours the 
reentrainment of the body temperature rhythm (Armstrong et at, 1986) and improves 
sleep and alertness (Folkard et at, 1993). However, in previous studies not all 
subjects responded beneficially to melatonin treatment (Arendt et at, 1985a; Mallo et 
at, 1988; Skene et at, 1988). This may be due to the incorrect timing of melatonin 
administration or perhaps inappropriate exposure to natural ambient light. 
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Light exposure to treat jet lag can be timed to induce phase-advances or phase- 
delays depending on its position with regard to the temperature minimum (Czeisler 
et at, 1989; Minors et at, 1991, van Cauter et at, 1994, section 1.4.3). However, 
in real life it is inconvenient and difficult to control natural light exposure. This may 
occur at inappropriate times for the most expeditious reentrainment of circadian 
rhythms and may counteract any beneficial influence of melatonin. 
In field studies, it is difficult to standardise conditions in a crossover design 
experiment. However, in a controlled environment it is possible to force a 9-10 hour 
delay phase-shift and then release the subjects back into their normal environment, 
simulating a rapid 9-10 hour eastward time-zone shift (see chapter 5). 
This present study was designed primarily to study the effects of morning 
bright light exposure potentially encountered by time-zone travellers or shift workers 
and the consequence it may have on melatonin treatment administered near bedtime, 
after a rapid 9h advance shift of external time cues, i. e. after a simulated eastward 
transmeridian flight over 9 time-zones. Bright light exposure was timed to phase- 
delay the biological clock and the melatonin treatment to facilitate the adaptation by 
phase-advancing. 
A second aim was to identify whether the beneficial influence of melatonin 
on behaviour corresponds to the phase-shifting or resynchronising effects on the 
endogenous "clock" in a placebo-controlled randomised crossover trial in the same 
environment. 
The effects of melatonin or placebo on adaptation to a rapid 9h advance phase- 
shift were investigated, in the presence and absence of bright light exposure, in a4 
leg, randomised, placebo-controlled, double blind crossover study. 
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6.2 SUBJECTS and METHODS 
6.2.1 Subjects 
See section 5.2.1 
6.2.2 Study design 
Figure 6.1 shows a diagrammatic representation of the study. Section 5.2.2 describes 
the initial part of the study in detail. In summary, volunteers were initially subjected 
to a gradual, forced synchronised phase-delay of 9h using a combination of bright 
light and imposed darkness (and sleep) in a controlled environment (D1-D5). The 
adaptation to a subsequent rapid 9h advance shift in the subjects normal environment 
was then studied under 4 different treatments. 
Treatments: 
Immediately following the maximum phase-delay (9h) induced by last 
light/dark treatment, subjects were released back into their normal environment and 
required to assume the baseline sleep/wake schedule, i. e. retiring to bed at 2330h and 
waking at 0800h for 6 days (D6-1 1). The subsequent readaptation of the subjects in 
their normal environment was then observed under 4 different treatments consisting 
of 1) melatonin + dim light (MT), 2) placebo + dim light (P), 3) melatonin + bright 
light (MT + BL) and 4) bright light + placebo (BL). Melatonin (5mg in gelatin- 
lactose capsules) or placebo (vehicle) was administered just before the desired bedtime 
at 2300h on D6-8. Bright light treatment occurred between 0800-1200h on D7-8 (dim 
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Figure 6.1 Diagrammatic design of the study 
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After a baseline period (days [D] -2 to 0), this study design was used to 
induce an initial, gradual 9h delay phase-shift (D 1-5) in volunteers using a 
combination of exposure to bright light (- 1200 lux, o) and darkness (ý). 
Subjects then resumed their normal baseline sleep/wake cycle in a normal 
environment on day 6 inducing a rapid 9h advance phase-shift of local time 
cues. In this 4 leg crossover study the readaptation was studied under four 
different treatments : melatonin, placebo, melatonin+bright light and bright 
light. ® Time of bright light treatment (2000 lux). + Time of melatonin 
(5mg) or placebo administration. O Natural ambient light exposure. 
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light, < 150 lux; bright light, 2000 lux). Subjects avoided bright sunlight by wearing 
sunglasses at all times when outdoors (transmitting < 10% of the light). At dusk, 
they were required to remain in ordinary domestic lighting (50-300 lux) until bedtime 
(and darkness). Each subjects' ambient lighting at work and home was monitored, 
see section 5.4.1. 
Subjects were only allowed to sleep during the periods of darkness throughout 
this study. Naps were forbidden. 
6.2.3 Sampling 
See section 5.2.3. 
6.2.4 Behavioural Measurements 
See section 5.2.4 
6.2.5 Hormone assays 
See section 5.2.5 
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6.3 STATISTICAL ANALYSIS 
6.3.1 aMT6s and core body temperature profiles 
Comparisons between treatments for the aMT6s rhythm were made on the 
post-treatment days 10 and 11 where exogenous melatonin (aMT6s) had cleared from 
the urine. On these days cosinor analysis gave 100 % fits at p<0.05. Temperature 
profiles gave 100% fits over the treatment and post-treatment periods. Repeated 
measures ANOVA followed by Duncan's post-hoc test were used to determine 
differences between treatments for the raw aMT6s profiles on D 10-11 and cosinor- 
derived rhythm parameters of aMT6s (D10-11) and temperature (D7-11). 
6.3.2 Mood and performance daily means and sleep data 
Treatment effects on the daily means for mood and performance parameters 
and sleep variables were identified using repeated measures ANOVA (factors: day of 
study and treatment), D7-11 (or nights 6-11 for sleep) followed by Duncan's multiple 
range test for comparison between treatments. 
6.3.3 Mood and performance rhythms. 
For comparison between treatments, 24h profiles for each mood and 
performance parameter were analysed by cosinor analysis over 3-day windows for 
more reliable estimates of acrophase (treatment: D7-D9_ and post-treatment: D9-D11) 
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followed by ANOVA (for repeated measures, factors: day of study and treatment, 
D7-D11) and Duncan's multiple range test. An estimate of reentrainment to the 24h 
day (and reestablishment of baseline cosinor rhythmicity with a period of 24h) is 
provided by (1) percentage number of subjects with significant 24h cosine fits and (2) 
percentage variance accounted for by a cosine curve, see section 2.8. All 
comparisons are made with respect to individuals' baseline values. 
6.4 RESULTS 
One subject did not conform to the protocol and was therefore excluded from 
the analysis. One subject did not exhibit a significant cosine rhythm (from cosinor 
analysis) or time of day effect (repeated measures ANOVA) for SAM-5 performance 
response time and was excluded from the analysis of this parameter. 
The phase position of the light and melatonin treatments with respect to the 
temperature and melatonin rhythms was determined on D6 during the placebo stage. 
Measurement of aMT6s and temperature on this day occurred in conditions of dim 
light (< 200 lux) or darkness with the subjects resting or asleep the entire 24h 
period. The midpoint of light treatment occurred 2.94 ± 1.21h (mean ± SD) before 
the temperature minimum. Melatonin administration occurred 12.4 ± 1.21h (mean 
± SD) before the temperature minimum and 7.4 ± 1.21h (mean ± SD) before the 
calculated melatonin onset in plasma. 
6.4.1 Ambient light monitoring 
See section 5.4.1 
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6.4.2 aMT6s 
Repeated measures ANOVA on raw aMT6s levels on D10-11 identified a 
significant time of day by treatment interaction (p=0.0018, Figure 6.2) where MT 
and MT + BL treatments favoured faster reentrainment of the aMT6s rhythm over 
placebo and bright light which remained delayed. No effect of treatment on aMT6s 
acrophase was evident (D10-11, p>0.1), Figure 6.3. Two subjects (AT5 and BT5) 
delayed with MT and MT + BL treatment whereas all others advanced, Figure 6.3. 
This differing effect of melatonin on certain subjects did not correlate with the 
direction of individuals natural entrainment (cf Figure 5.18) or baseline acrophase. 
BL delayed the aMT6s acrophase in 6 out of 7 subjects. 
6.4.3 Temperature 
No differences in temperature acrophase were seen between treatments 
(Figures 6.4 and 6.5), although a significant time by treatment interaction for rhythm 
amplitude (p=0.018) was evident where melatonin treatment favoured a faster return 
to baseline amplitude over placebo and bright light. 
6.4.4 Mood 
There was a trend for both melatonin groups to improve daily mean alertness 
and cheerfulness over placebo (p=0.06), Figure 6.6. BL improved alertness and 
cheerfulness transiently over placebo, during the treatment period. There were no 
significant effects on calmness. The alertness rhythm reestablished a normal baseline 
cosine rhythm under the melatonin treatment groups with complete reentrainment, 
Figures 6.7 and 6.8. 
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Figure 6.2 Effect of melatonin and bright light on aMT6s profiles during 
adaptation to a rapid 9h advance phase-shift 
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Adaptation of the circadian profiles of urinary aMT6s after a rapid 9h advance phase-shift 
under 4 different treatments: 1) melatonin (MT, A ), 2) placebo (P, 0 ), 3) melatonin + bright 
light (MT+BL, ") and 4) bright light (BL,   ). Melatonin treatment (? ) was timed to 
phase-advance (2300h on D6,7 and 8) . 
Bright light exposure (Q ) was timed to phase- 
delay (0800-1200h on D7 and D8). A significant time of day by treatment interaction 
(p<O. 002) on D 10-11 (exogenous melatonin days excluded) where both melatonin treatment 
groups facilitated faster reentrainment of the aMT6s rhythm over BL and P. M Darkness 
from 2330h to 0800h (< 1 lux), D6-11 .m Natural ambient light. Values represent mean +/- 
SEM (n=7) and are plotted with reference to the midpoint of the urine collection period. 
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Figure 6.3 Effect of melatonin and bright light on adaptation of 
aMT6s acrophase to a rapid 9h advance phase-shift 
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Acrophase estimates for urinary aMT6s during adaptation to a rapid 9h advance 
phase-shift (on day 6) showing (a) effect of 4 different treatments on group mean 
(n=7): melatonin (MT, A), placebo ( ), melatonin + bright light (MT+BL, ") 
and bright light (13 ), no significant effect of treatment, repeated measures 
ANOVA), and (b) two subjects who delayed with MT (A) and MT+BL (0) 
treatments compared to all others who advanced with MT (A) and MT+BL ("). 
Exogenous melatonin days excluded from the analysis (- --). Values 
represent mean +/- SEM. 4 Bright light exposure. Melatonin 
administration. 
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Figure 6.5 Effect of melatonin and bright light on adaptation of the 
temperature cosinor rhythm to a rapid 9h advance phase-shift 
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(a) acrophase and (b) amplitude estimates for the core body temperature 
rhythm during adaptation to a rapid 9h advance phase-shift (on day 6) under 4 
different treatments: melatonin (MT, A ), placebo (O), melatonin + bright 
light (MT+BL, ") and bright light ( ). The rhythm apparently reentrained 
for all treatment groups by D7. A time by treatment interaction (repeated 
measures ANOVA, p<0.02) for rhythm amplitude indicated faster adaptation 
with MT treatment. Values represent mean +/- SEM, n=7. 
4 Bright light exposure. M Melatonin administration. 
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Under bright light and placebo treatments, the normal baseline rhythm remained 
completely disrupted. The low % rhythm and low number of subjects with significant 
cosine fits with cosinor analysis prevented accurate estimates of acrophase to be 
determined. 
6.4.5 Performance 
An effect of treatment proved significant for daily mean performance 
efficiency only (SAM-1, p=0.022 and SAM-5, p=0.0044, D7-11, Figures 6.9 and 
6.10) where both MT and MT + BL significantly (p < 0.01) countered the decrements 
in daily means under P treatment. BL alone improved these ratings over P (p <0.01) 
but only transiently. 
No consistent and reliable cosine rhythm could be fitted to accuracy and 
efficiency data (see section 5.4.2). Both MT and the MT+BL treatment groups 
facilitated the reentrainment of the response time rhythms for both SAM-1 and SAM- 
5, Figures 6.11 and 6.12, respectively. Lack of fit and low % rhythm precluded 
estimates of reentrainment for bright light and placebo groups. 
6.4.6 Sleep 
MT and MT+BL improved sleep duration (p < 0.05), quality (p < 0.01, Figure 
6.13) and duration of night awakenings (reduced, p <0.05, Figure 6.13) over P and 
BL, N6-11. No differences were found between MT and MT+BL and between P 
and BL for any sleep parameter. 
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Figure 6.6 Influence of melatonin and bright light on adaptation of 
mood to a rapid 9h advance phase-shift 
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Daily means for (a) alertness and (b) cheerfulness during adaptation to a rapid 
advance phase-shift (on day 6) under 4 different treatments: melatonin (" ), placebo 
(a), melatonin + bright light (") and bright light (0). There was a trend for both 
melatonin groups to improve alertness and cheerfulness over placebo (repeated 
measures ANOVA, p=0.06). 
ý Melatonin administration days. 
4 Bright light exposure days 
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Figure 6.8 Influence of melatonin and bright light on adaptation of the 
alertness cosinor rhythm to a rapid 9h advance phase-shift 
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a) Cosinor-derived self-rated alertness acrophase estimates using 3-day windows during 
adaptation to a rapid 9h advance phase-shift (on day [D ] 6) under 4 different 
treatments: melatonin (MT, AL ), Placebo (P, 0 ), melatonin + bright light (MT+BL, ") 
and bright light (BL,   ). An estimate of reentrainment (to a 24h cosine rhythm) is 
provided by (b) % number of subjects with significant cosine fits (set at p<0.05) and (c) 
% variance accounted for by a cosine curve. Complete reentrainment was evident with 
MT and MT+BL treatments. Lack of fit and low % rhythm precluded reliable 
estimates of reentrainment for BL and P treatments, see Figs. (b) and (c). Values for 
Figs. (a) and (c) represent mean +/- SEM (n=7). D7-9: treatment period, D9-1 1: post- 
treatment. 
210 
Figure 6.9 Influence of melatonin and bright light on the adaptation 
of SAM-1 performance to a rapid 9h advance phase-shift 
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Daily mean performance measures for SAM-1 (a) efficiency, (b) accuracy and (c) 
response time during adaptation to a rapid advance phase-shift (on day 6) under 4 
different treatments: melatonin (A ), placebo (Q ), melatonin + bright light (9) and 
bright light (  ). Significant treatment effect for efficiency only (p<0.05, repeated 
measures ANOVA, D7-11) where placebo treatment was significantly worsethan MT 
(p<0.01) and MT+BL and BL treatments (p<0.05), Duncan's multiple range post-hoc. 
ý Melatonin administration days. 4 Bright light exposure days. Values 
represent mean +/- SEM, n=7. 
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Figure 6.10 Influence of melatonin and bright light on the adaptation 
of SAM-5 performance to a rapid 9h advance phase-shift 
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Daily mean performance measures for SAM-5 (a) efficiency, (b) accuracy and (c) 
response time during adaptation to a rapid advance phase-shift (on day 6) under 4 
different treatments: melatonin (& ), placebo (o ), melatonin + bright light ( ") and 
bright light (  ). Significant treatment effect for efficiency (p<0.005, repeated measures 
ANOVA, D7-11) where placebo treatment was significantly worse than MT and MT+BL 
(p<0.01) and BL treatments (p<0.05), Duncan's multiple range post-hoc. 
ý Melatonin administration days. Q Bright light exposure days. Values represent 
mean +/- SEM, n=6. 
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Figure 6.11 Influence of melatonin and bright light on the adaptation of 
SAM-1 performance cosinor rhythm to a rapid 9h advance phase-shift 
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a) Cosinor-derived SAM-1 response time acrophase estimates using 3-day windows 
during adaptation to a rapid 9h advance phase-shift (on day [D ] 6) under 4 different 
treatments: melatonin (MT, A ), Placebo (P, Q ), melatonin + bright light (MT+BL, 
") and bright light (BL,   ). An estimate of reentrainment (to a 24h cosine 
rhythm) is provided by (b) % number of subjects with significant cosine fits (set at 
p<0.05) and (c) % variance accounted for by a cosine curve. Significant 
reentrainment was evident with MT and MT+BL treatments. Lack of fit and low % 
rhythm precluded reliable estimates of reentrainment for BL and P treatments, see 
Figs. (b) and (c). Values for Figs. (a) and (c) represent mean +/- SEM (n=7). D7-9: 
treatment period, D9-11: post-treatment. 
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Figure 6.12 Influence of melatonin and bright light on the adaptation of 
SAM-5 performance cosinor rhythm to a rapid 9h advance phase-shift 
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a) Cosinor-derived SAM-5 response time acrophase estimates using 3-day windows 
during adaptation to a rapid 9h advance phase-shift (on day [D ] 6) under 4 different 
treatments: melatonin (MT, A ), Placebo (P, o ), melatonin + bright light (MT+BL, ") 
and bright light (BL,   ). An estimate of reentrainment (to a 24h cosine rhythm) is 
provided by (b) % number of subjects with significant cosine fits (set at p<0.05) and (c) 
% variance accounted for by a cosine curve. Significant reentrainment was evident 
with MT and MT+BL treatments. Lack of fit and low % rhythm precluded reliable 
estimates of reentrainment for BL and P treatments, see Figs. (b) and (c). Values for 
Figs. (a) and (c) represent mean +/- SEM (n=6). D7-9: treatment period, D9-11: post- 
treatment. 
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Figure 6.13 Influence of melatonin and bright light on the adaptation 
of sleep to a rapid 9h advance phase-shift 
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Subjective sleep measures of (a) sleep quality (SQ), (b) duration of night awakenings 
(DNA) and (c) sleep latency during adaptation to a rapid advance phase- shift (on 
day 6) under 4 different treatments: melatonin (A), placebo (O), melatonin + 
bright light (" ) and bright light ( ). Significant treatment effect for SQ and 
DNA (p<0.01, repeated measures ANOVA, nights 6-11) where both melatonin 
treatment groups improved ratings significantly over placebo and bright light 
(p<0.05, Duncan's post-hoc). ý Melatonin administration days. Q Bright light 
exposure days. Values represent mean +/- SEM, n=7. 
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6.5 DISCUSSION 
Time-zone travellers and shift workers are often exposed to natural bright light 
at times which may oppose the quickest adaptation of the circadian system. For 
example, after flying east to a destination 9 time-zones away, the quickest adaptation 
is generally to phase-advance the circadian system. However, working or relaxing 
in bright light the following morning may delay the biological clock according to 
phase-response curve theory (Czeisler et al, 1989; Minors et al, 1991, van Cauter et 
al, 1994, section 1.4.3, Figure 1.5), preventing the quickest adaptation, and 
prolonging the effects of "jet lag" in some individuals whose natural direction of 
entrainment is to advance. Eastman and Miescke (1990) described how evening light 
exposure of about approximately 2000 lux facilitated the entrainment of the 
temperature rhythm in 74% of the subjects to a 26h sleep/wake schedule but only 
25% of the subjects adapted with morning light exposure of the same intensity. 
Therefore, natural bright light exposure may oppose the phase-shifting effects of 
melatonin and negate any beneficial influence of melatonin on the circadian clock and 
behaviour. 
One of the aims of this study was to investigate the effects of melatonin timed 
to facilitate the reentrainment of circadian rhythms by phase-advancing and exposure 
to sufficiently intense morning bright light suitably timed to phase-delay. Of the four 
treatments, morning bright light alone phase-delayed the aMT6s rhythm relative to 
placebo in 6 out of 7 subjects. No such effect could be shown with the temperature 
rhythm, presumably due to masking. Interestingly, bright light treatment did not 
improve or worsen sleep and even improved daily mean performance scores and 
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mood ratings compared to placebo. However, this effect proved transient, in most 
cases ameliorating mood and performance only over the treatment period. In 
addition, the alertness and performance response time rhythms did not reestablish 
normal baseline patterns throughout the treatment and post-treatment periods. This 
suggests that the improvements seen with bright light were most likely due to direct 
psychostimulating effects (Campbell and Dawson, 1990; French et al, 1990; Myers 
and Badia, 1993). The combination of melatonin and bright light treatment was as 
effective as melatonin treatment alone at improving behaviour. In summary, bright 
light, which phase-delayed the aMT6s rhythm, did not cause any great detrimental 
effects on performance, sleep or mood relative to placebo and even had transient 
beneficial effects on mood and performance. 
The responsiveness of subjects to the phase-shifting effects of melatonin was 
variable. The aMT6s rhythm delayed in 2 subjects with melatonin treatment whereas 
the others advanced irrespective of the individuals natural direction of reentrainment. 
Other studies have also reported inconsistent effects of melatonin on the biological 
clock. Arendt et al (1985a) studied the effects of 2mg melatonin given at 1700h daily 
for one month in spring or 3 weeks in autumn, without environmental control. The 
endogenous melatonin rhythm (on the last day of the dose) was found to advance in 
only 5 out of 11 subjects in Autumn. However, the endogenous and exogenous 
components could not be easily distinguishable. In spring, the melatonin rhythm (on 
the day after the last dose) advanced in only 2 out of 12 subjects. Mallo et al (1988) 
found no phase-shift in the endogenous melatonin rhythm during administration of 
8mg at 2200h for four days, but found an advance 3 days after the final melatonin 
dose. Such inconsistencies may be due to the exposure of natural bright light 
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opposing the phase-shifting effect of melatonin in the latter studies or individual 
differences in circadian clock time. In the present study, there was no indication of 
significant differences in individual circadian clock time as shown by similar 
temperature minimums and aMT6s acrophases during the baseline and at the end of 
the gradual delay phase-shift. 
Using the melatonin phase-response curve (PRC) of Lewy et al (1992) as a 
guide (see Figure 1.5), melatonin was first given approximately 7.5 hours prior to the 
expected melatonin onset time in plasma which should have fallen within the phase- 
advance portion of the PRC for every individual. A recent report by Zaidan et al 
(1994) also predicts an advance phase-shift with melatonin administration at the time 
used in the present study. 
Previous studies have shown improvements in sleep patterns and alertness with 
either no effect on performance (Arendt et al, 1987; Samel et al, 1991) or small 
deleterious effects (Folkard et al, 1993) with melatonin treatment. However, baseline 
differences and learning effects in these experiments prevented studying performance 
variables effectively. In the present study, important improvements in performance 
were observed with melatonin treatment after a large phase-shift in external time 
cues. 
Melatonin, timed to theoretically phase-advance its own endogenous rhythm 
was consistently effective at improving sleep, mood and performance parameters even 
in the presence of bright light exposure timed to counteract the melatonin treatment. 
Using cosinor analysis, alertness and response time rhythms completely reestablished 
normal baseline patterns within 1-2 days (during treatment) with both melatonin and 
melatonin + bright light treatments unlike bright light alone and placebo treatments 
218 
which took at least 5 days. 
In contrast, there was no significant adaptation of the aMT6s rhythm 
immediately after treatment withdrawal, although a significant time by treatment 
interaction (ANOVA) in the raw aMT6s data indicated that both melatonin groups 
favoured faster reentrainment over placebo and bright light treatments. Thus it seems 
likely that the beneficial effects of melatonin on sleep and performance may not be 
mediated through the entrainment of the endogenous "clock" and all circadian 
rhythms. This is also suggested in a study where melatonin stabilised sleep patterns 
and improved mood in a blind man without entrainment of the temperature or cortisol 
rhythms (Folkard et al, 1990). 
Moreover, the improvements in behaviour observed in this study were 
obtained without a pre-shift (i. e. `pre-flight') treatment paradigm as used in other 
studies (Arendt et al, 1986; Arendt and Aldhous, 1988; Arendt et al, 1987; Petrie et 
al, 1989; Samel et al, 1991) and only 3 days post-shift (i. e. `post-flight') treatment. 
In field studies where melatonin treatment was administered only after the flight, self- 
rated jet lag still improved (Claustrat et al, 1992; Petrie et al, 1993). This treatment 
schedule becomes of great practical benefit since daytime treatment prior to travel 
may give rise to problems of increased drowsiness in some individuals (Lino et al, 
1993, see Chapters 9-10 and Table 2.1). 
In summary, all subjects responded similarly with immediate improvements 
in behaviour with melatonin alone and when used in combination with bright light, 
despite 2 subjects who phase-delayed and 5 who phase-advanced. Disturbances in 
sleep which are the most common complaint of shift workers on rotation (Kogi, 1985) 
may be the cause of the general feeling of discomfort, tiredness and poor performance 
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common to jet lag and shift work more than disturbances in circadian rhythms. The 
beneficial effect of melatonin on mood and performance coincides with improvements 
in sleep and may be directly related to sleep quality. However, an effect on the 
timing mechanisms of sleep, performance and mood cannot be excluded since the 
improvements were not transient. 
In conclusion, suitably timed melatonin treatment significantly alleviates 
behavioural disturbances associated with large shifts of external time cues in the 
presence or absence of bright light timed to counteract the phase-shifting properties 
of melatonin. This effect of melatonin is not wholly mediated through an effect on 
the biological clock or the reentrainment of all circadian rhythms. 
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CHAPTER 7 
PURIFICATION OF THE CORE BODY TEMPERATURE 
RHYTHNI AFTER SIMULATED TIME ZONE TRAVEL 
Purification of the core body temperature rhythm after simulated time-zone 
travel 
7.1 INTRODUCTION 
The circadian rhythms of melatonin and its urinary metabolite aMT6s, together 
with core body temperature are commonly used phase markers of the endogenous 
body clock. However, these rhythms are susceptible to powerful masking (disturbing) 
influences which can distort the rhythm and result in the unreliable estimation of 
circadian time. Although the melatonin/aMT6s rhythms appear to be minimally 
affected by exogenous influences apart from light and posture (Lewy et al, 1980; 
Deacon et al, 1994), core body temperature is susceptible to many exogenous factors. 
For example, sleep causes body temperature to fall (Mills et al, 1978b; Wever, 
1985b; Minors and Waterhouse, 1987) and activity, upright posture and bright light 
increases temperature (Moog and Hildebrandt, 1989; Dawson and Campbell, 1991; 
Minors and Waterhouse, 1989; Myers and Badia, 1993). 
Measured rhythms are therefore the product of two components. One is 
governed by the endogenous body clock, the other is dependent upon exogenous 
influences, often described as "masking" effects. The size of the masking effect will 
depend upon the relative strengths of the endogenous and exogenous components 
acting on the circadian rhythm. A rhythm which is highly susceptible to exogenous 
factors (such as the body temperature rhythm) will apparently adapt faster to changes 
in local time cues than rhythms which are more strongly influenced by the slow 
reentrainment of the internal body clock (such as the melatonin rhythm). 
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Attempts to separate these components may therefore provide more reliable 
information about the behaviour of the endogenous body clock. There are two main 
techniques for separating exogenous influences from the endogenous component. The 
first involves a "constant routine" procedure which eliminates or at least minimises 
exogenous masking effects. Subjects are kept awake for at least 24h in an 
environment of constant lighting, ambient temperature and humidity, and are given 
identical and small snacks at frequent and regular intervals in either a recumbent 
(Czeisler et al, 1989) or sedentary position with minimal movement (Mills et al, 
1978a). 
The second procedure involves changing the daylength in isolated 
environments free from everyday external time cues. There is a limited daylength to 
which the endogenous body clock can normally entrain to (23-27h) beyond which it 
will free-run with its natural endogenous m 25h period (Wever, 1983). By extending 
or shortening the day beyond this range of natural entrainment, it will effectively 
separate the two components. For example, requiring subjects to live on a 21h day, 
will allow the endogenous rhythm to free-run with a periodicity of approximately 25h. 
By observing the exogenous component (with a periodicity of 21h) over all phases of 
the endogenous cycling rhythm, it is possible to determine the degree of masking due 
to activity, sleep, posture and meals, etc (Wever, 1979; Minors and Waterhouse, 
1982). 
The constant routine procedures are impractical and laborious to study 
circadian rhythms on a day to day basis when investigating adaptation to time-zone 
shift or shift work. One of the major problems is depriving the subjects of sleep. 
However, an estimate of the masking effect can be determined by comparing the 
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circadian rhythm in a normal environment with that obtained under constant routine 
conditions. The difference between the two rhythms can then be used as a measure 
of the masking effect (Wever, 1985b). Then by simply subtracting the exogenous 
increment, a more reliable estimate of the endogenous behaviour of the body clock 
can be determined in a normal environment. This does assume that the endogenous 
and exogenous components are additive and independent of each other, however. 
One mathematical procedure which employs this idea has been developed by Minors 
and Waterhouse (1992,1993). 
It is the purpose of this chapter to describe the results obtained from using 
such a mathematical model to uncover the endogenous behaviour of the body clock 
after simulated time-zone travel, using the core body temperature rhythm as a 
circadian phase marker. Using comparisons with the raw temperature data and 
urinary aMT6s, the usefulness of this model will be assessed. 
Dr J. M. Waterhouse and Dr D. S. Minors kindly performed the "demasking" 
procedure on the raw temperature data. I then performed the subsequent analysis. 
7.2 METHODS 
The experiment is described in detail in Chapters 5 and 6. In summary, after 
a 3-day baseline (days [D] 1-3), 7 healthy volunteers were initially subjected to a 
gradual 9h delay phase-shift in partial isolation using a combination of exposure to 
bright light and darkness/sleep (over 5 days, Dl-5). Subjects then resumed their 
baseline sleep/wake cycle in a normal environment inducing a rapid 9h advance 
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phase-shift in local time cues and simulating a 9h eastward time-zone shift (on D6). 
In this 4-leg crossover study the readaptation was studied under four different 
treatments, 1) melatonin, 2) placebo, 3) bright light and 4) melatonin and bright light. 
Core body temperature was recorded every 6 minutes throughout the whole 
study and averaged into 30 minute bins for analysis. 
7.2.1 Purification procedure 
This "demasking" procedure relied on the individuals activity diaries, in which 
they recorded the type of activity during half hour segments throughout each day (see 
section 2.5). In addition, sleep logs were used to determine periods of recumbency 
(lying) and sleep. The main categories used for "purification" were `sleeping', 
`lying', `relaxing' (e. g watching TV, reading), `sitting alert' (e. g. sitting working at 
a computer or writing at desk) and `light activity'( e. g. walking). Subjects refrained 
from vigorous activity (e. g. playing squash). `Lying' was taken as the first 30 
minutes in bed, and other times indicated on their logs as in bed but not asleep. 
The principle of the purification procedure was as follows. Depending on the 
type of activity that occurred during the previous half hour, temperature data were 
either increased or decreased by 0.1°C increments or remained unchanged. For every 
adjustment made in the temperature data, the purified 24h data set was compared with 
the standard endogenous 24h profile obtained under constant routine conditions. This 
standard profile was compiled by pooling data from approximately 80 subjects and 
was taken to represent the normal population as a whole (Minors and Waterhouse, 
1992). By superimposing the two profiles and by altering the size of the masking 
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effects by 0.1°C increments, the best-fitting profile which produced the minimum 
summed square deviations between the purified data set and the standard profile was 
determined. 
All temperature data recorded when the subjects were lying were unchanged. 
"Lying" was taken to be the standard postural position/activity where no masking 
effects were present since the standard endogenous profile was obtained when the 
subjects were inactive and recumbent in constant routine conditions. Temperature 
data recorded when subjects were sleeping were increased and data recorded when 
subjects were relaxing (but sitting/erect), sitting alert or walking were reduced. 
This procedure was performed a number of times to cater for all the 
combinations of possible fits. For example, under the `sleep' category, every time 
the subject recorded being asleep (which depresses body temperature), the 
temperature data were increased in 0.1°C increments from 0 to 1.0°C. This means 
that the purification procedure needed to be performed 10 times for this parameter. 
For temperature data recorded whilst walking (light activity category, corresponding 
to an elevation in temperature), values were reduced from 0 to -1. IOC. This means 
that the purification procedure needed to be performed 11 times for this category. 
Therefore, just using these two categories the purification procedure was performed 
10 x 11 times to determine the best-fit. This was repeated for every subject for every 
day of the trial. All five categories were used. 
226 
7.3 STATISTICAL ANALYSIS 
Cosinor analysis was used to determine the rhythm parameters of acrophase 
and amplitude (section 2.8) for both the raw "masked" and purified temperature 
profiles. 
In order to obtain more reliable estimates, for each individual the cosinor- 
derived parameters were grouped on identical days during baseline and gradual delay 
phase-shift over the 4 legs of the study for body temperature under masked conditions 
and after purification, and for aMT6s for comparison. 
7.3.1 Baseline (D-2 to DO) 
Differences in purified temperature acrophase and amplitude estimates over 
the baseline were assessed by one way ANOVA. Comparisons between temperature 
parameters before and after purification were analysed by Student's paired t-test to 
determine the effect of purification on acrophase and amplitude values obtained under 
normal entrained conditions. 
7.3.2 Gradual 9h delay phase-shift (D1-5) 
Acrophase and amplitude values for masked and purified temperature rhythms 
(and aMT6s acrophases) were calculated as a difference from individuals' mean 
baseline. Subjects were then grouped to compare (a) degree of shift between purified 
temperature, raw temperature and aMT6s rhythms and (b) temperature amplitude 
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values before and after purification, using repeated measures ANOVA (factors: day 
of study and type of rhythm). Regression correlation was used to determine any 
relationship in the rate of adjustment between the rhythms. 
7.3.3 Rapid 9h advance phase-shift (D6-11) 
Comparisons of the normal rate of adaptation between aMT6s, purified 
temperature and masked temperature were assessed under placebo treatment. 
Due to the uneven number of subjects with significant cosine fits (and with 
variable estimates of acrophase, e. g. see Table 7.1) repeated measures ANOVA was 
not appropriate. One way ANOVAs were used to determine differences in the degree 
of adaptation between the aMT6s rhythm, and the temperature rhythm before and 
after purification across each day. The effect of treatment on adaptation of the 
purified temperature rhythm was determined in a similar way. 
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7.4 RESULTS 
Only the 24h data sets with significant cosine fits (p<0.05) were used. 86% 
of the purified 24h data sets were significant at p<0.05 compared to 99.5% of the 
masked temperature data. 
7.4.1 Normal baseline conditions 
No significant differences in the purified or raw temperature estimates of 
acrophase and amplitude were apparent over the baseline. The purified estimates of 
acrophase were significantly phase-delayed by 1.15 ± 0.13h relative to the raw 
estimates (p<0.02, masked rhythm = 16.16 ± 0.06h, purified rhythm = 17.31 ± 
0.15h, mean ± SEM, n =7). The amplitude of the rhythm was significantly reduced 
by approximately 50% after purification (p<0.0001, masked = 0.52 ± 0.02°C, 
purified = 0.26 ± 0.02°C, mean ± SEM), Figure 7.1. 
7.4.2 Adaptation to a gradual 9h delay phase-shift 
The purified temperature rhythm was significantly slower to adjust to the 
gradual 9h delay phase-shift than the masked temperature rhythm by an average of 
0.7 ± 0.4h per day and the aMT6s rhythm by 1.05 ± 0.31h per day (D1-5, mean 
± SEM, treatment and time by treatment interaction effect, p<0.05), Figures 7.2 
and 7.3. The maximum degree of shift in the purified temperature rhythm (compared 
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Figure 7.1 Purification of the core body temperature rhythm 
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Purification of the core body temperature rhythm for one subject during a baseline 
day in a normal environment showing (a) the temperature rhythm under masked 
conditions () and after purification (-), (b) the degree of masking effect from 
sleep and activity and (c) subjects activity diary. Arrow indicates calculated peak 
time of the rhythm. 
230 
Figure 7.2 Comparison of the rate of adjustment between the 
aMT6s and temperature (raw and purified) rhythms to a gradual 9h 
delay shift 
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Degree of delay phase-shift (from acrophase estimates) in the aMT6s rhythm 
(f ), and the core body temperature rhythm under masked conditions (0 ) 
and after purification (U) during adaptation to a gradual 9h delay phase- 
shift (days 1 to 5). The purified temperature rhythm was significantly slower 
to adjust than the masked temperature rhythm by a mean (+/- SEM) 0.7 +/- 
0.4h per day and the aMT6s rhythm by 1.05 +/- 0.31h per day (time by 
treatment interaction, p<0.05). Values represent mean +/- SEM, n=7 
subjects. 
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Figure 7.3 Relationship between the rate of adaptation of purified and 
raw temperature rhythms and aMT6s rhythm to a gradual 9h delay 
phase-shift 
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(c) raw temperature and aMT6s rhythms. Regression values inside brackets are +/- SEM. 
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to mean baseline) on D5 was 8.14 ± 0.38h and D6 was 8.98 ± 1.33h (mean ± 
SEM). There were no significant differences in the degree of shift obtained between 
aMT6s, purified temperature and raw temperature rhythms on D6 with only a 
tendency for the purified temperature rhythm to be slightly delayed compared to the 
raw temperature and aMT6s rhythms on D5 (p=0.06). 
The temperature rhythm amplitude under masked conditions was significantly 
reduced by 0.18 ± 0.02°C (D1-5, p <0.005) relative to the purified estimates, Figure 
7.4. After purification the rhythm amplitude showed no significant deviation from 
baseline. 
7.4.3 Adaptation to rapid 9h advance shift 
The masked temperature rhythm apparently adjusted to a rapid 9h advance 
phase-shift in one day whereas even after 5 days (D11) the purified temperature and 
aMT6s rhythms were not fully adjusted (p<0.05, significantly different from 
individuals baseline, n =7), Figure 7.5, Table 7.1. 
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Figure 7.4 Effect of purification on the temperature rhythm 
amplitude during a gradual 9h delay phase-shift 
I I 
012345 
Day of study 
-0.24 
Amplitude of the core body temperature rhythm under masked conditions (0) 
and after purification (  ) during adaptation to a gradual delay 9h phase-shift 
(days 1 to 5). The temperature rhythm amplitude under masked conditions was 
significantly reduced compared to the rhythm after demasking (ANOVA, 
p<0.005). Values represent mean +/- SEM, n=7. 
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Figure 7.5 Effect of purification on the rate of adjustment of the 
temperature rhythm to a rapid 9h advance phase-shift 
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Day of study 
I IIIII 
Degree of advance phase-shift (from acrophase estimates) in the aMT6s rhythm 
(f ), and the core body temperature rhythm under masked conditions ( 0) and 
after purification ( ) during adaptation to a rapid 9h advance phase-shift (on 
day 6). 5 days after the shift (day 11) the purified temperature and aMT6s 
rhythms were not fully adjusted (p<0.05) unlike the masked temperature rhythm 
which was apparently adjusted by day 7/8. Values represent mean +/- SEM (only 
data from subjects with significant (p<0.05) cosine fits used, n=7 for masked 
temperature and aMT6s, for purified temperature mean n=5.4 +/- 1.7 (+/- SD)). 
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Table 7.1. Individual difference in purified temperature acrophase estimates (on 
hours) from mean baseline (D-2 to DO) during adaptation to a rapid 9h advance 
phase-shift (on day 6) 
Subject 
Day of study ABCDEFG 
6 9.97 9.4 6.55 9.5 7.9 10.4 9.13 
7 11.77 ns ns ns 2.8 ns 0.73 
8 5.37 ns 8.35 3.7 2.8 ns ns 
9 2.57 10.4 0.35 7.9 6.2 3.3 0.63 
10 ns ns ns 8.1 8.6 10.1 0.83 
11 4.57 6.8 2.65 7.9 3.8 1 1.13 
ns: non-significant fits 
The temperature rhythm amplitude under masked conditions apparently did not 
adjust properly until the fourth and fifth days after the advance shift (D10 and D11), 
Figure 7.6. After purification amplitude estimates were not significantly affected. 
Of the four treatments, melatonin and melatonin + bright light treatments 
facilitated the reentrainment of the purified temperature rhythm with complete 
reentrainment by D II. Bright light and placebo treatments remained delayed. 
However, no significant treatment effect could be determined. No treatment 
differences in rhythm amplitude were apparent. 
236 
Figure 7.6 Effect of purification on the rate of adjustment of the 
temperature rhythm amplitude to a rapid 9h advance phase-shift 
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The amplitude of the core body temperature rhythm under masked conditions 
(0) and after purification (  ) during adaptation to a rapid 9h advance phase- 
shift (on day 6). Values represent mean +/- SEM (only data from subjects with 
significant (p<0.05) cosine fits used, n=7 for masked temperature and aMT6s, for 
purified temperature mean n=5.4 +/- 1.7 (+/- SD)). 
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Figure 7.7 Effect of melatonin and bright light on adaptation of the 
purified body temperature rhythm 
04 
02ý 
24- 
22 
20- 
18- 
16- 
14 I -FE II ---F 
56789 10 11 
Day of study 
4 
T 
mean 
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Acrophase estimates for the purified core body temperature rhythm during 
adaptation to a rapid 9h advance phase-shift (on day 6) under 4 different 
treatments: melatonin (A), placebo (O), melatonin + bright light (" ) 
and bright light (m). Values represent mean +/- SEM (only subjects data 
with significant (p<0.05) cosine fits used, mean n= 5.7 +/-1 (+/- SD)). No 
sý ficant treatment effect (ANOVA). 
Bright light exposure. = Melatonin administration. 
238 
7.5 DISCUSSION 
There are some assumptions of this purification procedure which are described 
in detail by Minors and Waterhouse (1992) and are outlined here. The endogenous 
component of the rhythm is considered to reflect the internal pacemaker whereas the 
exogenous component is assumed to be largely a result of the subjects' lifestyle. Both 
are independent and the exogenous component amplifies the endogenous rhythm. It 
is assumed that every individuals endogenous circadian rhythm reflects the standard 
endogenous rhythm derived from constant routine experiments in period and shape, 
i. e. one which closely represents a cosine curve. Furthermore, masking effects are 
assumed not to be dependent on circadian phase. However, there is some evidence 
to suggest that the masking effect of sleep on temperature is greater on the descending 
phase of the endogenous temperature rhythm than at other times (Wever, 1985b; 
Mills et al, 1978b). The effects of posture, light activity and exercise at different 
circadian phases are considered to be small or insignificant (Moog and Hildebrant, 
1986; Minors and Waterhouse, 1989). 
7.5.1 Normal baseline conditions 
In entrained (baseline) conditions, the exogenous component accounted for 
approximately 50% of the temperature rhythm amplitude, suggesting that the ratio 
between the endogenous and exogenous components is approximately 1: 1 in normal 
entrained conditions. This ratio agrees with that determined by Folkard (1989). The 
phase of the rhythm was also delayed after purification. The endogenous temperature 
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rhythm peaked around 1700h (in the presence of little or no masking effects). 
However, elevated temperature values due to activity during the day especially in the 
morning caused the cosine curve to fit slightly differently such that the calculated 
peak of the rhythm was estimated to be earlier in the day, for example see Figure 
7.1. 
7.5.2 Adaptation to a gradual 9h delay phase-shift 
During the slow 9h delay phase-shift, designed so that behavioural and 
physiological rhythms shifted in synchrony, the adjustment of the purified temperature 
rhythm was slower compared to the masked rhythm. The imposed delay shift in the 
sleep/wake cycle delayed the exogenous masking effects such that activity occurred 
during times when body temperature was naturally low (elevating the values) and 
sleep occurred during times when body temperature was naturally high (lowering the 
values). This effectively shifted the acrophase estimates in the direction of the 
imposed phase-shift. The degree of masking due to sleep and activity could be 
clearly observed in the amplitudes of the temperature rhythm before and after 
purification. After purification no significant reduction in the amplitude of the 
temperature rhythm was observed compared to the raw temperature profiles. 
The maximum degree of shift induced was assessed on the last day of the 
gradual delay phase-shift. However, comparison with the shift in the aMT6s rhythm 
may be more reliable on day 6 since the masking effects of bright light on melatonin 
concentrations (e. g. Lewy et al, 1980) and body temperature (French et al, 1990; 
Myers and Badia, 1993) may have influenced acrophase estimates during the shift. 
240 
On this day (D6) subjects were exposed to conditions of dim light (<200 lux) or 
darkness. It is assumed that the magnitude of the actual induced delay shift in the 
aMT6s rhythm was greater than or equal to the measured shift on this day. The 
degree of shift was comparable to that obtained for both the purified and raw 
temperature rhythms, indicating that 9h shifts can be induced in major endogenous 
physiological circadian rhythms without disruption using this experimental model. 
7.5.3 Adaptation to a rapid 9h advance phase-shift 
After the rapid 9h advance phase-shift (simulated eastward time-zone shift) and 
observing the readaptation without treatment, masking caused the raw temperature 
rhythm to reentrain within one to two days. However, it was clear that the rhythm 
amplitude had not established its normal baseline pattern even after 5 days. This 
could be explained by the inappropriate phase relationship between the endogenous 
and exogenous components of the temperature rhythm as explained above. The 
temperature rhythm after purification showed slow apparent readaptation similar to 
the aMT6s rhythm. Of the known masking influences on the aMT6s rhythm, the 
masking effects of ambient bright light were controlled and considered minimal 
during readaptation (intensity of light <500 lux). The rate of adjustment of the 
aMT6s rhythm was therefore considered to be a reliable indication of circadian time 
and an appropriate reference rhythm marker for the temperature purification method. 
The aMT6s rhythm adjusted at a steady and slow rate. By the fifth day the 
rhythm had only readapted by approximately 2.5h (with great individual variations, 
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see Figure 5.18). In comparison, after purification the temperature rhythm apparently 
"phase jumped" by about 4h immediately after the rapid advance shift followed by 
a more gradual adaptation. After five days (D 11), the purified temperature rhythm 
had adjusted by approximately 5h. When this temperature purification procedure was 
used to determine the adaptation of nurses to night shift work, a similar "phase jump" 
was observed on the first switchover day, after which a slow and gradual adaptation 
to the new schedule was observed (Minors and Waterhouse, 1993). This "phase- 
jump" may suggest that some masking effects were still present in these studies. In 
another simulated time-zone shift, where the exogenous component was taken into 
account using a similar mathematical model, no immediate "phase jump" was evident 
(Folkard et al, 1991). Instead, a gradual adaptation, calculated to be approximately 
30 minutes per day (2.5h after five days) was observed. By determining the 
endogenous component of the temperature rhythm in this way the rate of adaptation 
of the internal clock was found to be smaller compared to the rate of about lh per 
day determined by other studies under normal conditions (Klein and Wegmann, 1980; 
Wegmann et al, 1983), using a version of the constant routine procedure which 
allows sleep (Moog and Hildebrandt, 1989) and using a mathematical simulation (Tsai 
et al, 1988). 
Unfortunately, in the present study it was not possible to determine accurately 
the rate of adjustment to the rapid 9h advance phase-shift due to the lack of subjects 
with significant cosine fits and highly variable acrophase estimates. A number of 
reasons may account for this. Firstly, not all masking effects may have been 
removed. The categories of masking used concentrated on activity/sleep and posture. 
Other masking factors may be important. For example, the masking effects of hot 
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showering or bathing, stress and heavy meals on body temperature has not been fully 
investigated. These masking effects may well be attenuated in normal life compared 
to the effects of activity and sleep. However, the purification method reduces the 
amplitude of the rhythm and hence weak masking factors under normal conditions 
may have more pronounced effects on cosinor-derived rhythm parameters after the 
stronger masking factors are removed. The purification process is therefore 
influenced by the number of categories of masking used. As Minors and Waterhouse 
(1992) suggest, by increasing the number of categories used overestimation of the 
degree of shift is less likely to occur. 
However, even if all sources of variation due to masking were removed, the 
chance of error from other sources such as temperature measurement and inaccurate 
activity diaries still exist and would result in more erratic acrophase estimates. There 
were indeed cases where the activity diaries did not coincide with the raw data. 
Computerised activity monitors may provide a more reliable reference source for 
future experiments. A more reliable estimate of circadian time was achieved by 
averaging individuals acrophase and amplitude values on the same days during 
baseline and the gradual delay shift over the 4-leg crossover study. 
It was difficult to assess correctly the cosinor-derived parameters of the 
purified temperature rhythm during the treatment period due to the temperature- 
elevating effects of bright light (French et al, 1990; Myers and Badia, 1993) and 
temperature-lowering effects of melatonin (Chapter 9 and 10). Treatment effects on 
the aMT6s rhythm were compared after exogenous melatonin had cleared, on days 
10-11. The purified temperature rhythm exhibited a similar acrophase profile to that 
observed with the aMT6s rhythm for each treatment, Figure 6.2. Under bright light 
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and placebo treatments the endogenous temperature rhythm remained phase-delayed, 
whereas both melatonin treatment groups facilitated the adaptation of the temperature 
rhythm with complete adjustment on D11. These results, however, do remain 
tentative for the reasons outlined above. For a detailed account of the effects of 
treatment on adaptation to a rapid 9h advance shift, see Chapter 6. 
There is little doubt that masking causes apparent overestimates of the degree 
of shift leading to inaccurate estimates of circadian time. An example of the 
problems encountered in interpreting masked data comes from fractional 
desynchronisation studies where the daylength was progressively shortened or 
lengthened until the endogenous rhythms free-ran (Wever, 1983; Folkard et al, 1984; 
Minors et al, 1988). Such protocols allowed deductions as to whether a particular 
endogenous rhythm was more likely to be governed by the "strong" oscillator with 
a limited range of entrainment or by a weaker pacemaker which has a much greater 
range of entrainment. Temperature apparently adjusted more easily to longer or 
shorter days than the urinary melatonin rhythm (Folkard et al, 1984; Minors et al, 
1988). However, taking into account the exogenous component, the temperature 
rhythm followed a similar path to the aMT6s rhythm (Minors and Waterhouse, 1992). 
Although constant routine protocols are effective in minimising masking 
influences, they are inappropriate for studying the detailed adjustment of circadian 
rhythms in every day life in the presence of normal zeitgebers. A major problem of 
constant routine protocols is sleep loss. It is not known whether this effect or indeed 
the procedure itself imposes a masking effect. It is quite possible that fatigue 
associated with sleep loss may affect subjective ratings of sleep and mood and 
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performance measurements. Moog and Hildebrandt (1986) have, however, adapted 
the constant routine protocol to allow sleep when desired. 
In conclusion, masking can lead to overestimations of the degree of adaptation 
of the body clock using the core body temperature rhythm as a circadian phase 
marker. This method of temperature purification should prove useful by allowing a 
more accurate estimation of circadian time of the endogenous body clock in normal 
everyday life. 
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CHAPTER 8 
INDUCING CIRCADIAN RHYTHM DISTURBANCES IN 
PARTIAL ENVIRONMENTAL ISOLATION: ADAPTATION 
TO A 9h DELAY PHASE-SHIFT AFTER A GRADUAL 9h 
ADVANCE SHIFT 
Inducing Circadian Rhythm Disturbances in Partial Environmental Isolation: 
Adaptation to a Rapid 9h Delay Phase-Shift After a Gradual 9h advance Shift. 
8.1 INTRODUCTION 
In field studies, the length of time required for readjustment tends to be faster 
after westbound transmeridian travel, which requires the circadian system to delay, 
than eastbound travel requiring a phase-advance. An average reentrainment speed of 
lh per day when travelling east and 1.5h per day when travelling west over 5-11 
time-zones has been estimated in field conditions (Aschoff et al, 1975; Klein and 
Wegmann, 1980). These are estimates encompassing different circadian rhythms, 
conditions, subjects and the whole readaptation period. However, this direction 
difference seems to be independent of whether the flight was outward bound or 
homeward bound or whether the flight occurred at night or during the day (Klein, 
1970; Wegmann et al, 1970; Klein et al, 1972a, 1972b). 
The present study was designed to simulate a rapid 9h westward bound 
transmeridian flight using a similar experimental model to that described in Chapter 
5 but in the opposite direction. The readaptation of various circadian rhythms and 
behavioural functions were studied in detail in a normal environment and compared 
to the simulated 9h eastward transmeridian flight described before. 
This trial was a collaborative project in association with final year project 
students L. Bhattacharjee, A. Curnow, N. Lawrence, Z. Wright, A. Tasoula. It 
included a separate study investigating the response of various gut hormones to a set 
meal before and after a 9h advance phase-shift. Sampling details from the latter study 
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will be provided since frequent and heavy blood collections were required and were 
important considerations when interpreting behavioural measurements. 
I will report here on the analyses I have performed. 
8.2 SUBJECTS and METHODS 
8.2.1 Subjects 
6 healthy volunteers (3M: 3F), aged 20-24 years (mean ± SD, 20.7 ±2 
years), under no medication and all non-smokers, followed similar sleep/wake 
schedules and lifestyles prior to the trials. They refrained from heavy exercise and 
restricted their alcohol consumption (maximum 2 units per day) throughout the 
experiment. 
8.2.2 Study Design 
-3 
The design was as follows: 
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Regular sleep/wake 
cycle and normal 
environment 
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Readaptation in normal 
environment with baseline 
sleep/wake cycle. 
Rapid 9h delay 
phase-shift 
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Baseline: For 4 days prior to the phase-shift (days (D) -3 to 0), the subjects were 
required to maintain a regular sleep/wake schedule, retiring to bed at approximately 
2330h and waking at 0730h, remaining in the dark (< 1 lux) between these times. 
Gradual 9h advance phase-shit: Immediately following the baseline days, the 
subjects were exposed to 10h pulses of moderately bright (average 1200 lux at eye 
level), full spectrum light at progressively 3h earlier times over the first three days 
(D1-3) and then at the same times on D 4-5 as for D3. The periods of light exposure 
were as follows: 
Dl: 0430-1430h, D2: 0130-1130h, D3,4,5: 2230-0830h. 
Except for D1, each period of light treatment was preceded by 8 hours of 
imposed darkness (< 1 lux) when they slept. On DI, light exposure was preceded 
by 5h of darkness/sleep. During the remaining hours of each day, subjects were in 
dim light (< 300 lux, indoors) or moderately bright light (< 1000 lux, outdoors with 
sunglasses) until dusk (1630/1700h). Throughout the phase-shift (D1-5) meal-times 
were shifted progressively earlier by 3 hours on days 1-3 and then maintained at the 
same times on D4-5 as for D3, in line with the imposed light/dark and sleep/wake 
cycles. Subjects were allowed to choose their activity (e. g. reading, writing, 
watching videos) as long as they glanced regularly (at least every 5 minutes) at the 
light source. The patterns of exposure to bright light, natural ambient light and 
darkness are summarized in Figure 8.1. 
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Figure 8.1 Diagrammatic design of the study 
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Diagrammatic design of the study showing patterns of exposure to bright light 
(0 
,- 1200 
lux), darkness/sleep (=) and natural ambient light (r m). 
After a4 day baseline (D-3 to DO), a gradual 9h advance phase-shift was 
induced over 3 days (D1-3) and then the 9h shift was maintained for the 
following 2 days (D4-5). On day 6, subjects resumed their baseline 
sleep/wake schedule in a normal environment, thus experiencing a rapid 9h 
delay phase-shift of local time cues. 
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9h rapid delay phase-shift: Immediately following the last light/dark treatment on 
day 6, subjects were required to assume the baseline sleep/wake schedule in their 
normal environment, inducing a rapid 9h delay phase-shift in external time cues, i. e. 
retiring to bed at 2330h and rising at 0730h for 5 days (D6-10). The subsequent 
readaptation of the subjects in their normal environment was then observed. Subjects 
were asked to avoid bright sunlight and wore sunglasses when outdoors (filtering out 
>90% of the light). At dusk, they were required to remain in ordinary domestic 
lighting (50-300 lux) until bedtime (and darkness). 
Subjects were only allowed to sleep during the periods of darkness throughout 
this study. Naps were forbidden. 
8.2.3 Sampling 
Urine: Sequential 4-hourly urine samples (8-hourly when asleep) were collected 
throughout each stage. All urine was collected throughout each four hour period and 
the bladder completely emptied at the end of that collection period. See section 2.2. 
Blood: Blood samples (16mis) were collected frequently (6 x 15mins. followed by 
4X 30 mins. followed by 3x 60 mins. ) from 1315h until 1945h on days 0 and 6. 
Temperature: Rectal temperature was recorded continuously every 6 minutes 
throughout the trial as described in section 2.5. 
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8.2.4 Behavioural Measurements 
These were measured as described in section 5.2.4. 
8.2.5 aMT6s assay 
Urinary aMT6s was measured by L. Withey (University of Surrey) as 
described in section 2.3.4. The interassay coefficients of variation were 13.2,13.5 
and 12.7% at 3.3,23.7 and 57 ng/ml. The minimum level of detection was 0.21 f 
0.13 ng/ml (mean ± SD). 
8.3 STATISTICAL ANALYSIS 
8.3.1 Temperature and aMT6s rhythms 
Urine collections were not complete due to ill health of 2 of the investigators. 
58% of the 24h collections were complete. D-2, D4 and D9 were used for the 
analysis of urinary aMT6s since 5 subjects had complete 24h urine collections on 
these days. 
Repeated measures ANOVA (factors: day of study and time of day) were 
applied to raw temperature (averaged every hour) and urinary aMT6s data. Cosinor- 
derived parameters of acrophase and amplitude for both rhythms were subjected to 
ANOVA (factor: day of study), over the baseline, gradual delay phase-shift and 
readaptation periods. Degrees of shift were determined by comparison with 
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individuals mean baseline. 
8.3.2 Mood and performance rhythms 
These were analysed as described in section 5.3.24h profiles for each mood 
and performance parameter were subjected to cosinor analysis over 1-day windows 
and then 3-day windows for more reliable estimates of acrophase and amplitude 
(baseline: D-3 to D-1, changing phase shift: D1-3, stable phase shift: D3-5, 
readaptation period: D6-8 and D8-10). 
8.3.3 Sleep data and daily means for mood and performance 
Daily means for every mood and performance parameter were determined. 
All sleep, mood and performance data were calculated as a percentage of, or 
difference, from individuals own mean baseline (D-3 to D-1). Both DO and the 
following night were omitted for this calculation since heavy blood sampling and a 
shortened night may have compromised behavioural parameters. All data were then 
analysed by repeated measures ANOVA (factor: day of study) over baseline (D-3 to 
D-1), gradual advance phase-shift (D-3 to D5) and the rapid delay phase-shift (D6- 
10), compared to baseline (D-3 to D-1). 
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8.4 RESULTS 
Cosinor analysis did not consistently and reliably fit 24h profiles of mood and 
performance data even during the baseline. No reliable inferences could therefore be 
made regarding the cosinor-derived estimates of phase and amplitude of mood and 
performance rhythms. One subject did not carry out a sufficient number of mood 
ratings and performance tests to determine accurately daily means and was therefore 
excluded from all mood and performance analysis. 
Cosinor analysis gave 100% (at p<0.005) significant fits for 24h temperature 
data. The percentage variance accounted for by a cosine curve for all aMT6s profiles 
on D-2, D4 and D9 were > 80%. 
8.4.1 Baseline 
No significant baseline differences for any sleep, mood, aMT6s or temperature 
parameters were evident (p > 0.1). A significant time of day effect (p < 0.001) was 
established by ANOVA for aMT6s, body temperature and alertness (except for D-3), 
Figures 8.2,8.3 and 8.4, respectively. 
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Figure 8.2 Temperature profiles before and during a gradual 9h 
advance phase-shift 
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Clock time/ Day of study 
Circadian profiles for core body temperature over a4 day baseline (D-3 to DO) and a 
gradual 9h advance phase-shift (D 1-6). A significant phase-advance was indicated by 
ANOVA for repeated measures (time of day by day of study interaction, p<0.001, D-1 
versus D5). A decline in amplitude was observed over the phase-shift (p<0.05). Bars show 
patterns of exposure to bright light (1200 lux, o), darkness (< 1 lux, M) and natural 
ambient light (®). Temperature was recorded continously every 6 minutes then averaged 
and plotted every hour as the mean of 6 subjects (+ SEM). 
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Figure 8.3 Adaptation of the urinary aMT6s rhythm to a 
gradual 9h advance phase-shift 
0730- 1130- 1530- 1930- 2230- 0330- 
1130 1530 1930 2230 0330 0730 
Time (hour of day) 
Mean circadian profiles of urinary aMT6s for 5 subjects (+ SEM) showing 
phase-advance on the fourth day (D4,  ) of the gradual 9h advance 
phase-shift compared to baseline (D-2, [3). Phase-advance indicated by 
repeated measures ANOVA (time of day by day of study interaction, 
p<0.02). Darkness from 2330 to 0730h on D-2 and from 1430 to 2230h 
on D4. 
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Figure 8.4 Alertness profiles before and during a gradual 9h 
advance phase-shift 
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Daily profiles for self-rated alertness over a4 day baseline (D-3 to DO) and a gradual 
9h advance phase-shift (D 1-5). = Bright light exposure (1200 lux), - darkness (< 
I lux), ® normal ambient light. Values represent mean (+ SEM), n=5 every 2h 
during wakefulness. I Blood sampling day. A phase-advance was indicated by 
repeated measures ANOVA (time of day by day of study interaction, baseline versus 
D5, p<0.0001). 
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8.4.2 Adaptation to a gradual 9h advance phase-shift 
Using individuals as their own controls the degree of advance shift in the 
aMT6s rhythm was 9.16 ± 1.22h (mean ± SEM, n =5, D4 compared to D-2), 
Figure 8.5. The masked temperature rhythm shifted by a similar degree, 8.63 ± 
0.57h (mean ± SEM, n=6, D5 compared to mean baseline), Figure 8.5. An 
advance phase-shift was also indicated with ANOVA on the raw aMT6s, temperature 
and alertness data, Figures 8.2,8.3 and 8.4 (time of day by day of study interaction: 
alertness: p<0.001 (n=5, D5 versus mean baseline), temperature: p<0.001 (n=6, 
D5 versus mean baseline) and aMT6s: p<0.02 (n=5, D4 versus D-2). Significant 
suppression of the temperature rhythm amplitude was observed over the forced phase- 
shift (ANOVA, p<0.05) with clear disruption of the 24h profile on D1-3, Figure 
8.2. No significant suppression of the aMT6s rhythm was evident on D4 compared 
to baseline. 
No significant deleterious effects on daily mean values were evident for any 
mood or performance variables, Figures 8.6 and 8.7. However, the daily alertness 
profiles were clearly disrupted on D0-3, Figure 8.4. More striking behavioural 
disturbances were evident with subjective sleep measurements, over the initial few 
days of the phase-shift, Figure 8.8. Significantly longer duration of night awakenings 
and poorer sleep quality were evident (p < 0.01, nights 1-5 compared to baseline). 
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Figure 8.5 Acrophases of aMT6s and temperature rhythms during a 
gradual 9h advance phase-shift 
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Acrophase estimates for (a) aMT6s and (b) core body temperature ('masked') before 
and during a gradual 9h advance phase-shift (DO-5). A highly significant phase- 
advance was indicated by ANOVA (p<0.0001) for both temperature and aMT6s 
rhythms. Mean (+/-SEM) degree of shift: aMT6s = 9.16 +/- 1.22h (D4 from D-2), 
temperature = 8.63 +/- 0.57h (D5 from mean baseline). Values represent mean +/- SEM 
(n=6 for temperature, n=5 for aMT6s). 
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Figure 8.6 Adaptation of mood to a gradual 9h advance phase- 
shift 
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Figure 8.7 Adaptation to a gradual 9h advance phase-shift : 
daily mean performance 
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Figure 8.8 Adaptation of sleep to a gradual 9h advance phase-shift 
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8.4.3 Adaptation to a rapid 9h delay phase-shift 
After the subsequent rapid 9h delay shift of external time cues on day 6 no 
significant disturbances in any mood or performance parameters were apparent, 
Figures 8.9-8.12. Sleep latency was significantly reduced (p <0.005, nights 6-10) 
compared to baseline. The alertness rhythm apparently reentrained by D7 (ANOVA: 
no significant time of day by day of study interaction, compared to baseline, p>0.1), 
Figure 8.9. The temperature rhythm reestablished a normal baseline pattern on D10 
(5 days after the shift), Figure 8.13. Reentrainment was confirmed by ANOVA on 
cosinor-derived acrophase estimates, Figure 8.14 (p>0.1, D 10 compared to 
baseline). aMT6s acrophase estimates on the fifth day (D10) were significantly 
earlier by 2.28 ± 0.49h (mean ± SEM) than baseline values. However, ANOVA 
performed on the raw aMT6s data could not confirm a significant phase-advance on 
D 10 compared to D-2, Figure 8.15. 
The direction of the subjects natural entrainment of the body temperature 
rhythm was to delay in at least 4 subjects, Figure 8.16. 
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Figure 8.9 Alertness profiles during adaptation to a rapid 9h 
delay phase-shift 
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(ANOVA: no significant time of day by day of study interaction, p>0.1). Values 
represent mean (+ SEM, n=5) alertness rated every 2h during wakefulness. 
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Figure 8.10 Adaptation of mood to a rapid 9h delay phase-shift 
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Figure 8.11 Adaptation to a rapid 9h delay phase-shift : 
daily mean performance 
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Figure 8.12 Adaptation of sleep to a rapid 9h delay phase-shift 
a) Sleep latency b) Duration of night awakenings 
30 
-30 J -10 
6789 10 
c) Number of night awakenings 
3- 
2.5- 
2- 
1.5- 
0.5- 
T10 
-0.5 
-1 1 
6789 10 
T 
Night of study 
Mean 
baseline 
a) a 
..,, 
H 
ý 
O 
i- 
Mean 
baseline 
6789 10 
d) Sleep quality 
T 
789 10 
Night of study 
Mean 
baseline 
Mean 
baseline 
Subjective measures of sleep showing adaptation to a rapid 9h delay phase-shift 
(on day 6) in a normal environment. No significant deleterious effects on any 
sleep parameter were evident. Sleep latency was significantly reduced 
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Figure 8.13 Adaptation of the temperature rhythm to a rapid 9h 
delay phase-shift 
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every hour as the mean of 6 subjects (+ SEM). 
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Figure 8.14 Adaptation of aMT6s and temperature rhythms to a rapid 
delay phase-shift 
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Acrophase estimates for (a) aMT6s and (b) core body temperature ('masked') showing 
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rhythm apparently readapted by 10 (ANOVA, p>0.1). The aMT6s rhythm on D10 was 
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Figure 8.15 Adaptation of the urinary aMT6s rhythm five 
days after a rapid 9h delay phase-shift 
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Figure 5.16 Direction of reentrainment of individual masked temperature 
rhythms after a rapid 9h delay phase-shift 
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Individual acrophase estimates for the masked temperature rhythm showing 
reentrainment by delay in at least 4 subjects after a rapid 9h delay phase-shift (on day 6) 
in a normal environment. 
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8.5 DISCUSSION 
8.5.1 Adaptation to a gradual 9h advance phase-shift 
The light/dark treatment was chosen to advance the circadian system gradually 
without causing desynchrony between circadian rhythms and the external time cues. 
In the present study, using a 21h sleep/wake schedule over 3 days, with bedtime and 
waketime 3h earlier each day, the morning light treatment was aimed to hit the phase- 
advance portion of the phase-response curve each day (Czeisler et al, 1989; Minors 
et al, 1991; van Cauter et al, 1994). The following 2 days (D4 and 5) restored a 
normal 24h sleep/wake schedule with further light treatment to reinforce the 9h 
advance shift. Normally a 21h day is beyond the range of natural entrainment (23- 
27h) (Wever, 1979; Minors and Waterhouse, 1982). However, bright light (3000 
lux) has been found to increase the range of entrainment (19-31h) of circadian 
rhythms (Wever et al, 1983; Wever, 1989). 
In the present study, the bright light and darkness/sleep schedule was effective 
at inducing and maintaining a 9h advance phase-shift in the aMT6s and masked 
temperature rhythms by the end of the shift. However, significantly increased sleep 
disturbances and poorer sleep quality were evident over the first few days of the 
gradual phase-shift. Daily profiles of subjective alertness and body temperature were 
also adversely affected initially. 
Sleep loss on the night of DO may have have been an important determinant 
of behavioural disturbances on D1 (Carskadon and Dement, 1979,1981), however, 
subjective sleep, mood and performance measures had apparently recovered and 
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adapted by the end of the gradual advance phase-shift. 
An advance phase-shift of 0.6-2.2h in the melatonin rhythm has been 
demonstrated after exposure to a single pulse of bright light (3000 lux) between 0300- 
0900h (Buresovä et al, 1991) and it is possible that the light treatment in this present 
study was not of sufficient intensity or duration to promote the immediate adaptation 
to the 21 h advancing sleep/wake schedule each day over 3 days. Gallo and Eastman 
(1993) showed poor adaptation to a 22h `daylength' for 5 days during a gradual 10h 
advance phase-shift, using bright light (2000-4000 lux) for 2h after waking. Indeed 
much previous work underlines the difficulty in forcing the circadian system to phase- 
advance. However, the present study shows that a three cycle advance of bright light 
and darkness/sleep together with `reinforcement' days (D4-5) can induce large phase- 
shifts in the circadian system with minimal disturbances in subjective sleep, mood and 
performance by the end of the treatment. The relative effectiveness of this design 
over that of Gallo and Eastman may be due to the greater duration of light exposure 
and additional days to reinforce the shift. In addition, the gradual advance shift was 
controlled using partial environmental isolation whereas Gallo and Eastman carried 
out the study in field conditions in the presence of competing everyday 24h 
zeitgebers. 
8.5.2 Adaptation to a rapid 9h delay phase-shift 
On day 6 the subjects returned to the normal environment and resumed their 
baseline sleep/wake cycle. This rapid 9h delay phase-shift in local time cues can be 
related to a westward bound transmeridian flight. Westward bound flights are usually 
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day flights. A flight at 1130h from Paris to Los Angeles after a 12h flight over 9 
time zones, would arrive in Los Angeles at 1430h local time or 2330h Paris time (LA 
time 9h delayed with respect to Paris time). This schedule was simulated in the 
present experiment where subjects `boarded the flight' at 0230h clock time on day 6 
(or 1130h body time). `On arrival', having adopted the new local time schedules in 
their normal environment, sleep was delayed by 9h. Thus sleep eventually occurred 
at an abnormal circadian phase after an unusually long time awake. Yet subjective 
sleep measures were not compromised. Sleep latency was significantly reduced, 
probably as a result of prior sleep deprivation. 
No significant deleterious effects on mood or performance measures were 
evident. This is in marked contrast to the 9h rapid advance phase shift described in 
Chapter 5, where behavioural patterns took at least 5 days to establish normal 
baseline patterns. 
The masked body temperature rhythm completely adjusted after 5 days (on 
D 10) when the aMT6s rhythm was approximately 2h earlier than baseline values. 
This is in striking contrast to the rapid 9h advance phase-shift (Chapter 5) where 
urinary aMT6s and core body temperature (purified) rhythms were still M 6.5h and 
4h phase-advanced by the 5th day, respectively. Reentrainment of individuals 
temperature rhythm followed a phase-delay path in at least 4 subjects. Masking due 
to the imposed shift in the sleep/wake/activity cycle clearly affected the temperature 
rhythm in the remaining 2 subjects since a phase-shift of 10h or more, in either an 
advance or delay direction, after one day was unlikely. 
This present study underlines the preferred direction of reentrainment of the 
circadian system and confirms previous findings from field studies that greater 
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disruption of physiology and behaviour occurs after eastward (phase-advance shift) 
rather than after westward flights (phase-delay shifts) (Aschoff et al, 1975; Klein and 
Wegmann, 1980; Graeber et al, 1986; Gander et al, 1989). This experimental model 
also provides an appropriate and inexpensive model to study adaptation mechanisms 
of various biological parameters to rapid and large delay shifts in local time cues in 
a normal environment. 
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CHAPTER 9 
ACUTE EFFECTS OF A SINGLE MELATONIN TREATMENT 
ON CIRCADIAN PHASE, BODY TEMPERATURE AND 
BEHAVIOUR 
Acute effects of a single melatonin treatment on circadian phase, body 
temperature and behaviour 
9.1 INTRODUCTION 
Human circadian rhythms can become dissociated from one another and from 
the environmental zeitgebers, for example after rapid time-zone travel and during 
night shift work and this can lead to detrimental disturbances in human physiology 
and behaviour (see Chapters 5 and 8). Alleviation of these problems is thought to 
accompany faster adaptation of circadian rhythms and since several reports show that 
the pineal hormone melatonin has both phase-advancing and phase-delaying properties 
(Arendt et al, 1985a; Zaidan et al, 1994; Lewy et al, 1992; McArthur et al, 1991; 
Sack et al, 1987), melatonin has been proposed as a treatment for circadian rhythm 
disorders (Arendt et al, 1986; Lewy et al, 1992; Arendt, 1993,1994). 
The mechanism through which melatonin may achieve this effect is unknown 
but it may act directly on the biological clock to regulate the timing of the circadian 
system. Putative melatonin receptors have been located in the human SCN (Reppert 
et al, 1988), which is the major rhythm generating system of the hypothalamus 
(Rusak and Zucker, 1979; Ralph et al, 1990), and in vitro melatonin, together with 
its specific agonist S20098, can directly shift the rhythm of electrical activity in the 
suprachiasmatic nucleus (McArthur et al, 1991, Mason et al, 1993). However, as 
described in chapter 7,5mg melatonin significantly facilitated the adaptation of mood, 
performance and sleep to a rapid 9h advance phase-shift within one day before 
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significant reentrainment of the biological clock occurred (using the urinary aMT6s 
rhythm as a phase marker). Therefore other mechanisms of melatonin action cannot 
be ruled out. 
Exogenous melatonin has acute effects on body temperature (Carman et al, 
1976; Cagnacci et al, 1992; Dollins et al, 1993,1994) and sleepiness (Cramer et al, 
1974; Vollrath et al, 1981; Arendt et al, 1984; Tzischinsky et al, 1992a; Dollins et 
al, 1993,1994), which may prove to be important in the spectrum of therapeutic 
effects. 
In humans, melatonin has been used in repeated daily doses to achieve a 
phase-shift (Arendt et al, 1985a; Lewy et al, 1992) and to facilitate readaptation after 
time-zone transitions (Chapter 7). The acute phase-shifting effects of melatonin have 
received little attention until recently when intravenous administration of melatonin 
at physiological concentrations was found to have time-dependent phase-shifting 
effects on the endogenous melatonin rhythm (Zaidan et al, 1994). 
The present study investigates the relationship between the acute phase-shifting 
effects of an oral 5mg dose of melatonin -a dose commonly used in the treatment of 
circadian rhythm disorders - and its effects on core body temperature and behaviour 
in a normal environment. 
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9.2 SUBJECTS AND METHODS 
9.2.1 Subjects 
8 healthy males, aged 23-28 years (mean ± SD: 25.6 ± 1.8 years) continued 
their normal daily activities during the study, except where specified, and refrained 
from heavy exercise and alcohol consumption. 
Using the Home and Österberg questionnaire to determine morning and 
evening type individuals, 2 definite evening types (scores > 70) and 2 moderate 
morning types were detected. 
9.2.2 Study design 
Melatonin (5mg) or placebo was administered to all subjects in a randomised, 
double-blind, placebo-controlled, cross-over study. Both stages of the study began 
on the same day of the week and were performed over 5 days (D1-5) with at least one 
week separating the start of each stage. The volunteers maintained a regular 
sleep/wake cycle, (bedtime at 2400h, awaken at 0800h, darkness between these times, 
<1 lux), and natural environment (Winter, 52°N) throughout the experiment. From 
dusk (approximately 1600h) until 2400h throughout the experiment, subjects remained 
in dim artificial lighting (< 100 lux) and refrained from exposure to bright sunlight 
at all other times, wearing sunglasses when outside (transmitting < 10 % of the light 
intensity). 
D1-2 served to establish a common sleep/wake cycle and accustom subjects 
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to rectal thermometers. At 1700h on D3, subjects received either melatonin (5mg in 
lactose-gelatin capsules) or placebo (vehicle), administered with water. 
All subjects consumed the same standard meals at set times on D3-4. 
9.2.3 Sampling and measurements 
Rectal temperature was recorded continuously every 6 minutes from 0800h on 
D2 to 0800h on D5. Saliva samples were collected at 30 minute intervals from 1600h 
until 2330h on D3 and D4, for the determination of melatonin. See section 2.2 for 
details of collection and storage of samples. Subjects remained seated throughout the 
saliva sampling period, except for brief periods (< 5 minutes) if urination/defecation 
was necessary. 
Subjective alertness was rated on a visual analogue scale (VAS: " Very drowsy 
"--º Very alert") every 30 minutes from 1600h bedtime on D3 and every hour from 
0800h -º bedtime on D4. Daily sleep logs were kept detailing quality (VAS), 
duration, latency and number and duration of night awakenings. Section 2.7 
describes these subjective assessments in detail. 
9.2.4 Hormone assay 
Salivary melatonin was measured by Mrs Judie English (University of Surrey) 
as described in section 2.3.3. The interassay coefficients of variation were 6.7%, 
8.7%, 4.9% and 3.4% at 10.4,19.6,35.5 and 56.8 pg/ml. The minimum detection 
limit of the assay was 0.95 ± 0.43 pg/ml (n =10, mean ± SD). 
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9.3 STATISTICAL ANALYSIS 
Differences in body temperature and alertness between melatonin and placebo 
after 1700h on D3 were assessed by repeated measures ANOVA and area under the 
curve (AUC) analysis followed by Student's paired t-test. The phase of the core body 
temperature rhythm from 0800h on D4 to 0800h on D5 was determined by cosinor 
analysis (section 2.8). The onset of melatonin secretion was determined one day after 
treatment on D4 as the time after which two consecutive values exceeded 4 pg/ml. 
Changes in melatonin were determined by repeated measures ANOVA. Any 
relationship between the temperature suppression, exogenous salivary melatonin levels 
and degree of phase-shift in melatonin onset time was assessed by Pearson's 
correlation. Sleep quality was determined as a percentage of a baseline night (night 
before treatment) and differences from placebo assessed by paired t-test. 
9.4 RESULTS 
The melatonin was unmeasurable in one subject due to food contamination. 
This subject was therefore discarded from the analysis of salivary melatonin. 
9.4.1 Acute effects of melatonin treatment (D3) 
Salivary melatonin levels: Mean salivary melatonin concentrations are illustrated 
in Figure 9.1. Salivary melatonin levels reached a maximum at 1730h in all subjects 
(4291.71 ± 2823pg/ml, mean ± SD). 
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Figure 9.1 Saliva concentrations of melatonin after ingestion 
of 5mg of melatonin taken orally in gelatin/lactose capsules 
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Mean (+/- SEM) saliva melatonin profiles for 7 subjects after administration of 
5mg melatonin (0) or placebo (0) at 1700h. 
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Figure 9.2 Acute effects of 5mg melatonin on body temperature and 
alertness 
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Time (hour) 
Immediate and significant suppression of a) core body temperature (p=0.02) 
and b) subjective alertness (p=0.009) after administration of melatonin () 
at 1700h compared to placebo () (area under the curve analysis from 
1700-2400h, followed by paired t-test). All values are mean +/- SEM, n=8. 
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Temperature and alertness: Melatonin clearly induced a transient but significant 
suppression of body temperature between 1700-2400h (p=0.02) with a concomitant 
effect on subjective alertness (p=0.009), Figure 9.2. ANOVA identified a significant 
treatment effect between 1812h and 2030h (p=0.046) with a mean (± SD) fall in 
temperature of 0.26 ± 0.19°C. The minimum temperature achieved following 
melatonin administration was observed at 1934h ± 49 minutes (mean ± SD). 
9.4.2 Delayed effects of melatonin (one day after treatment, D4) 
Melatonin onset: A significant time by treatment interaction was observed 
(p<0.01), whereby melatonin advanced the melatonin onset time in saliva by 1.14 
± 0.19h (p < 0.001), Figure 9.3. 
Temperature: The observed minimum (nadir) of the body temperature rhythm 
advanced with melatonin treatment compared to placebo, Figure 9.4. This was also 
indicated using cosinor-derived acrophases over the period from 0800h on D4 to 
0800h on D5, where the rhythm tended to advance by 0.83 ± 0.35h (p=0.053; 
acrophase after placebo: 17.01 ± 1.25h, after melatonin: 16.18 ± 1.32h, mean t 
SD). 
Alertness: There were no significant differences in the phase of the rhythm or 
daily mean values. 
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Figure 9.3 Acute phase-shifting effects of 5mg melatonin 
treatment on the endogenous melatonin rhythm one day 
after treatment 
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Phase-advance in the salivary melatonin onset time after treatment at 1700h 
the previous evening with 5mg melatonin (p) or placebo ( ). A significant 
phase-advance was indicated by ANOVA for repeated measures (time by 
treatment interaction, p<0.008). Melatonin treatment advanced the onset 
time by 1.14 +/- 0.19h (mean +/- SEM), p<0.001, paired t-test. Values 
represent mean +/- SEM, n=7. 
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Figure 9.4 Influence of melatonin on the body temperature 
nadir during the second night after late afternoon treatment 
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Mean (+/- SEM) core body temperature profiles for 8 subjects during the night 
following D4 after treatment with either 5mg melatonin (- ) or placebo (-) 
at 1700h on D3. A phase-advance and elevation of the temperature nadir was 
observed with melatonin treatment. Temperature was recorded continuously and 
plotted every 6 minutes. 
9 
36.90 Al 
36.80 -I 1 
36.70= 
36.60- 
36.50- 
36.40- 
: 3' 
3 T 
7 
ý 
.,. J- . ý 
3630 
36.20 
ý- -ýr! 
"ý ... 
I I 
E! #' 
z. ý 
36.10 
ý 
.ý 
I 
36.00 
; fr 
1 ýWýW 
286 
Figure 9.5 Effect of late afternoon melatonin treatment on sleep 
the following nights 
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Subjective sleep quality on the first (N3) and second (N4) nights following 5mg 
melatonin (  ) or placebo treatment ( 0) treatment on D3 at 1700h. Melatonin 
significantly improves subjective sleep quality over placebo on the first night after 
treatment (p=0.006) with a similar tendency on the second night (p=0.053) - 
paired t-test. Values are mean +/- SEM, n=8. 
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Sleep: Sleep quality on the first night after melatonin treatment (N3) significantly 
improved by 70 ± 18.4% (p<0.05) and also showed a tendency to improve (by 50 
± 21.6%, p =0.053) on the night following D4, Figure 9.5. No significant effects 
on other sleep parameters were evident. 
9.4.3 Relationship between temperature suppression, exogenous melatonin 
levels and degree of shift. 
The degree of individual melatonin-induced temperature suppression (using 
AUC analysis from 1700-2400h) was positively correlated to the degree of shift in 
melatonin onset time in all but one subject (r=0.853, p=0.031), Figure 9.6. This 
subject slept, periodically, for 3 hours after receiving melatonin treatment and showed 
an exceptional fall in temperature (0.65°C) which was more than 2SD from the mean. 
This was presumably due to masking by sleep. There was no significant correlation 
between the individual maximum of exogenous melatonin concentrations and the 
degree of temperature suppression. 
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Figure 9.6 Relationship between individual degree of phase- 
shift and temperature suppression 
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Relationship between the individual degree of phase shift in the salivary 
melatonin (MT) onset time (on D4) and the magnitude of temperature 
suppression (from AUC analysis from 1700-2400h on D3) 
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9.5 DISCUSSION 
In a normal environment a single 5mg melatonin treatment phase-advanced its 
own endogenous rhythm 24h after treatment, with a similar effect in core body 
temperature. Repeated doses of oral melatonin are therefore not necessary to see an 
effect on the human biological clock. Recently, the acute phase-shifting effects of 
intravenous administration of physiological levels of melatonin have been described 
(Zaidan et al, 1994). The observation that a phase-shift in the endogenous melatonin 
rhythm was still apparent 24h after treatment and after exogenous melatonin had 
cleared, indicates that a single pulse of melatonin has a prolonged effect on the phase- 
adjustment of the clock. This resetting of the biological clock is comparable to the 
work of McArthur et al (1991) who demonstrated, in vitro, that a shift in the rhythm 
of electrical activity of the SCN could still be seen for at least 24h after melatonin 
treatment. 
In the present study, the induced phase-shift in the salivary melatonin onset 
was preceded by the immediate suppression of core-body temperature and subjective 
alertness. The timing of the fall in temperature and alertness correspond closely to 
the reported increae in sleep propensity after 5mg melatonin given in the late 
afternoon (Tzischinsksy et al, 1992a). 
Immediate increases in drowsiness and deleterious effects on performance have 
recently been observed after oral ingestion of low doses of melatonin in the morning 
(0.1-10mg at 1145h, Dollins et al, 1994). In the present study, transient sleepiness, 
and in one case periodic sleep, during the late afternoon and early evening did not 
compromise sleep during the subsequent night. In addition, no deleterious effects on 
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alertness were observed the following day. Considering the short half-life of 
melatonin (Aldhous et al, 1985) and the transient nature of its acute drowsiness and 
temperature-lowering effects, these sedative-like qualities could not account for the 
delayed effects on sleep quality during the subsequent nights. An effect on the timing 
of sleep onset/offset was unlikely to be seen since these times were fixed. However, 
an effect of melatonin on the timing mechanisms of sleep cannot be ruled out, in 
addition to any transient sedative ability. Administration of 5mg melatonin at midday 
can delay the so-called nocturnal "sleep gate" where the sleep propensity normally 
rises steeply around 2300h (Tzischinsky et al, 1992a). This delayed effect is in 
addition to an increase in sleep propensity shortly after administration. In this present 
study, melatonin may have indirectly affected sleep quality by synchronising the 
endogenous sleep/wake rhythm to the imposed sleep/wake schedule and environmental 
zeitgebers, i. e. strengthening the phase relationship between them. 
The individual magnitude of melatonin-induced temperature suppression 
correlated highly with the degree of phase-shift in the melatonin onset time in saliva, 
such that the greater the suppression the larger the induced phase-shift. Cagnacci et 
al (1993) and Strassman et al (1991) have provided evidence that melatonin 
counteracts the stimulatory effect of bright light on body temperature at night. In 
view of the present results, it is possible that the phase-shifting effects of melatonin 
and bright light may be related to their ability to acutely change core body 
temperature in humans. The next chapter follows on from this preliminary study to 
investigate in detail the dose-relationship of melatonin between the acute phase- 
shifting properties and its immediate effect on temperature and behaviour. 
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CHAPTER 10 
DOSE-RESPONSE EFFECTS OF MELATONIN ON 
CIRCADIAN PHASE, BEHAVIOUR AND TEMPERATURE 
SUPPRESSION 
Dose-response effects of melatonin on circadian phase, behaviour and 
temperature suppression 
10.1 INTRODUCTION 
In humans, melatonin has phase-shifting effects on the internal biological clock 
(Arendt et at, 1985a; Lewy et at, 1992; Zaidan et at, 1994) which are preceded by 
acute effects on temperature and behaviour (see Chapter 9; Deacon et at, 1994). 
Melatonin has acute temperature lowering properties (Carman et at, 1976; Cagnacci 
et at, 1992; Dollins et at, 1993,1994, Deacon et at, 1994; Chapter 9) and the 
stimulatory effects of bright light on temperature are mediated through the 
suppression of melatonin (Cagnacci et at, 1993; Strassman et at, 1991). Melatonin 
also has acute transient sleep-inducing effects (Vollrath et at, 1981; Arendt et at, 
1984; Dollins et at, 1993,1994) and time-dependent effects on the sleep propensity 
function (Tzischinsky et at, 1992a). 
It is possible that there is a direct relationship between the acute effects of 
melatonin and its ability to induce phase-shifts in the biological clock. 
In the previous chapter, the degree of individual phase-shift in the endogenous 
melatonin rhythm after 5mg of oral melatonin at 1700h was shown to relate to the 
magnitude of temperature suppression. The present study was designed to investigate 
the dose-response relationship between acute effects of oral melatonin on temperature, 
sleep, mood and performance and the subsequent phase-shift in core body temperature 
and melatonin rhythms. It will also help determine the optimal doses of melatonin 
required to treat circadian rhythm disorders. 
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10.2 SUBJECTS AND METHODS 
10.2.1 Subjects 
6 healthy volunteers (3M: 3F), aged 23-34 years (27.2 ± 3.7 years, mean ± 
SD), under no medication and all non-smokers were recruited from research students 
and staff of the University of Surrey. They followed similar sleep/wake schedules 
and lifestyles. No definite morning or evening types were detected (scores > 70 or 
< 31) using the Home and Östberg questionnaire (1976). However, one subject 
tended to be a morning type (score of 63) and two were rather of the evening type 
(scores of 41 and 42). 
Except where specified, subjects continued their normal daily activities during 
the experimental period but refrained from heavy exercise and alcohol consumption. 
Female subjects were screened to check the stage and regularity of their menstrual 
cycles. 
10.2.2 Preparation of melatonin/placebo 
300mg melatonin was dissolved in 30 ml absolute ethanol to give 10mg/ml. 
This solution was then diluted as follows: 
1) 5mls diluted to 50m1 with corn oil to give lmg/ml 
2) 5mls of 0. ing/ml diluted to 50m1 with corn oil plus 10% absolute ethanol to give 
0.1mg/ml 
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3) 5mls of 0.1 mg/ml diluted to 50m1 with corn oil plus 10 % absolute ethanol to give 
0.01mg/ml. 
Each dose was 5mls of the above to give 5mg, 0.5mg and 0.05mg melatonin. 
Placebo consisted of the equivalent amount of corn oil with 10% absolute ethanol. 
The melatonin or placebo dose in corn oil was suspended by thorough mixing in 50m1 
semi-skimmed milk before administration. 
10.2.3 Study design 
Melatonin (0.05mg, 0.5mg, 5mg) or placebo was administered to all subjects 
in a randomised, double-blind cross-over study. The 4 stage study was divided into 
two periods and took place during the first 11 days of February and March 1994 at 
52° N. The study was designed such that the female subjects began each period of 
the study 1 to 2 days into the follicular phase of their menstrual cycle, to minimise 
any possible influence of the menstrual cycle on circadian temperature and melatonin 
rhythm parameters (Nakayama et al, 1992; Wetterberg et al, 1976). Each stage 
began on the same day of the week and was performed over 5 days (D1-5) with 1 
week separating the start of each stage in each period. 
Subjects were required to maintain a regular sleep/wake cycle, retiring to bed 
between 2330-2400h and rising between 0730-0800h. They remained in darkness 
(< 1 lux) between 2400-0800h. From dusk (approximately 1800h) until 2400h they 
remained in dim artificial lighting (<50 lux) throughout the experiment. Subjects 
were asked to avoid exposure to bright sunlight throughout the study and wore 
sunglasses when outside. 
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Days (D)1-2 served to establish a common sleep/wake (and light/dark) cycle, 
accustom the subjects to rectal thermometers and practice performance tasks every 2h. 
On D3, after fasting for 4h, subjects received either a single dose of melatonin 
(0.05mg, 0.5mg or 5mg) or placebo at 1700h and remained seated throughout the 
evening. 
On D4 subjects remained sedentary, by watching TV or reading/writing to 
minimise the influence of activity on temperature. The volunteers received the same 
standard breakfast, lunch and evening meals at set times on D3 (0900h, 1300h and 
2130h) and D4 (0900h, 1300h and 1900h). The meal was later on D3 to allow 6.5h 
for the acute effects of melatonin on body physiology and behaviour to be measured 
"unmasked" in the absence of meals. 
10.2.4 Sampling 
Rectal temperature was recorded every 6 minutes from 0800h on D2 until 
0800h on D5. 
An indwelling cannula was inserted into the forearm of each subject, under 
local anaesthetic, between 1600-1645h on D3 and 1700-1745h on D4. Blood samples 
(5m1) were obtained every 30 minutes from 1700-2300h on D3 and from 1800-2330h 
on D4. A total of 510 ml of blood was removed from each person over the whole 
experiment. 
Subjects remained seated for at least 30 minutes before blood sampling 
commenced on D3 and D4 and remained seated throughout the entire sampling 
period, except for brief periods (<5 minutes) for urination/defecation if necessary, 
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immediately after blood sampling. This was necessary to control for postural effects 
on melatonin concentrations (see Chapter 3). Sampling times differed on D3 and D4 
to minimise blood sampling but to provide a sufficient number of sample points to 1) 
obtain an adequate profile of exogenous melatonin in plasma on D3 and 2) determine 
the melatonin onset time on D4. 
10.2.5 Behavioural measurements 
Daily sleep logs were recorded on waking in order to estimate sleep onset, 
offset, latency and the number and duration of night awakenings. Sleep quality was 
rated on a visual analogue scale (VAS; Best ever -a--º Worst ever). Subjective 
alertness was also rated on a VAS (Drowsy *--> Alert) every 30 minutes from 1700- 
2400h on D3, every hour from 0800-2400h on D4 and at 0800h on D5. 
Performance tests in the form of 1- and 5-target search and memory tasks 
(SAM-1 and SAM-5, respectively) were carried out every hour from 1700-2400h on 
D3, every 2 hours from 0800-2400h on D4 and on waking at 0800h on D5. On D1- 
2, subjects practised the tests regularly, approximately every 2/3h. 
It was necessary to measure mood and performance as frequently as possible 
after melatonin/placebo administration on D3 to assess acute transient effects of 
treatment, but without overwhelming the subjects and compromising subsequent 
behavioural measurements. To enable subjects to continue as normal a routine as 
possible on D4 and to prevent performance `boredom', the interval between 
performance tests and alertness ratings was doubled. 
Section 2.7 describes these behavioural measurements in detail. 
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10.2.6 Melatonin assay 
Plasma melatonin was measured as described in section 2.3.2. The interassay 
coefficients of variation were 8.5,7 and 6.2% at 33.3,64 and 228 pg/ml (n=10). 
The minimum level of detection (defined as the concentration at 2SD from the mean 
at maximum binding) was 4.8 ± 0.43 pg/ml (mean ± SEM). 
10.3 STATISTICAL ANALYSIS 
The performance parameters accuracy, response time and efficiency were 
defined as the percentage of correct responses, time taken to complete the task and 
accuracy/response time, respectively. Response time data were normalised by square 
root determination. 
Comparisons were made between treatments for acute effects on D3 and for 
delayed effects on D4. 
Acute effects of melatonin on D3 
Core body temperature, plasma melatonin, alertness and performance were 
expressed as area under the curve (AUC) from 1700-2400h (timed to encompass the 
whole acute effect of treatment). Alertness and performance data were calculated as 
a percentage difference from the value at 1700h for each individual. Grouped 
differences were then assessed by one-way ANOVA and Duncan's multiple range 
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post-hoc test. 
Delayed effects of melatonin (one day after treatment, D4-5) 
Plasma melatonin was analysed by two-factor ANOVA for repeated measures 
(factors: time and treatment) followed by Duncan's multiple range test to identify 
specific differences between treatments. The onset of plasma melatonin secretion in 
plasma was defined as the time when plasma concentrations exceeded twice the 
minimum detection limit of the assay, when two consecutive values exceeded this 
amount. 
Alertness and performance data were calculated for each individual at each 
time point as a percentage difference from the daily mean (D4). Daily means of 
percentage differences for each individual were then determined. All sleep data were 
calculated as a difference from the baseline night (N2, i. e. the night of D2). Group 
differences for all sleep parameters and performance and alertness daily means were 
analysed by one-way ANOVA followed by Duncan's multiple post-hoc test. 
The phases of the core body temperature, alertness and performance rhythms 
were determined by cosinor analysis (0800h on D4 to 0800h on D5, section 2.8) and 
assessed for treatment differences by one-way ANOVA and Duncan's multiple range 
test. 
The shift in the temperature nadir during the night following D4 (0200-0800h) 
was assessed by repeated measures ANOVA (factors: time and treatment). 
Pearson's correlation was used to determine any relationship between 
temperature suppression, exogenous plasma melatonin levels and the degree of phase- 
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shift in the temperature and melatonin rhythms. 
10.4 RESULTS 
10.4.1 Acute effects of melatonin treatment (D3) 
Plasma melatonin levels: Mean plasma melatonin concentrations are illustrated in 
Figure 10.1. Plasma melatonin levels significantly increased with increasing doses 
of melatonin treatment (p<0.001) and in a linear fashion (r=0.72, p<0.0001). A 
maximum (mean ± SEM), which was significantly different from 1700h for all 
doses, (p<0.02) was reached at 1730h for 0.05 mg (118 ± 37 pg/ml) and 5 mg 
melatonin (18495 ± 3326 pg/ml) and at 1800h for 0.5mg melatonin (1327 ± 491 
pg/ml). Normal nocturnal levels of melatonin (< 200pg/ml) were achieved 3.16 ± 
0.30h (mean ± SEM) after 0.5 mg melatonin. Only two subjects showed 
physiological concentrations before the last blood sample at 2300h after 5mg 
melatonin. 
Temperature: Melatonin clearly induced an acute, transient, but significant 
suppression of core body temperature which was dependent upon the dose given 
(p <0.001), Figure 10.2.0.5mg and 5mg melatonin were significantly more effective 
than 0.05mg melatonin and placebo (p<0.01). Mean ± SEM fall in temperature 
(from 1700-2400h) was: 0.02 ± 0.02°C, 0.1 ± 0.01°C and 0.14 ± 0.02°C for 
0.05mg, 0.5mg and 5mg melatonin, respectively, compared to placebo. The times 
of the temperature minima were not significantly different from each other (p > 0.1): 
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0.05mg = 19: 16 ± 12 minutes, 0.5mg = 19: 14 ±4 minutes and 5mg = 19: 30 ± 
10 minutes. The maximum suppression compared to placebo was: 0.05mg = 0.18 
± 0.03°C, 0.5mg = 0.3 ± 0.03°C and 5mg = 0.35 ± 0.02°C, (mean ± SEM). 
Alertness: Subjective alertness decreased with increasing doses of melatonin 
(p<0.001), Figure 10.3.0.5mg and 5mg melatonin treatments were significantly 
more effective at reducing alertness than 0.05mg melatonin and placebo treatments 
(p < 0.05), Table 10.1. 
Performance: SAM-5 accuracy and efficiency (Figures 10.4 and 10.5) decreased with 
increasing doses of melatonin (p<0.01 and p<0.001, respectively), with a trend 
towards slower response times (Table 10.1). 5mg melatonin treatment was 
significantly more deleterious than all other treatments (p<0.05), Table 10.1. No 
significant treatment effects were observed on SAM-1 performance parameters 
(Figures 10.4 and 10.5 and Table 10.1). 
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Figure 10.1 Plasma concentrations of melatonin after ingestion of 
low doses of melatonin taken orally in corn oil. 
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Time (hours) 
Mean (+/- SEM) plasma melatonin profiles for 6 subjects after 
administration of 5mg (0), 0.5mg (f), 0.05mg (p) of 
melatonin or placebo ( ) at 1700h on D3. 
302 
Figure 10.2 Acute dose-dependent suppression of body temperature 
by melatonin 
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Mean core body temperature for 6 subjects after an oral dose of placebo 
(  ), 0.05mg (0), 0.5mg (f), 5mg (Q) melatonin at 1700h 
(recorded every 6 minutes, plotted every 12 minutes for clarity). The 
higher the dose the greater the suppression (ANOVA: p<0.001, using 
the difference from placebo after AUC analysis from 1700-2400h). 
Average SEM = +/- 0.090C. 
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Figure 10.3 Dose-dependent decrease in subjective alertness 
immediately after melatonin treatment 
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Subjective alertness ratings after an oral dose of placebo ( ), 0.05mg 
(0 ), 0.5mg (A ), 5mg (0) melatonin at 1700h. Alertness 
decreased with increasing doses of melatonin (ANOVA: p<0.001, after 
AUC analysis from 1700-2400h). 0.5mg and 5mg were significantly 
more deleterious than 0.05mg and placebo (p<0.05, Duncan's multiple 
range test). Values represent mean +/- SEM (n=6). 
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Table 10.1 Acute effects of melatonin treatment (D3) 
Effects of low oral doses on alertness and performance, mean (SEM), % difference from 
placebo with AUC analysis (1700-2400h). 
Performance 
Alertness 
0.05mg 
-7.0 (4.0)a, 
b 
SAM-5 Accuracy -4.7 (9.6)al 
SAM-5 Response Time* +0.9 (4.0)al 
SAM-5 Efficiency -3.1 (8.6) 
SAM-1 Accuracy -1.5 (8.0) 
SAM-1 Response Time* -2.2 (2.9) 
SAM-1 Efficiency +0.5 (7.4) 
0.5mg 
-18.0 (. 03)a 
-13.4(6.3)b 
+ 2.7 (2.8)bl 
-15.9 (6.1) 
-5.7 (8.5) 
+0.7(2.3) 
-6.1 (9) 
5mg 
-21.0 (3.0)b 
-31.6 (6.7)ß1, 
b 
+ 2.1(301, b1 
-34.2 (6.9) 
-9.5 (3.3) 
+3.4(2.4) 
-13.5 (2.1) 
* "+" indicates slower response time, "-" faster response time 
Melatonin doses with the same letters represent significant differences between 
treatments (Duncan's multiple range test): a and b: p<0.05, al and bl: p<0.01, 
Melatonin 
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Figure 10.4 Acute dose-dependent effects of melatonin on 
performance accuracy 
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Accuracy scores for a) low- (SAM-1) and b) high- (SAM-5) memory capacity 
tests, after oral administration of either placebo ( ), 0.05mg melatonin (MT) 
(0), 0.5mg MT(A) or 5mg MT (O)at 1700h. Significant treatment effect for 
SAM-5 only (ANOVA: p<0.01 after AUC analysis 1700-2400h): accuracy scores 
after 5mg melatonin were significantly worse than all other treatments. Values 
represent mean +/- SEM, n=6. 
306 
Figure 10.5 Acute dose-dependent effects of melatonin on 
performance efficiency 
120 
110- 
100- 
90- 
80 -ý 
70 f- 
17: 00 19: 00 
17: 00 19: 00 21: 00 23: 00 
Time (hour) 
tMeal 
I 
21: 00 
I -Tý 
23: 00 
I 
Efficiency scores for a) low- (SAM-1) and b) high- (SAM-5) memory capacity 
tests, after oral administration of either placebo (  ), 0.05mg melatonin (MT) 
(0 ), 0.5mg MT (f) or 5mg MT (Q) at 1700h. Significant treatment effect for 
SAM-5 only (ANOVA: p<0.001 after AUC analysis 1700-2400h): efficiency scores 
after 5mg melatonin were significantly worse than all other treatments. Values represent 
mean +/- SEM, n=6. 
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10.4.2 Delayed effects of melatonin treatment (one day after 
treatment, D4) 
Melatonin onset: A significant time by treatment effect (p < 0.0001) was seen, where 
increasing doses of melatonin advanced the plasma melatonin onset time relative to 
placebo by 0.36 ± 0.13h, 0.69 ± 0.15h and 1.43 ± 0.16h (mean ± SEM) for 
0.05mg, 0.5mg and 5mg melatonin, respectively, Figure 10.6. The 5mg melatonin 
treatment significantly (p<0.05) advanced the onset time more than all other 
treatments. 
Temperature: There was a clear and dose-dependent phase-advance in the nadir of the 
temperature rhythm during the night following D4 (ANOVA for repeated measures, 
p<0.02, Figure 10.7). This was also evident by cosinor analysis over the period on 
D4 to D5 (0800h on D4 to 0800h on D5). A significantly greater advance phase-shift 
was seen with increasing doses of melatonin using differences in acrophase from 
placebo (p<0.0001). The rhythm advanced further (p<0.01) with 0.5mg and 5mg 
melatonin treatments compared to 0.05mg, and 0.5mg treatment compared to 5mg 
melatonin (p<0.05), Table 10.2. 
Alertness: There was no significant treatment effect on the phase of the alertness 
rhythm or on daily mean values one day after treatment. However, there was a trend 
for melatonin to advance the rhythm with increasing doses compared to placebo 
(p=0.067), Figure 10.8, Table 10.2. 
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Performance: No significant performance rhythm could be established (cosinor 
analysis) and no treatment effect on daily mean values was seen. 
Sleep: Figure 10.9 shows the effect of low doses of oral melatonin on various sleep 
parameters on the night following treatment (D3). On the first night only, a 
significant treatment effect was seen with an increase in sleep quality 
(p < 0.05), a decrease in the duration of night awakenings (p < 0.05) and an earlier 
sleep onset time (p <0.01), Table 10.2. The 5mg treatment proved more effective 
than all other treatments (p<0.05). The quality of sleep improved by = 30%, 43% 
and 61 % for 0.05mg, 0.5mg and 5mg melatonin treatment respectively, compared to 
placebo. On the second night (night following D4), there were no significant 
differences between groups in any sleep parameter. 
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Figure 10.6 Dose-response relationship between oral melatonin and 
degree of induced phase-shift in melatonin rhythm one day after 
treatment 
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Phase-advance in plasma melatonin onset time after treatment at 1700h the 
previous evening with 5mg (0 ), 0.5mg (f), 0.05mg (0) 
melatonin or placebo ( ). A significant dose-response phase-shifting 
effect identified by ANOVA (for repeated measures, time by treatment 
interaction: p<0.0001). Melatonin treatment advanced the onset time by 
0.36 +/- 0.13h, 0.69 +/- 0.15h and 1.43 +/- 0.16h (mean +/- SEM) for 
0.05mg, 0.5mg and 5mg melatonin, respectively. Values represent mean +/- 
SEM, n=6. 
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Figure 10.7 Dose-dependent phase-advance in the temperature nadir 
during the second night after melatonin treatment 
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Mean core body temperature profiles for 6 subjects during the night following D4 
(from 0200h to 0800h) - one day after treatment with either placebo (  ), 0.05mg 
melatonin (MT) (0), 0.5mg MT (f) or 5mg MT (Q) treatment. Rectal 
temperature was recorded every 6 minutes, averaged and plotted every 30 minutes 
for clarity. There was a dose-dependent phase-advance in the nadir of the rhythm 
(ANOVA for repeated measures: time by treatment interaction, p<0.02). This was 
confirmed by cosinor analysis (from 0800h on D4 to 0800h on D5, ANOVA: 
p<0.0001). Mean (+/- SEM) difference in phase-shift from placebo: 0.05mg 
melatonin (MT) _ -0.27 +/- 0.16h, 0.5mg MT = 0.48 +/- 0.12h and 5mg MT = 1.0 
+/- 0.09h. 
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Figure 10.8 Delayed effects of low oral doses of melatonin 
on the alertness rhythm one day after treatment 
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Mean subjective alertness ratings (calculated as a% of individuals daily mean) 
for 6 subjects on D4, one day after treatment (at 1700h, on D3) with either 
placebo (-- ), 0.05mg melatonin (MT) (.... ), 0.5mg MT () or 5mg 
MT (_ ). * p<0.05: significant treatment effect seen at 1000h (ANOVA), 
where placebo had significantly (p<0.05) lower ratings than 0.5mg and 5mg 
melatonin treatment. Using cosinor-derived acrophases, there was a trend for 
the rhythm to phase-advance (ANOVA: p=0.07). Mean (+/- SEM) difference in 
phase from placebo was an advance shift of 0.37 +/- 0.31h with 0.05mg MT, 
0.97 +/- 0.35h with 0.5mg MT and 1.6 +/- 0.3h with 5mg MT. 
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Table 10.2 Delayed effects of melatonin treatment (D4, one day after treatment) 
Effect of low oral doses of melatonin on the magnitude of temperature suppression 
(%) and degree of advance phase-shift (hours) in the rhythms of body temperature, 
melatonin, alertness and sleep. Mean (SEM), difference from placebo. 
Parameter Melatonin 
Temperature 
suppression (%) 
0.05mg 0.5mg 5mg 
1.64 (1.23)a, b 7.32 (0.96)a 10.2 (1.59)b 
Shift (h) in: 
Body Temperature -0.27(0.16)a, 
bl 0.48 (0.12)a, c 1.0 (0.09)b1, c 
Plasma melatonin 
onset time 0.36(0.13)a1 0.69 (0.15)b1 1.43(0.16)11, b1 
Alertness 0.37 (0.31) 1.07 (0.43) 1.6 (0.3) 
Sleep onset 0.28 (0.08)a. b 0.35 (0.1)a 0.59 (0.14)b 
Sleep offset 0.32 (0.2) 0.39 (0.16) 0.49 (0.18) 
Melatonin doses with the same letters represent significant differences between treatments 
(Duncan's multiple range test): a, b and c: p<0.05, al and bl: p<0.0 1, 
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Figure 10.9 Dose-dependent effects on sleep on the first night following 
melatonin treatment 
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Subjective sleep measurements for the first night following late afternoon treatment 
with placebo (0), 0.05mg ( ), 0.5mg (Q), 5mg (M ) melatonin. There were 
significant treatment effects for advancing sleep onset (p<0.01), improving sleep 
quality (p<0.05) and reducing the duration of night awakenings (p<0.05), where the 
5mg treatment was significantly more effective than all other treatments, ANOVA. 
Values represent mean +/- SEM, n=6. 
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10.4.3 Relationship between individual degree of phase-shift and 
magnitude of temperature suppression 
Table 10.2 shows the mean magnitude of temperature suppression and the degree 
of shift in the temperature, melatonin, alertness and sleep rhythms. 
A highly significant correlation existed between the individual magnitude of 
temperature suppression and both the degree of phase-shift in the plasma melatonin onset 
time (r=0.77, p<0.0005) and the temperature rhythm (r=0.549, p<0.05), Figure 
10.10, but not the alertness rhythm. The magnitude of the phase-shift of the temperature 
and melatonin rhythms also correlated closely (r=0.699, p<0.001). 
10.4.4 Relationship between individual exogenous plasma melatonin 
levels, temperature suppression and degree of phase-shift 
Individual exogenous melatonin concentrations in plasma on D3, as assessed by 
AUC, correlated with the magnitude of temperature suppression (r=0.468, p <0.05) and 
the degree of phase-shift in the melatonin rhythm (r=0.782, p<0.0002), but not the 
degree of phase-shift in the body temperature rhythm (r=0.462, p=0.053). 
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Figure 10.10 Relationship between individual degree of phase- 
shift and temperature suppression 
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a) Relationship between the individual magnitude of melatonin-induced temperature 
suppression and the shift in i) plasma melatonin onset time, ii) body temperature 
rhythm. b) Relationship between the individual degree of melatonin-induced phase- 
shift in the temperature rhythm and plasma melatonin onset time. 
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10.5 DISCUSSION 
The previous chapter describes how the individual degree of phase-shift in the 
endogenous melatonin rhythm relates to the magnitude of temperature suppression. The 
present study confirms this finding, where greater temperature suppression was associated 
with a larger phase-shift. In addition, a dose-response relationship between the dose of 
oral melatonin, temperature suppression and phase-shift in the endogenous melatonin 
rhythm has been established. With increasing doses of melatonin a greater magnitude of 
temperature suppression and degree of phase-shift in the endogenous melatonin rhythm 
was achieved. The rhythm of core body temperature shifted in a similar fashion and 
correlated with the shift in the endogenous melatonin rhythm, but the relationship was 
less marked. Body temperature is more susceptible to masking by exogenous influences 
such as meals, activity and sleep (Wever, 1985b; Minors and Waterhouse, 1989) than the 
melatonin rhythm (Lewy, 1983). The design of the study controlled for the two major 
masking influences on melatonin, light and posture (Lewy et at, 1980; Deacon et at, 
1994). Although the subjects ambient lighting and activity were strictly controlled during 
the evening of D3 and throughout D4, some masking of the temperature rhythm was still 
possible. 
There is considerable support for a thermoregulatory role for melatonin 
(Strassman et at, 1991; Cagnacci et at, 1992,1993; Badia et at, 1993). The peak of 
melatonin secretion at night corresponds closely to the nadir in body temperature and 
Cagnacci et at (1992) have suggested that about 40% of the diurnal variation in core body 
temperature may be the direct consequence of the acute effects of endogenous melatonin. 
Whether or not these phenomena are representative of physiological mechanisms is a 
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question of interest. In the present study and in previous work (Chapter 9, Deacon et al, 
1994), the time of maximum suppression of body temperature occurred approximately 
2h after the observed peak in (physiological and pharmacological) levels of exogenous 
melatonin. This 2h lag is consistent with the relationship between the endogenous 
melatonin and body temperature rhythms before and after a forced phase-shift with bright 
light (Shanahan and Czeisler, 1991). Both melatonin and body temperature shifted in a 
similar direction and magnitude with the melatonin fitted maximum preceding the 
temperature minimum by nearly 2h. These changes were observed in constant routine 
conditions, i. e. in the absence of external time cues with either constant, or no disturbing 
(masking) influences. Furthermore, a recent study has demonstrated that the core body 
temperature rhythm is exactly inverse to the urinary aMT6s rhythm under similar 
constant routine conditions (Kräuchi and Wirz-Justice, 1994). Considering the time taken 
for hepatic metabolism and renal excretion, the urinary aMT6s rhythm will be delayed 
by m 1-1.5h compared to the melatonin rhythm in plasma (Matthews et al, 1991; Deacon 
and Arendt, 1994). However, this time lag between the melatonin rise and temperature 
fall is not apparent in some situations. Wehr et al (1993) demonstrated, under constant 
routine conditions, a phase dissociation between the melatonin and temperature rhythms 
with the body temperature rhythm declining before the rise of the melatonin rhythm when 
subjects were transferred to a winter from a summer photoperiod. Taken together, these 
results suggest that the primary effect of endogenous melatonin may not be direct 
suppression of the nighttime fall in body temperature but is more probably an indirect 
role in regulating the timing and amplitude of body temperature. 
The exact mechanism and site of action by which melatonin influences body 
temperature is unknown. It is possible that melatonin acts centrally in the preoptic area 
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and anterior hypothalamus - the main thermoregulatory centres (Hellon, 1972; Hensel, 
1973; Satinoff, 1978) - and/or peripherally to adjust heat loss. In rats, a major site of 
heat loss occurs in the brain arteries of the circle of Willis and tail arteries where high 
affinity melatonin receptors have been located (Viswanathan et al, 1990; Seltzer et al, 
1992). A low level of specific melatonin binding has been reported in the preoptic area 
of the hypothalamus in rodents (Williams et al, 1989). In addition, high affinity 
melatonin binding sites have been found in other areas of the mammalian hypothalamus 
including the SCN and paraventricular nucleus (PVN) (review: Stankov et al, 1993; see 
section 1.2.11). Direct and indirect neural and anatomical associations between these 
sites and the preoptic area have been described (review: Watts et al, 1991; see section 
1.2.11), and suggest possible pathways through which melatonin (and the SCN) may 
modulate the rhythmicity of body temperature. 
The plasma melatonin concentrations achieved with different doses varied from 
normal nocturnal night time levels with 0.05mg to 2 orders of magnitude higher than 
physiological concentrations with 5mg. There was a log-linear relationship between 
plasma melatonin levels and the degree of phase-shift in the endogenous melatonin 
rhythm. In addition, the magnitude of temperature suppression related to plasma 
melatonin levels, although the results were less striking. There was also a trend towards 
a relationship between the degree of phase-shift in the core body temperature rhythm and 
plasma melatonin levels. The range and direction of shift observed in plasma melatonin 
onset was comparable to that obtained by Zaidan et al (1994) with a single physiological 
melatonin infusion from 16: 00-19: 00h (shift in onset time = 21 ± 50 minutes, mean f 
SD) and Lewy et al (1992) after 4 days with 0.5mg/day (shift in onset time " 1h). 
The acute sedative-like effects of melatonin have been known for many years 
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(Cramer et al, 1974; Vollrath et al, 1981). Recently, Dollins et at (1994) have reported 
an increase in sleepiness and deleterious effects on performance after administration of 
0. lmg and 0.3mg melatonin at 1145h when volunteers were tested in a controlled 
environment from 0930-1730h and suggested that endogenous melatonin may be a direct 
factor in sleep-inducing mechanisms. The present study, also in a controlled 
environment, showed a dose-dependent significant decrease in alertness and SAM-5 
efficiency only with 0.5mg and 5mg melatonin but not with 0.05mg. The latter was the 
only dose to achieve normal physiological concentrations and argues against a 
physiological sleep-inducing role for melatonin. Rather, as discussed previously (Arendt 
et al, 1984; Tzischinsky et al, 1992a), the results could be interpreted on the basis that 
melatonin influences the timing mechanisms of sleep and wakefulness. The fact that the 
night's sleep immediately following melatonin treatment was markedly enhanced, in a 
dose-dependent manner compared to placebo, with an earlier sleep onset and a trend 
towards earlier sleep offset also supports this contention. There was also a trend for the 
self-rated alertness rhythm to shift to an earlier time the following day. Even without 
taking into account the sleep `inertia' which influences alertness during the first hour or 
two after waking (Folkard and Akerstedt, 1989; Akerstedt and Folkard, 1990; Dijk et al, 
1994), there was a clear elevation in alertness in the morning which was dose-related. 
Arendt et al (1984) have reported on the delayed effects of 2mg melatonin given 
at 1700h on self-rated `fatigue' in a normal environment. The response was not 
immediate in all subjects and achieved group significance after 4 days and suggests an 
effect on the timing mechanisms of fatigue. Tzischinsky et al (1992a) have demonstrated 
a time-dependent delayed effect of melatonin on the nocturnal sleep gate. These studies 
lend further support for an effect of melatonin on the timing mechanisms of sleep and 
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wakefulness. 
In consideration of the present results and of the other studies described above, 
acute changes in core body temperature induced by melatonin may be a primary event 
in phase-shifting mechanisms. 
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CHAPTER 11 
GENERAL DISCUSSION 
General Discussion 
11.1 DETERMINING THE BEHAVIOUR OF THE ENDOGENOUS BODY 
CLOCK 
When developing models to study circadian rhythm disturbances in a normal 
environment, it is important to use a circadian rhythm marker that gives a reliable 
indication of the behaviour of the endogenous body clock. 
11.1.1 Masking 
Most measured circadian rhythms are influenced by external factors which 
disturb or mask the endogenous component of the rhythm and this can lead to 
inaccurate estimates of the phase and amplitude of the internal biological clock. It 
is therefore important to consider any factors that may influence the endogenous 
rhythmicity of measured of circadian rhythms. 
Melatonin and core body temperature are extensively used as circadian phase 
markers. Of the exogenous factors known to alter melatonin levels in humans, light 
is well recognised (Lewy et al, 1980). The influence of gravity on melatonin 
concentrations has now been demonstrated in this thesis. 
Melatonin in plasma and saliva is concentrated by moving from a supine to a 
standing position, and diluted after an opposite change in posture. Like other plasma 
constituents, the effect can be explained through the influence of gravity which causes 
plasma volume to fall on standing and increase on lying down (e. g. Tan et al, 1973). 
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Potential masking effects on the melatonin rhythm due to light and posture can 
therefore be avoided by controlling the exposure to light and ensuring subjects 
maintain the same posture for at least 20 minutes prior to sampling. Controlling 
potential masking influences on body temperature is more difficult. Sleep, activity, 
posture and bright light are all known to influence core body temperature (Mills et 
al, 1978b; Wever, 1985b; Moog and Hildebrant, 1986; Minors and Waterhouse, 
1987,1989; Dawson and Campbell, 1991; Myers and Badia, 1993). Masking 
influences on the core body temperature rhythm can be eliminated or minimised by 
the use of constant routine protocols (Mills et al, 1978a; Czeisler et al, 1989). 
However, this procedure is inappropriate for the day to day study of circadian 
rhythms in a normal environment. 
An alternative method for separating the two components was developed by 
Minors and Waterhouse (1992,1993). This mathematical procedure was employed 
to purify the core body temperature rhythm after simulated time-zone travel (in 
collaboration with Drs Waterhouse and Minors). Masking appeared to lead to 
overestimates in the rate of adaptation of the endogenous circadian pacemaker with 
the purified data showing slower adaptation. Such methods may provide a means of 
obtaining more reliable estimates of the behaviour of the endogenous body clock and 
allow data to be collected under normal conditions. 
11.1.2 Different markers of melatonin secretion 
Melatonin is considered to be a reliable marker of the endogenous body clock 
and a number of methods are now used to determine the circadian parameters of 
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melatonin secretion. There are obvious difficulties in the frequent collection of blood 
in order to obtain the complete circadian profile of melatonin. Measuring only the 
onset of its secretion in blood as a phase marker reduces blood loss and does not 
compromise sleep in most situations (Lewy et al, 1989). However, this approach 
gives no information on amplitude or offset of melatonin secretion. Non-invasive 
techniques have also been employed to measure the melatonin rhythm in saliva and 
its metabolite, aMT6s, in urine and have been variously compared under normal 
conditions (section 4.5). The usefulness of these methods in determining circadian 
parameters of melatonin secretion had not previously been evaluated after a phase- 
shift. This thesis describes the close relationship between plasma melatonin onset and 
the calculated peak times of melatonin in plasma and saliva, and aMT6s in urine and 
suggests that all indices give reliable information about the behaviour of the 
endogenous melatonin circadian rhythm. If saliva is not sampled during the sleep 
phase cosinor estimates of the melatonin rhythm are inadequate. 
When the melatonin rhythm adapts to an advance shift, onset times in plasma 
and saliva will usually occur during the sleep phase and thus cannot be measured. 
Offset times may be appropriate in these situations. However, there is some evidence 
for different mechanisms affecting the onset and offset of melatonin secretion 
(Illnerovä and Vanecek, 1982; Illnerovä et al, 1989; Skene et al, 1994). The 
melatonin offset as a phase marker therefore needs further evaluation. The most 
appropriate index of melatonin secretion clearly depends upon the experimental 
design. 
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11.2 AN EXPERIMENTAL MODEL TO STUDY ADAPTATION 
STRATEGIES 
On arrival at their destination, time-zone travellers encounter a pattern of 
sunrise and sunset, activity and social schedules shifted in time. The endogenous 
circadian timing system is slow to adapt to the new time cues, and until the correct 
phase relationship between biological rhythms and external zeitgebers is established, 
a host of physiological and behavioural problems are manifest. A similar problem 
is encountered with shift workers operating to new work schedules out of phase with 
the normal light/dark cycles, other competing zeitgebers and their endogenous 
biological clock. 
11.2.1 Adaptation to gradual phase-shifts 
The circadian system usually takes 0.5-1.5h/day to adjust to new local time 
cues (Aschoff, 1975; Klein and Wegmann, 1980; Folkard et al, 1991). However, by 
increasing the strength of the zeitgebers at suitable times it is possible speed up the 
rate of adjustment. 
In a partially controlled environment, suitably timed bright light (" 1200 lux) 
and darkness combined with a shift in the sleep/wake cycle successfully promoted the 
adaptation of various physiological and behavioural functions to a gradual 9h delay 
and advance phase-shift within 3-5 days. No major detrimental effects on body 
physiology and behaviour were evident throughout the whole adjustment to such a 
delay phase-shift. This method may therefore provide a means of facilitating 
326 
adaptation to new time-zones or shift work. For example, by using this paradigm for 
night shift workers starting a new shift from midnight to 0900h, individuals could be 
shifted or "nudged" progressively later by 3h a day for 3 days (perhaps over the 
weekend) before the first night shift, with further light treatment on the night shift to 
reinforce the 9h phase-shift. 
This "nudging" technique has also been employed by Eastman (1987,1991) 
using a 26h light/dark schedule (i. e. daylength progressively lengthened by 2h/day) 
with bright light to phase-shift circadian rhythms to the desired time. It is important 
to note that in the studies conducted by Eastman and colleagues, strict control of 
natural ambient light after sleep was necessary to achieve this effect. 
Both these techniques may be impractical for individuals not wishing to 
undergo such an elaborate sleep/wake and light/dark schedule prior to the new shift 
or new time-zone. An alternative method involves the use of much brighter intensity 
light (=10 000 lux) centred directly over the temperature minimum; a time at which 
the circadian system is most sensitive to large phase-shifts (Czeisler et al, 1989). 
This technique has been employed in a shift work study by Czeisler et al (1990) using 
bright light during the night shift together with darkness during the day and with no 
treatment administered prior to the new shift. Complete adaptation of circadian 
variables and improvements in alertness and performance were evident within 6 days. 
However, in a study comparing the bright light "nudge" technique with the rapid shift 
method, Eastman (1987) found that although the latter technique induced a faster 
phase-shift, sleep and alertness were compromised. Clearly, further research is 
needed to evaluate the most effective and practical method of promoting adaptation 
to new time schedules. 
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11.2.2 Adaptation to rapid shifts - simulation of jet lag and 
maladaptation to shift work 
Although laboratory simulations can provide detailed information about the 
adaptation process of the circadian system to changes in local time cues, there is still 
a considerable difference to the real life situation. The critical feature of 
environmental isolation studies is the elimination of every day zeitgebers. Treatment 
strategies to facilitate adaptation to shift work or new time-zones must be effective 
in the presence of competing zeitgebers which are present in normal every day life. 
After successful adaptation to a gradual 9h delay or advance phase-shifts, the 
subjects in these studies returned to their normal environment and baseline sleep/wake 
cycle, thus experiencing a rapid 9h delay or advance phase-shift in local time cues. 
The subsequent disturbances in behavioural and physiological functions was 
comparable to that found in field conditions after transmeridian flight. For shift 
workers, this is equivalent to a fully-adapted night shift worker returning to a day 
shift. This experimental model therefore provides an effective and inexpensive 
method of simulating aspects of jet lag and shift work so that the effectiveness of 
various treatment strategies can be assessed in real life. 
11.2.3 Preferred direction of adaptation 
The faster rate of adaptation observed with westward (delayed time) 
transmeridian flights compared to travelling east (advanced time) in field studies (e. g. 
Klein and Wegmann, 1980) has been confirmed by our studies comparing the rate of 
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adjustment to both rapid and gradual 9h advance and delay phase-shifts. The most 
striking observation was that the direction of the phase-shift was more important than 
the speed of the shift. 
Whereas bright light was effective in adjusting the circadian system to a 
gradual 9h delay, it was less successful in the adaptation to a gradual 9h advance 
phase-shift; sleep, mood and performance were initially compromised in the latter 
case. In addition, physiological and behavioural variables took far longer to adapt to 
a rapid 9h advance phase-shift compared to a rapid 9h delay shift. This underlines 
the preferred direction of reentrainment of the biological clock and confirms that the 
direction of the rotating shift schedule is important to consider when designing new 
work timetables. Studies directly comparing the direction of shift rotation have 
shown that delaying the shift schedule (i. e. mornings - afternoons -* nights -º 
mornings) reduces fatigue and improves sleep compared to advancing them (i. e. 
nights -º afternoons -º mornings -º nights) (Landen et al 1981; Epstein et al, 1991; 
Barton and Folkard, 1993). 
11.3 EFFECTS OF BRIGHT LIGHT AND MELATONIN DURING 
ADAPTATION TO RAPID PHASE-SHIFTS. 
Can bright light counteract the beneficial effects of melatonin ? 
Light and melatonin, suitably applied, can reset the timing of the endogenous 
biological clock, but their actions are opposite in phase. Time-zone travellers and 
shift workers are often exposed to bright light at times which oppose rapid adaptation. 
It is conceivable that such exposure may compromise the beneficial effects of 
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melatonin treatment. This possibility was therefore investigated after a rapid 9h 
advance phase-shift. 
Melatonin (5mg), timed to phase-advance, clearly improved subjective sleep, 
alertness and performance and facilitated the adaptation of the aMT6s rhythm, after 
a rapid 9h advance shift of external time cues both in the presence or absence of 
bright light (2000 lux) timed to counteract the phase-shifting properties of melatonin. 
This observation has practical benefits for time-zone travellers and shift workers since 
they may carry out their normal activities in natural ambient light (at least up to 2000 
lux) during melatonin treatment. Although melatonin proved to be the dominant 
`zeitgeber' in this study, stronger intensities of light may prove more effective in 
opposing the effects of melatonin treatment. 
11.4 REPEATED MELATONIN ADMINISTRATION: quickest adaptation by 
changing times of administration? 
Repeated doses of melatonin were not necessary to observe phase-shifting 
effects on the biological clock. A single melatonin treatment (0.05mg to 5mg) was 
sufficient to induce phase-shifts in the endogenous circadian rhythms of core body 
temperature and melatonin secretion. The use of repeated melatonin administration 
at the same times each day for circadian rhythm disorders may be questionable. 
Lewy et al (1992) have described a phase-response curve for melatonin after repeated 
administration of melatonin for 4 days. However, the current results suggest that the 
phase-response curve would shift after each melatonin treatment. Therefore, repeated 
treatment at the same times over many days or weeks could conceivably be ineffective 
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or counterproductive depending on the part of the PRC on which treatment falls. If 
the phase-response curve shifted with each treatment such that the following treatment 
fell within the zones of little or no response, or across the inflexion point where 
phase-delays are induced instead of phase-advances and vice versa, melatonin may 
prove to have little beneficial effect. 
Clearly repeated administration of melatonin at the same clock times is 
effective when administered just before the desired bedtime and may provide a 
constant entraining effect (e. g. Arendt et al, 1987; Folkard et al, 1990; Jan et al, 
1994). However, changing the time of administration each day so that the treatment 
falls within the zone of maximum phase-shift may speed up the resynchronization 
process for jet travellers and shift workers. 
11.5 MECHANISM OF ACTION OF MELATONIN 
11.5.1 Phase-shifting effect on the biological clock 
The most commonly reported effects of melatonin treatment in circadian 
rhythm disturbances have been improvements in mood and sleep (e. g. Arendt et al, 
1987; Folkard et al, 1990; Jan et al, 1994). Redman et al (1983) suggested that 
melatonin's effect on rest (sleep)/activity may occur via a phase-resetting action on 
the biological clock. Certainly, as has been demonstrated in this thesis and by Zaidan 
et al (1994) single melatonin treatments can phase-shift the endogenous clock, but by 
less than 1.5h in entrained conditions. However, after a rapid 9h advance phase-shift, 
subjective sleep improved significantly on the first night following administration (one 
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hour before bedtime) with no significant adaptation of the urinary aMT6s or purified 
temperature rhythms. It seems unlikely that this immediate effect on sleep was 
attributable to an effect on the endogenous clock and suggests that other mechanisms 
are involved. 
11.5.2 `Hypnotic' effects 
It has been suggested that the beneficial effects of melatonin on sleep are due 
to its `hypnotic' properties similar to that seen with benzodiazepines, and that 
endogenous melatonin is involved in normal physiological sleep inducing mechanisms 
(Waldhauser et al, 1990; Dollins et al, 1993,1994). However, studies investigating 
alterations in sleep architecture have been conflicting and any changes seen were 
minor (see section 1.2.10). At a dose commonly used to treat circadian rhythm 
disorders, 5mg melatonin has been found to slightly increase REM latency (James et 
al, 1987) in normal individuals and reduce the latency from bedtime to stage 2 sleep 
in patients suffering from delayed sleep phase syndrome, suggesting a phase-resetting 
and initiation mechanism (Dahlitz et al, 1991). 
Benzodiazepines have proved beneficial in facilitating sleep adaptation after 
transmeridian flight (Nicholson et al, 1985; Donaldson and Kennaway, 1991). 
Melatonin has been shown to interact with the GABAergic system (Rudeen et al, 
1980; Rosenstein and Cardinali, 1986; Coloma and Niles, 1988) through which the 
benzodiazepines are likely to exert their sedative and anxiolytic properties (Enna and 
Mähler, 1987). Although melatonin may enhance these properties of 
benzodiazepines, it does not itself behave like a benzodiazepine (Guardiola-Lemaltre 
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et at, 1992). In rodents sedative and anxiolytic activity occurs at much higher doses 
than the levels needed to entrain circadian rhythms (Tobler et al, 1994). Sedative 
effects of melatonin were only significant at pharmacological doses in the studies 
described in this thesis. 
It must also be noted that the acute drowsiness observed in the experiments 
described in this thesis and of Dollins et al (1993,1994) using low oral doses of 
melatonin may be related to the experimental conditions whereby subjects seated in 
a warm room in dim light and were asked to perceive sleepiness more clearly than 
when active. Other studies in a normal environment have shown that administration 
of 2mg melatonin at 1700h induced clear drowsiness only after 4 days (Arendt et al, 
1984,1985a), which suggests an effect on the timing mechanisms of sleep rather than 
a sedative effect. In addition, in previous experiments using 5mg melatonin to 
facilitate adaptation to a new time-zone, subjects could not usually distinguish 
melatonin from placebo (Arendt et at, 1987; Samel et al, 1991). Clearly the activity 
of the subject may easily override any melatonin-induced sleepiness. 
Melatonin-induced drowsiness may simply be a result of temperature lowering 
effects (Dawson and Encel, 1993). The sedative-like effects of melatonin on mood 
and performance followed the same time course as the suppression of body 
temperature. Certainly there is strong evidence for a thermoregulatory role for 
melatonin (Strassman et al, 1991; Cagnacci et al, 1992,1993; Badia et al, 1993) and 
a strong relationship between the free-running rhythms of sleep propensity, body 
temperature and melatonin (Nakagawa et al, 1992). 
Although, it seems unlikely that endogenous melatonin induces physiological 
sleep, melatonin may prepare the body for sleep in some way. With pharmacological 
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doses, melatonin may exert its beneficial effects through a combination of sedation, 
temperature regulation and phase-shifting mechanisms. 
11.6 MASKING OR CUE FOR ENTRAINMENT ? 
Although external masking by the subject's behaviour and environment is 
considered undesirable by those interested in the pattern of the internally generated 
rhythm, some types of masking may well be important in normal physiology as a part 
the adaptive homeostatic mechanisms of the body, enabling the body to respond to 
environmental changes. 
Aschoff (1987) suggests that external masking from zeitgebers (e. g. from light 
and sleep) augments endogenous circadian rhythms and strengthens the temporal 
relationship with other circadian rhythms and the environment. In addition to this 
direct effect on the endogenous clock, Minors and Waterhouse (1989) underline the 
importance of "internal masking". In this case, physiological or biochemical changes 
occurring within the body as result of external factors could affect the circadian 
timing system. For example, the acute changes in body temperature in response to 
melatonin or bright light may provide additional input distinct from direct 
entraining/phase-shifting effects. When external time cues such as the light/dark 
cycle and sleep/wake schedule are in phase with the internal body clock, they may 
strengthen the circadian timing system. When out of phase, acute masking effects of 
the external zeitgebers such as the light/dark and sleep/wake cycles are in phase with 
the new shift in local time, a time to which the body needs to adapt to. Clearly 
masking from exogenous zeitgebers may provide an appropriate time cue. Suitably 
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timed exogenous melatonin may have similar effects. 
11.7 RELATIONSHIP BETWEEN THE ACUTE EFFECTS AND PHASE- 
SHIFTING PROPERTIES OF MELATONIN AND BRIGHT LIGHT 
The intensity of light required to shift the timing of circadian rhythms is 
enough to cause the suppression of melatonin secretion (Arendt, 1988; Lewy et al, 
1980; McIntyre et al, 1989). The phase-shifting ability of bright light is associated 
with a short term fall in the body temperature rhythm amplitude (Czeisler et al, 1989; 
Jewett et al, 1991). Cagnacci and co-workers (1992) have suggested that this 
reduction in amplitude is similar to that obtained with atenolol suppression of 
melatonin and speculate that the suppression of melatonin may be involved in the 
phase-shifting mechanisms of bright light. 
The phase-response curves for light (using core body temperature and 
melatonin as circadian phase markers, Czeisler et al, 1989; Minors et al, 1991; van 
Cauter et al, 1994) and melatonin (using its own endogenous rhythm as a marker, 
Lewy et al, 1992; Zaidan et al, 1994) are nearly opposite in phase. Furthermore, 
through indirect and direct evidence, the acute effects of bright light and melatonin 
on body temperature have been shown to be inversely related (Strassman et al, 1991; 
Badia et al, 1993; Campbell and Dawson, 1990). 
This thesis describes the dose-dependent suppression of core body temperature 
with a concomitant fall in alertness following melatonin treatment during the day. 
Conversely, Myers and Badia (1993) describe the dose-dependent stimulation of body 
temperature and alertness with bright light. In the latter study, light-induced 
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stimulation of temperature and alertness occurred only at light intensities found to 
suppress melatonin secretion and after the melatonin onset time. Furthermore, bright 
light exposure during the day does not appear to elevate body temperature (Murphy 
et al, 1991; French et al, 1990). 
These acute effects of bright light on body temperature are only clear during 
the late evening, nighttime hours and early morning (i. e. during periods of darkness), 
and at times when the circadian system is susceptible to the phase-shifting effects of 
bright light. Unfortunately, the acute effects of exogenous melatonin on temperature 
have not been studied during the nighttime hours in the presence of endogenous 
melatonin. However, administration during the day causes suppression of body 
temperature (Cagnacci et al, 1992; Dollins et al, 1993,1994; Deacon et al, 1994). 
It would be interesting to establish any time-dependency of the acute effects of 
melatonin on body temperature. The suggestion is that melatonin would only be 
effective at times when phase-shifts can be induced. This thesis has clearly shown 
that prior to its phase-shifting action on the endogenous body clock, melatonin has 
acute dose-related effects on body temperature, and that these acute effects are highly 
correlated to the degree of shift in the endogenous biological clock. A recent study 
indicates that slow changes in ambient temperature at night can phase-shift the 
temperature rhythm (Dewasmes et al, 1994), strengthening the suggestion that 
thermoregulatory responses may be involved in phase-shifting mechanisms. 
In consideration of the results shown in this thesis and of the other studies 
described, acute changes in body temperature by bright light and melatonin may be 
a primary event in phase-shifting mechanisms. 
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11.8 FUTURE WORK 
Given that bright light can induce large phase-shifts in the endogenous clock 
which are nearly opposite in phase to those of melatonin, a combination of 
treatments, when suitably timed, may reinforce each other and provide the most 
effective phase-shifting strategy. Future experiments should consider the use bright 
light (of varying intensities) in combination with melatonin to facilitate the gradual 
and rapid adaptation to advance phase-shifts. This direction of shift clearly induces 
the greatest behavioural problems and circadian rhythm disturbances. 
A complete intensity-response curve showing the degree of shift with varying 
intensities and duration of light should be carried out to determine the optimum 
conditions for efficient phase-shifting. Relating the degree of shift to the magnitude 
of melatonin suppression, stimulation of temperature and alertness, will strengthen the 
suggestion that light-induced effects on physiology and behaviour are mediated 
through changes in melatonin and body temperature. 
It is still not known whether the duration of exogenous melatonin treatment 
is important. Clearly oral doses of fast-release melatonin do not reflect the nocturnal 
profile of melatonin secretion. Intravenous infusions (Strassman et al, 1987; Zaidan 
et al, 1994) and sustained release preparations (Beni s et al, 1993) which mimic 
nocturnal melatonin secretion should provide a useful tool to study the role of 
endogenous melatonin in thermoregulation and phase-shifting mechanisms. The 
ability of a single melatonin treatment to phase-shift the endogenous body clock 
indicates the importance of establishing a PRC based on single oral treatments similar 
to that described by Zaidan et al (1994) using intravenous infusions. For clinical 
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purposes, a PRC based on single oral melatonin treatment would be of great practical 
benefit. The most effective dose of melatonin for phase-shifting the endogenous body 
clock was 5mg. This particular oral dose has been used extensively to treat circadian 
rhythm disorders (Arendt et al, 1987; Petrie et al, 1989; Folkard et al, 1990; Dahlitz 
et al, 1991; Tzischinsky et al, 1993). It will be of interest to study higher doses in 
future experiments. 
As single melatonin treatments can shift the endogenous body clock and 
therefore the PRC within one day, future experiments should compare the phase- 
shifting effects of repeated daily melatonin administration at the same times with a 
schedule which alters the time of melatonin treatment daily to take account of the 
altered PRC each day. Changing the time of administration should provide the 
optimum phase-shifting efficiency. However, such a treatment paradigm may be 
impractical when the desired administration time falls within the sleep phase, although 
delayed release preparations may prove beneficial in these situations. Furthermore, 
melatonin administration during the day may induce undesirable drowsiness. 
Melatonin treatment strategies should therefore be evaluated with these considerations 
in mind. 
Melatonin can induce temperature suppression and drowsiness and poor 
performance. Drugs which inhibit the secretion of melatonin may therefore reverse 
this effect. There is indirect evidence for this. B-antagonists, which suppress 
melatonin synthesis, are associated with elevated body temperature at night (Cagnacci 
et al, 1992) and disturbed sleep together with reduced alertness during the day 
(Dimenas et al, 1990, McAinsh and Cruickshank, 1990). 
In contrast, it would be interesting to see whether drugs or situations which 
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alter body temperature affect melatonin production. There is limited evidence to 
suggest that non-steroidal anti-inflammatory drugs reduce melatonin production in 
humans (Bird et al, 1986; Murphy et al, 1993) and elevate body temperature at night 
(Badia et al, 1993; Murphy et al, 1993). It would be interesting to see if preventing 
melatonin-induced temperature suppression hinders the phase-shifting properties of 
melatonin. 
It is not known whether melatonin acts peripherally to adjust body temperature 
or centrally within the thermoregulatory centres of the hypothalamus. It is possible 
that the acute effects of melatonin on temperature provide information to the SCN 
indirectly via thermoregulatory responses. This in turn may modulate the timing and 
amplitude of the temperature rhythm as part of the "adaptive homeostatic" 
mechanisms of the body. The close anatomical and neural association between the 
thermoregulatory centres in the hypothalamus and the SCN, the presence of putative 
melatonin receptors within the hypothalamus, together with the close association 
between melatonin-induced temperature suppression and its phase-shifting effects, 
suggest the involvement of hypothalamic control of body temperature in phase-shifting 
responses and provides a new direction for future research into circadian phase- 
shifting mechanisms. 
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Summary 
OBJECTIVES Shift work and rapid travel across several 
time zones leads to desynchronization of Internal circa- 
dian rhythms from the external environment and from 
each other with consequent problems of behaviour, phy- 
siology and performance. Field studies of travellers and 
shift workers are expensive and difficult to control. This 
investigation concerns the simulation of such rhythm 
disturbance in a laboratory environment. The main objec- 
tives are to assess the ability of controlled exposure to 
moderately bright light and darkness/sleep to delay 
circadian rhythms in volunteers without environmental 
isolation and, secondly, to evaluate the use of different 
Indices of melatonin (MT) secretion together with self- 
rated alertness as marker rhythms. 
PATIENTS Six normal volunteers aged 22-26 years 
(mean ± SD 24.3±1.4). 
DESIGN Subjects were exposed to the following periods 
of moderately bright light (1200 lux) on three consecutive 
days in early December 1991: Day (D)1: 2000-0200 h, 02: 
2200-0400 h and D3: 2400-0600 h. Each period was 
followed by 8 hours of darkness (< I lux). Hourly blood, 
sequential 4-hourly urine (8-hourly when asleep) and 
hourly saliva (except when asleep) samples were taken 
throughout a 24-hour period on DO (baseline), D4 (1 day 
post-light treatment) and D7 (4 days post-light treatment). 
During waking hours, subjective alertness was rated 
every 2 hours on a visual analogue scale. 
MEASUREMENTS MT was measured in plasma and 
saliva, and Its metabolite, 6-sulphatoxymelatonin 
(aMT6s), was measured in urine. MT, aMTBs and alertness 
scores were analysed by ANOVA and a cosinor analysis 
program. 
RESULTS A delay shift was present in the aMT6s, plasma 
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MT and salivary MT rhythms (degree of shift: 2.67±0.3 h 
(P<0.001, n=5); 2.35±0.29 h (P<0.001, n=6); and 
1.97±0.32 h (P<0.01, n=6), mean ±SEM, respectively) 1 
day post-light treatment compared to baseline. Adaptation 
to the Initial phase position was apparent by the 4th post- 
treatment day. Significant correlations were obtained 
between plasma MT onset (degree of shift: 3.12±0.74 h 
(P < 0.001, n=6, mean ± SEM)) and the acrophases (calcu- 
lated peak times) of plasma MT (P<0.001), salivary MT 
(P < 0.05) and urinary aMT6s (P < 0.01). A significant phase 
delay In the alertness rhythm was also evident 1 day post- 
treatment (3.08 ± 0.67 h (P < 0.01, n=6, mean ± SEM)) with 
adaptation by the 2nd post-treatment day. 
CONCLUSIONS This study suggests that these methods of 
determining MT secretion are comparable and give reli- 
able assessments of the MT circadian phase position even 
after a phase-shift. Significant phase-shifts of similar 
magnitude can be induced In both MT and alertness 
rhythms using moderate intensity bright light at night. 
Rapid time zone change and shift work can lead to conflict 
between the new external time cues (zeitgebers) and the 
internal biological clock with consequent physiological 
disturbances and deleterious effects on, for example, sleep 
and performance (Seigel et al., 1969; Fevre-Montange et al., 
1981; Winget ei al., 1984; Touitou et al., 1990). Pharmaco- 
logical and non-pharmacological interventions to promote 
adjustment to rapid change of external time cues have been 
proposed (Lewy et al., 1985; Arendt et al., 1986; Czeisler et 
al., 1990; Redfern, 1992). 
Suitably timed bright light of sufficient intensity and 
duration will induce phase-shifts in physiological variables 
such as core body temperature, cortisol and melatonin 
secretion (Czeisler et al., 1986; Broadway et al., 1987; Lewy et 
al., 1987; Minors et al., 1991; Shanahan & Czeisler, 1991). In 
constant routine ('unmasked') conditions, the magnitude 
and direction of shift of melatonin and core body tempera- 
ture are similar (Shanahan & Czeisler, 1991) suggesting a 
common control mechanism. Under normal environmental 
conditions, however, MT is less influenced by external 
factors (other than light, Lewy et a!. (1980)), compared to 
other circadian rhythms such as core body temperature and 
cortisol secretion. One primary aim of this study was to 
devise a simple, rapid and inexpensive method to study the 
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adaptation of circadian (about 24-hour) rhythms during and 
after a phase-shift without complete environmental isola- 
tion. In this initial study a combination of moderately bright 
light and subsequent imposed darkness was used to induce a 
phase-shift and MT was employed as a circadian rhythm 
marker together with self-rated alertness. 
Melatonin has been variously measured and compared in 
plasma, saliva, and its metabolite aMT6s in urine (Markey et 
al., 1985; Vakkuri, 1985; Bojkowski et a!., 1987; McIntyre et 
al., 1987; Nowak et a!., 1987) under normal environmental 
conditions. The onset of its secretion in dim light has been 
extensively used by Lewy and co-workers (e. g. Lewy & Sack, 
1989) as a circadian phase marker. A second aim of this study 
was to assess the relative validity of these various approaches 
in determining the circadian phase position under normal 
and phase-shifted conditions. 
Subjects and methods 
Subjects 
Six healthy volunteers (3M: 3F), aged 22-26, under no 
medication (except oral contraceptives) and all non- 
smokers, were recruited from research students and staff of 
the University of Surrey. All subjects gave informed consent 
and the study protocol was approved by the Ethical 
Committee of the University of Surrey. Prior to the study all 
volunteers underwent standard biochemical and haemato- 
logical tests. 
They refrained from heavy exercise and caffeine-contain- 
ing drinks for 12 hours before sampling of body fluids and 
restricted their alcohol consumption (maximum 2 units per 
day) throughout the experiment. 
Study design 
The study was performed in early December 1991. Consis- 
tent with other related studies (e. g. Czeisler et al., 1986), 
individual responses were evaluated in comparison to their 
own baseline values. 
Baseline. For one week prior to light treatment (days (D) -7 
to 0), the subjects were required to maintain a regular sleep/ 
wake schedule, retiring to bed at 2330 h and waking at 
0800 h, remaining in the dark (< I lux) between these times. 
Light treatment. Immediately following the baseline week, 
the subjects were exposed to the following periods of 
moderately bright, full spectrum light (average 1200 lux at 
eye level, irradiance 492 pW/cm2; True-Lite, Duro-Test 
Corporation, Fairfield, NJ, USA, obtained through Full 
Spectrum Lighting, High Wycombe, Buckinghamshire, UK) 
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on 3 consecutive days: D1: 2000-0200 h, D2: 2200-0400 h, 
D3: 2400-0600 h. Each period of light treatment was 
followed by 8 hours of imposed darkness (< I lux). During 
the remaining hours of each day strict light control was not 
imposed until dusk (1630 h), but the subjects were asked to 
refrain from periods of exposure to bright sunlight. From 
dusk until the light treatment period, subjects remained in 
domestic intensity light (cool, white fluorescent, 150-300 lux 
at eye level, irradiance 45-90 pW/cm2). Throughout the light 
treatment (Dl-3) meal-times were shifted progressively by 2 
hours each day in line with the imposed light/dark cycle. 
Subjects were allowed to choose their activity (e. g. reading, 
writing, watching videos) as long as they glanced periodically 
(at least every 5 minutes) at the light source. They were 
continuously supervised throughout these periods. 
Post-light treatment. Immediately following the last light 
treatment, subjects were required to assume the baseline 
sleep/wake schedule, i. e. retiring to bed at 2330 h and waking 
at 0800 h for 4 days (D4-8). The subsequent readaptation of 
the subjects in their normal environment was then observed. 
Subjects were allowed to sleep only during the periods of 
darkness throughout this study. Naps were not allowed. 
Sampling 
During body fluid sampling and light treatment the subjects 
remained in the Clinical Investigation Unit at the University 
of Surrey. Blood, urine and saliva samples were taken on the 
last baseline day (DO), the first post-light treatment day (D4) 
and the fourth post-treatment day (D7). All blood and saliva 
samples obtained throughout the dark-phase were taken in 
the recumbent position and daytime samples after sitting for 
at least 10 minutes. 
Blood. An indwelling cannula was inserted into the forearm 
of each subject, under local anaesthetic, between 1630 and 
1700 h. Blood samples (5 ml) were obtained hourly from 1700 
h for 24 hours on each sampling day and collected into 
lithium heparin tubes. The plasma was separated within 20 
minutes by centrifugation (2500 g for 10 minutes) and stored 
at - 20° C until analysis. Sampling during darkness was 
performed in dim red light (< I lux). A total of 396 ml of 
blood was removed from each person. 
Saliva. 2-3 ml were obtained hourly from 1700 h for 24 
hours, except during sleep, on the sampling days (following 2 
minutes of chewing on Parafilm), collected into labelled 
plastic vials and frozgn at -20°C until analysis. Meals and 
drinks were taken just after saliva sampling and a thorough 
mouthwash taken afterwards to reduce any possible interfer- 
ence with salivary MT estimation. 
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Urine. Sequential 4-hourly urine samples (8-hourly when 
asleep) were collected from 1600 h throughout 24 hours on 
DO, 4 and 7. Each subject voided at 1600 h on each sampling 
day. All urine was then collected throughout each 4-hour 
period and the bladder completely emptied at the end of that 
collection period. The volume of each sample was noted and 
a 5-ml aliquot from each sample was collected into a labelled 
vial and frozen at -20°C until analysis. 
Behavioural measurements 
Throughout the entire experimental period, alertness was 
rated every 2 hours on a 10-cm visual analogue scale (VAS, 
`Drowsy. -. Alert'), except when asleep. In addition, daily 
sleep logs were kept and performance tasks were carried out. 
The effects of an induced phase-shift on various sleep and 
performance parameters will be reported elsewhere. 
Hormone assays 
Plasma MT levels were determined by direct RIA using the 
method described by Fraser et al. (1983), with antiserum (no. 
G/S/704-8403) obtained from Stockgrand Ltd (University 
of Surrey, Guildford, UK). The interassay coefficients of 
variation were 10.4,15.2 and 9% at 97,142 and 905 pmol/l 
(n=10). The minimum detection limit (defined as the 
concentration at 2 SD from the mean at maximum bound 
counts) was 26 pmol/l. 
Salivary MT was determined using a GCMS-validated 
modification (English et a!., 1993) of the direct plasma MT 
RIA described by Fraser et al. (1983) using an iodinated 
tracer, with antiserum no. 19540/16876 from Stockgrand 
Ltd. The interassay coefficients of variation from routine 
quality control samples were 15.3,11.7 and 5.5% at 105,169 
and 288 pmol/I (n = 6). The minimum level of detection was 
13.8 pmol/l. 
Urinary aMT6s was determined using the method de- 
scribed by Aldous and Arendt (1988) with antiserum (no. 
HP/S/1118-23884) from Stockgrand Ltd. The interassay 
coefficients of variation were 16.8,11.6 and 5.8% at 7.2,63.3 
and 132 nmol/l (n = 6). The minimum level of detection was 
1.2 nmol/l. 
Statistical analysis 
The raw hormonal data were subjected to two-way ANOVA 
with replication. Subsequently, a cosinor analysis program 
(written by Dr D. S. Minors, University of Manchester, UK) 
was used to derive the rhythm characteristics of both the 
alertness and hormonal data. ANOVA followed by Dun- 
can's Multiple Range Test, or Student's t-test where appro- 
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priate, were applied to the cosinor-derived parameters of 
acrophase (calculated peak time), amplitude and daily mean 
(for alertness). All data below the limit of detection were 
excluded from the analysis, except for the purposes of the 
cosinor program where values lower than this limit were 
assigned a value of half the minimum detection limit of the 
assay. 
The onset and offset of plasma MT secretion were defined 
as twice the minimum detection limit of the assay when two 
consecutive values either exceeded or were below this 
amount. The relations between concentrations of MT in 
saliva and plasma, and aMT6s in urine, and between their 
respective acrophases and plasma MT onset time, were 
determined by linear regression analysis and Pearson's 
correlation. 
Mean daily alertness scores were also determined for each 
individual and calculated as a percentage of their own 
baseline. All values quoted are mean±SEM unless stated 
otherwise. 
Results 
No subjects reported any oral lesion or discomfort during the 
study and no saliva sample appeared to be contaminated 
with blood. On four of the baseline days (D -6 to - 3) one 
subject suffered from flu-like symptoms which subsequently 
resulted in reduced alertness and disrupted his sleep pattern. 
The alertness data obtained on these days were excluded 
from the analysis. 
The profiles of urinary aMT6s, plasma MT and salivary 
MT are shown in Fig. 1. 
Inspection of the aMT6s data indicated a marked phase 
delay on the first post-light treatment day (D4) in five out of 
six subjects. One subject showed a threefold increase in the 
amplitude of aMT6s on D4 with no phase change and, in 
contrast to all the other subjects, a poor correlation with 
plasma and salivary MT. This subject was consequently 
excluded from the analysis of aMT6s. 
A significant time-dependent effect of treatment 
(ANOVA-phase delay) was shown by two measures of MT 
secretion (aMT6s, P<0.01; plasma MT, P<0.05) but not 
with salivary MT, on the first post-light treatment day (D4), 
which was no longer present on the fourth post-light 
treatment day (D7) (P<0-l). 
Cosinor analysis gave most significant fits of plasma MT 
(17 out of 18 profiles at P<0.001), followed by salivary MT 
(14 out of 18 at P<0.05) and urinary aMT6s (10 out of 15 at 
P<0.1) reflecting the missing data during sleep for both 
salivary MT and aMT6s. However, the percentage of the 
variance accounted for by a cosine curve was greater than 
81 % in the aMT6s profiles. 
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Fly. 1 Circadian profiles for a, urinary aMT6s; b, plasma MT; and c, salivary MT showing (i) phase delay on  , the first post-light 
treatment day (D4) compared to Q, baseline (DO) and (ii) readaptation by  , &, the fourth post-light treatment day (D7), i. e. no significant 
difference from baseline (DO). Darkness from 2330 to 0800 h. *P<0.05, **P<0.01 significant time-dependent treatment effect: phase delay 
(two-way ANOVA with replication). Values represent mean±SEM (n=6; urinary aMT6s: n=5). 
Using the acrophase data derived from the cosinor 
program, a significant phase delay (ANOVA) was present in 
all measures of MT secretion on the first post-light treatment 
day. The mean peak time was shifted by 2.67±0.3 h (n=5) 
for aMT6s (P<0. OO1), 2.35±0.29 h (n=6) for plasma MT 
(P<0.001) and 1.97±0.32 h (n=6) for salivary MT 
(P<0.01), l day post-light treatment (Fig. 2). Plasma MT 
onset also showed a significant delay on D4 (3.12±0.74 h, 
n=6, P<0.001). These shifts did not significantly differ from 
each other (P> 0.1). The acrophase estimates and MT onset 
time for the fourth post-light treatment day (D7) were not 
significantly different from baseline (P>0.1, ANOVA), but 
were significantly different from D4 (P<0.05, ANOVA), 
indicating re-entrainment by D7. The plasma MT offset time 
shifted to a lesser degree (1.33 +0-35 h, n= 6) compared to its 
onset time. 
Table I shows the correlation of acrophases between 
plasma and salivary MT and urinary aMT6s, together with 
plasma MT onset times. The urinary aMT6s acrophase 
occurred on average 1.45 and 2.09 hours after the plasma and 
salivary MT acrophases, respectively, and 5.6 hours after the 
plasma MT onset. 
There was a direct correlation between plasma and 
salivary MT in samples taken simultaneously (r=0.758, 
P<0-001) before the light treatment, immediately after the 
phase-shift (r=0.792, P<0.001) and on D7 (r=0.576, 
P<0.01). The difference between plasma and salivary MT 
levels remained constant throughout the study. Salivary MT 
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levels were estimated to represent a mean ± SD of 40 ± 6.9% 
of the corresponding plasma levels throughout the baseline 
day (DO), 441 ±4.9% over the first post-light treatment day 
and 37.4±4.6% on the fourth post-light treatment day, to 
give an overall mean±SD value of 40.4±5.3%. 
The degree of shift for aMT6s on D4 was significantly 
correlated (P>0.05) to the pretreatment amplitude of the 
aMT6s rhythm, such that the greater the amplitude the 
smaller the phase-shift. No such correlations were found to 
be statistically reliable with plasma or salivary MT rhythms. 
No significant change in the rhythm amplitude was apparent 
after the phase-shift with any of the measures of MT 
secretion. 
Alertness 
No significant difference in the timing of the alertness 
acrophase was found throughout the baseline days (mean 
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Fig. 2 Acrophase estimates for ", urinary aMT6s; Q, plasma MT; 
f, salivary MT;  , plasma MT onset; and 0, alertness on the 
baseline day (DO), I day post-light treatment (D4) and 4 days 
post-light treatment (D7). Darkness from 2330 to 0800 h. 
Acrophase estimates are represented as mean ± SEM (n=6, n=5 
for aMT6s). **P<0. O1, ***P<0.001: significant difference from 
baseline (ANOVA). D7 was significantly different from D4 
(P<0.05) but not from DO for all variables. This suggests a 
significant phase-shift on the Ist post-light treatment day and re- 
entrainment by the 4th post-light treatment day (2nd-post 
treatment day for the alertness rhythm (Fig. 3)). 
acrophase 1484±0.28 h). There was a reliable condition 
effect (P < 0-0 1, ANOVA), with a clear phase delay in the 
rhythm (shift: 3-08+0-67h, P<0.01, n=6, ANOVA; 1 day 
post-light treatment compared to DO). This effect is shown in 
Fig. 2. The alertness rhythm re-entrained by the second post- 
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Table 1 Correlation and linear regression analysis of acrophase 
estimates between plasma MT, salivary MT and urinary aMT6s, 
together with the time of plasma MT onset. y=mean (±SEM)x 
+mean (±SEM) 
Plasma MT/urinary aMT6s 
y =0"82 (±0-18)x + 1-45 (±0"93) 
r=0"754, P<0"001, n= 15 
Plasma MT/salivary MT 
y=0-60 (±0.2)x+2"35 (±0"93) 
r=0"6, P<0.01, n= 18 
Urinary aMT6s/salivary MT 
y=0"78 (±0.19)x+2"09 (±0-78) 
r=0.718, P<0"001, n= 18 
Plasma MT onset/plasma MT 
y=0.62 (f0"I)x+5"06 (±0"23) 
r=0"849, P<0"001, n= 18 
Plasma MT onset/urinary aMT6s 
y=0.7 (±0"14)x+5"6 (±0"23) 
r=0.69, P<0"01, n= 15 
Plasma MT onset/salivary MT 
y=039 (t0"15)x+4"55 (±0-24) 
r=0S3, P<0"05, n=18 
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Fig. 3 Alertness acrophase estimates (mean ± SEM, n=6; D-6 to 
D-3, it = 5) throughout an 8-day baseline (D- 7 to DO), a 3-day 
light treatment period (D1-3) and a 4-day post-light treatment 
(D4-7). 'P<0.05, "'P<0.01: significant difference from baseline 
(Duncan's multiple range test). A significant phase-shift can be 
observed on D3 and D4 with re-entrainment by D5. 
f Bright light 
administration. 
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light treatment day (Fig. 3). No reliable difference in 
amplitude was apparent although the daily mean alertness 
fell significantly during the first day of the light treatment 
(P<0.01, Duncan's multiple range). The degree of shift in 
the alertness rhythm on D4 (compared to DO) was not 
significantly different from the shift in urinary aMT6s, 
plasma MT, salivary MT and the plasma MT onset time 
(P>0.1). 
Discussion 
One object of this study was to assess the usefulness of non- 
invasive methods of determining MT secretion in the form of 
salivary MT and urinary aMT6s before and after a phase- 
shift. The close relationship between plasma MT onset as a 
phase marker, and the calculated peak times of MT in 
plasma and saliva, and aMT6s in urine, suggests that all these 
approaches give valid information. 
The light treatment schedule was chosen to enhance the 
natural tendency of circadian rhythms in the majority of 
people to delay. During the light treatment it was not 
possible to assess correctly the phase position of circadian 
rhythms due to the direct, acute effects (`masking') of light. 
For example, with sufficiently bright light MT is suppressed 
and core body temperature is increased (Lewy et al., 1980; 
Badia et al., 1990). For this reason, the immediate post-light 
treatment period provides the nearest estimate to the actual 
phase-shift induced. During this period (D4), during the 
baseline (DO), and after readaptation (D7) the MT onset and 
mean peak values occurred in conditions of dim light or 
darkness. In such conditions, it is assumed that the measured 
phase position of MT represented the actual phase position 
on those days, and that the magnitude of the actual induced 
shift was greater than or equal to the measured shift on D4. 
In order to minimize sleep disturbance which may have 
compromised behavioural measurements, saliva and urine 
sampling were avoided during the sleep-phase. There was 
thus some loss of definition in circadian profiles, particularly 
for salivary MT. In spite of this problem a comparable 
phase-shift in the salivary MT rhythm was obtained. Clearly, 
however, the saliva data would have been greatly enhanced 
by night-time sampling. The salivary MT onset time was not 
a useful index of the rhythm since a high proportion (67%) of 
onset times occurred during the sleep-phase after the phase- 
shift. 
In this present study the ratio of salivary MT levels to 
plasma MT levels remained constant and the correlation 
remained highly significant even immediately after the 
phase-shift. These results agree well with the other reports 
(Vakkuri, 1985; McIntyre et al., 1987; Nowak et al., 1987) 
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where samples were obtained throughout 24 hours in a 
normal environment. McIntyre and colleagues (1987) also 
showed a good correlation (r = 0.92, P<0.005) when plasma 
MT and salivary MT levels were suppressed with one hour of 
bright light between 2400 and 0100 h. Nickelson et al. (1991) 
suggested that the relationship between salivary MT and 
urinary aMT6s may change following a 9-hour forced phase- 
shift. There is no evidence for this phenomenon in this 
present study. However, the induced shift was much smaller 
and more frequent saliva collections were made, at least 
during waking hours. 
The practical advantage of urinary aMT6s is that it 
provides an integrated measure for MT production over the 
night-time period. However, due to limited frequency of 
sampling it is not able to measure subtle changes in the 
rhythms. The delayed aMT6s acrophase compared to that of 
plasma MT is presumably due to both hepatic metabolism 
and renal excretion mechanisms. 
A clear phase delay in the alertness rhythm was evident, 
comparable to that of MT. This may imply a causal 
relationship as suitably timed MT administration can 
modify alertness (Arendt et al., 1987). However, in this study 
it is more likely that the treatment induced a shift in central 
rhythm generating mechanisms common to both variables. 
Whilst the contemporary shift in the timing of meals (social 
zeitgebers) and the sleep/wake cycle may have had some 
effect, previous work indicates (for review see Eastman, 
1990) that bright light has the more powerful rapid phase 
shifting ability. A significant decline in daily mean alertness 
was apparent only on the day of the first light treatment. It is 
likely that this was due to blood sampling the previous night 
and throughout the day. On all other days bright light 
treatment, blood sampling and the effects of the phase-shift 
did not affect the amplitude or daily mean alertness. 
Although field studies have the advantage of being able to 
expose the individual to the whole range of environmental 
and social time cues, and associated psychological factors, it 
is expensive and difficult to standardize these influences in a 
number of subjects, with the collection of biochemical data 
an obvious problem. The use of a three-cycle stimulus of 
moderate intensity bright light (1200 lux), suitably timed and 
coupled with periods of 
imposed darkness (<I lux) and 
sleep, clearly induces significant phase-shifts in a major 
endogenous hormonal circadian rhythm (MT) and a major 
behavioural rhythm (self-rated alertness). It should therefore 
be possible to simulate circadian rhythm disorders and 
related problems such as jetlag and shiftwork, similar to 
those seen in field studies, in an inexpensive and controlled 
environment which is convenient for biochemical sampling 
and where the subjects are left in their normal environment 
for most of the time. 
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Abstract 
Appropriately administered melatonin is able to phase shift circadian rhythms, to induce transient sleepiness and to suppress core 
body temperature. The relationships between these phenomena have not been fully explored. In a double-blind, placebo-controlled 
crossover study, 8 healthy males maintained a regular sleep-wake cycle in a natural environment throughout. From dusk until 2400 
h on days (D) 1-4 subjects were in dim artificial lighting (< 100 lux) with darkness (< 1 lux) from 2400-0800 h. Sunglasses were worn 
during the day when outside. At 1700h on D3 either melatonin (5 mg) or placebo was administered. Saliva samples were collected 
at 30 min intervals, 1600-2400 h on D3 and D4, and subjective alertness rated at 30 min intervals from 1600-2400 h on D3 and 
hourly from 0800-2400 h D4. Sleep quality was rated on nights 2,3 and 4 and core temperature was recorded throughout. Melatonin 
induced a significant suppression of temperature and alertness peaking 2.5 h after the dose, together with improved sleep quality 
on the night of D3 and a phase advance of the endogenous melatonin rhythm on D4. The degree of phase shift was related to the 
amount of temperature suppression in 6 of 7 subjects with detectable melatonin, suggesting that temperature suppression is an integral 
part of the phase-shifting mechanism. 
Key words: Melatonin; Temperature; Circadian rhythm 
The pineal hormone melatonin has been proposed as 
a treatment for circadian rhythm disorders such as jet lag 
and maladaptation to shift work [1]. Several reports have 
indicated that melatonin has both phase-advancing and 
phase-delaying effects on the internal biological clock 
[3,6,11,13,14] and that the successful alleviation of dis- 
turbed sleep and mood associated with a rapid shift of 
local time cues is accompanied by a quicker adaptation 
of various circadian rhythms [2,15]. Melatonin also has 
acute transient effects on body temperature [4,7,9], sub- 
jective sleepiness [7,9] and the sleep propensity function 
[16]. The mechanism of action is unknown, but the rhyth- 
mic electrical activity of the suprachiasmatic nucleus (the, 
major central rhythm generating system of the hypothal- 
amus) can be shifted in vitro by melatonin [13]. Human 
studies have generally used daily timed administration of 
melatonin to induce a cumulative phase shift [3,11 ]. Only 
one report to date has considered the acute phase shifting 
*Corresponding author. Fax: (44) 483-576 978. 
effects of melatonin using its own endogenous rhythm as 
a phase marker [6]. We report here that even in a normal 
environment a single oral melatonin treatment can 
phase-advance its own endogenous rhythm (arguably the 
best marker of the circadian clock) within 24 h, with a 
similar tendency in core body temperature, and that this 
is preceded by immediate suppression of core body tem- 
perature and subjective alertness. These effects were ac- 
companied by an improvement in subjective sleep quality. 
Eight healthy men aged 23-28 years, taking no medi- 
cation, were recruited from members of staff and post- 
graduates of the University of Surrey. All volunteers 
gave informed consent and the study was approved by 
the University of Surrey Advisory Committee on Ethics. 
Except where specified, subjects continued their normal 
daily activities during the experimental period but re- 
frained from heavy exercise and alcohol consumption. 
Melatonin (5 mg) or placebo was administered to all 
subjects in a randomised, double-blind cross-over study. 
Each leg of the study began on the same day of the week 
and was performed over 5 days (D1-D5) with at least a 
0304-3940/94/$7.00 © 1994 Elsevier Science Ireland Ltd. All rights reserved 
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week between treatments, during winter at 52°N. Sub- 
jects were required to keep a regular sleep--wake cycle, 
sleeping and/or in darkness (< I lux) from 2400 0800 h, 
and from dusk (approximately 1630h) until 2400 h they 
remained in dim artificial lighting (< 100 lux) throughout 
the experiment. Sunglasses were worn during the day 
when outside. Rectal temperature was recorded continu- 
ously every 6 min using Squirrel Minilogger devices 
(Grant Instruments, Cambridge, UK) from 0800 h on 
D2 to 0800 h on D5. 
Days I and 2 served to establish a common sleep 
wake cycle and to accustom subjects to the rectal ther- 
mometers. On D3 subjects received either a single dose 
of oral melatonin (5 mg in lactose-gelatine capsules) or 
%placebo (vehicle) at 1700 h. From 1600 h on D3 and D4 
they remained seated, except for brief (less than 5 min) 
periods if urination/defecation was necessary. They re- 
ceived the same standard meal at 2130 h on D3 and D4. 
At 30 min intervals from 1600 h until 2400 h on D3 and 
D4 saliva samples were collected after rinsing the mouth 
with tap water and subjective alertness scores (visual 
analogue scale-drowsy-alert') were rated. Alertness was 
also rated hourly from 0800-2400 h on D4. Sleep quality 
was rated on a visual analogue scale (best ever-worst 
ever) on awakening for the nights of D2, D3 and D4. 
Melatonin was measured in saliva by GCMS-vali- 
dated radioimmunoassay (limit of detection, 0.95 ± 0.43 
pg/ml, mean ± S. D., n= 10) [10]. Differences in core 
body temperature, alertness and melatonin were assessed 
by two-way analysis of variance (ANOVA) for repeated 
measures (factors: time, treatment) and area under the 
curve (AUC) analysis followed by Student's paired t-test. 
The phase of the core body temperature rhythm on D4- 5 
was determined by cosinor analysis (program written by 
Dr. D. S. Minors, University of Manchester, UK) fol- 
lowed by paired Student's t-test. The onset of melatonin 
secretion was determined on D4 and was defined as the 
time when concentrations exceeded 4 pg/ml, when 2 con- 
secutive values exceeded this amount. Any relationship 
between the magnitude of temperature suppression 
(AUC) and degree of phase shift of melatonin onset time 
was determined by regression correlation. Differences in 
sleep quality between placebo and melatonin, deter- 
mined as a percentage of a baseline night (D2) were 
assessed by paired Student's t-test. 
Melatonin clearly induced an acute, transient but sig- 
jr nificant suppression of body temperature between 1700 
and 2400 h and alertness between 1700 and 2100 h (AUC 
analysis, paired t-test, P=0.02) (Fig. 1). ANOVA identi- 
fied a significant treatment effect on temperature be- 
tween 1812 and 2030 h (F = 5.02, df = 1,242, P<0.05) 
with a mean (±S. D. ) fall in temperature of 
0.26 ± 0.19°C, together with a significant fall in alertness 
by 31.1 ± 1.1% (mean ± S. D. ) between 1700-2130 h 
(F= 6.67, df = 1,12, P<0.05). Salivary melatonin was 
undetectable in one subject, however in 7 subjects a sig- 
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Fig. I. Time course of the suppression of core body temperature, meas- 
ured every 6 min (a) and subjective alertness measured every 30 min (b) 
following a single oral administration of melatonin (5 mg) at 1700 h. 
Temperature, 1700-2400 h, alertness 1700- 2100 h: AUC analysis, 
paired I-test, P=0.02. Temperature: repeated measures ANOVA be- 
tween 1812 and 2030 h, F= 5.02, dl'= 1.242, P<0.05. The following 
day, onset of mclatonin secretion was advanced after receiving mela- 
tonin compared to placebo (c), ANOVA, time by treatment, 
P=0.0078, shift 1.14 ± 11.49 h (mean ± S. D. ). All values are 
mean ± S. E. M., n=8 (n =7 for salivary mclatonin). 
nilicant time by treatment erect (ANOVA, F=2.73, 
df= 10,60, P<0.01) was seen, where melatonin ad- 
vanced the melatonin onset time relative to placebo by 
1.14 ± 0.49 h (mean ± S. D. ) on D4, the day following 
administration. Melatonin concentrations in saliva 
reached a maximum at 1730 h in all subjects 
(4363 ± 2621 pg/m1, mean ± S. D. ), whereas the mini- 
mum temperature following melatonin administration 
was found at 1934 h± 49 min (mean ± S. D. ). There was 
no significant correlation between the individual maxi- 
mum salivary melatonin concentration and the degree of 
temperature suppression. A recent report [9] suggests 
that a dose response relationship exists between the 
exogenous dose of melatonin and the amount of temper- 
ature suppression. In the present study the limited 
frequency of saliva sampling precludes accurate correla- 
tions. 
T Time (hour) 
Meal 
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The distortion of the temperature rhythm by mela- 
tonin during the evening and night of day 3 invalidates 
any phase estimates. However the calculated peak time 
(acrophase) of the temperature rhythm from 0800 h on 
D4 to 0800 h on D5 also tended to phase advance (acro- 
phase after placebo, 17.01 ± 1.25 h, after melatonin, 
16.18 ± 1.32 h, mean ± S. D., P=0.053). One subject 
slept, intermittently, for 3h after receiving melatonin 
and showed an exceptionally large drop in temperature 
(0.65°C), presumably due to masking. Excluding this 
subject there was a significant correlation between the 
magnitude of melatonin-induced temperature suppres- 
sion from 1812-2030 h and the degree of phase shift in 
melatonin onset time the following day in 6 subjects with 
detectable melatonin (r = 0.843, P=0.035). Expressed 
as a percentage of the baseline night, sleep quality on the 
night of D3 was improved by 70 ± 52% (mean ± S. D., 
P<0.05, n= 8) and also showed a tendency to improve 
(by 50 ± 61%, P=0.053, n= 8) on the night of D4. 
There were no significant changes in alertness on D4. 
The timing of the fall in temperature and alertness 
correspond closely to the reported increase in sleep pro- 
pensity after 5 mg melatonin given in the late afternoon 
[16]. This acute `masking' is followed by a significant 
advance in the timing of the melatonin onset time in 
saliva the following evening which may be related to the 
degree of temperature suppression. The temperature 
rhythm itself is more susceptible than melatonin to ex- 
ogenous influences [17]. Thus, whilst it is possible to 
avoid masking of the melatonin rhythm by control of 
bright light exposure and posture [8,12], phase shifts in 
the temperature rhythm may have been obscured in a 
normal environment. It is clear that acute induction of 
early evening drowsiness by melatonin does not compro- 
mise and indeed appears to enhance sleep quality during 
the subsequent night. 
Whilst the maximum of the endogenous melatonin 
rhythm corresponds closely to the nadir in core body 
temperature (e. g. [4]), the maximum suppression of tem- 
perature obtained using a pharmacological dose of mela- 
tonin in this study occurred approximately 2h after 
treatment. The observed effect may not therefore be rep- 
resentative of endogenous mechanisms. 
In previous experiments using 5 mg melatonin to has- 
ten adaptation to phase shift, subjects could not nor- 
mally distinguish treatment from placebo [2,15]. The 
acute drowsiness, and in one case intermittent sleep re- 
corded here, and in recent experiments using even lower 
doses of melatonin [9], may be related to the experimen- 
tal conditions whereby subjects seated in a warm room 
in dim light, or indeed requested to try to sleep, perceive 
transient sleepiness more clearly than when active. 
Cagnacci et al. [4] reported acute suppressant effects 
of melatonin when given in divided doses in the morning. 
They and others have provided evidence [5] that mela- 
tonin counteracts the stimulatory effect of bright light on 
body temperature at night. In view of the present results 
it would not be unreasonable to suggest that the primary 
event in the induction of a phase shift by bright light or 
by melatonin is an acute change in body temperature. If 
this proves to be the case it provides substantial scope for 
investigation of phase-shifting mechanisms via the cen- 
tral hypothalamic control of body temperature. 
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Posture influences melatonin concentrations in plasma and saliva in 
humans 
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Melatonin is extensively used as a circadian marker rhythm and thus any factors influencing its concentrations other than endogenous rhythmicity 
must be assessed. We report here the effects of posture on melatonin concentrations in plasma and saliva. The study was performed during the rising 
phase of the melatonin rhythm between 21: 00 and 01: 30 It. From 23: 00 h, 7 healthy subjects remained sitting until 24: 00 h and in dim light (< 10 lux) 
until 01: 30 h. From 24: 00 h, they assumed a different postural position in one of the following stages: Stage 1 a: 24: 00-00: 30 It - standing, 00: 30-01: 00 
It - supine, 01: 00-01: 30 It - standing; Stage lb - reverse of Stage la, Stage 2a: 24: 00-01: 30 h- supine; and Stage 2b: 24: 00-01: 30 h- standing. Blood 
and saliva samples were obtained every hour from 21: 00-24: 00 h and then every 10 min from 24: 00-01: 30 It. Plasma and salivary melatonin 
concentrations, measured by radioimmunoassay, increased when moving from a supine to a standing position and decreased when these positions 
were reversed. These changes, as seen with other blood components, can be explained through the influence of gravity which causes a decrease in 
plasma volume on standing and an increase in plasma volume on lying down. 
The force of gravity causes significant changes in the 
human circulatory system and with the continual chang- 
ing of posture in everyday life the influence of gravity on 
various blood parameters becomes apparent. In healthy 
subjects, when an upright position is adopted after lying 
recumbent (supine), the plasma volume is reduced and 
the concentration of various plasma components, espe- 
cially that of the proteins and of the constituents bound 
to them, increases. This rise in plasma constituent con- 
centration is in the order of 10-20% (e. g. ref. 7) and the 
effect is reversible on reversing the postural position. 
Such studies suggest that other plasma constituents such 
as hormones and metabolites might show similar 
changes in plasma levels. 
The pineal hormone melatonin is secreted into the 
blood in a highly stable and reproducible pattern within 
individuals [2]. The rhythm is endogenous, and governed 
by an internal circadian pacemaker: the suprachiasmatic 
nucleus of the hypothalamus. An important feature of 
melatonin secretion is that, with the exception of light [8], 
it is less susceptible to behavioural and environmental 
masking (disturbing) influences, than other overt (meas- 
ured) circadian rhythms such as core body temperature 
and cortisol secretion. Masking influences include sleep, 
'Corresponding author. Fax: (44) 483-509712. 
waking, meals and stress and can result in the unreliable 
estimation of the circadian time of the internal biological 
clock. For this reason the melatonin circadian rhythm is 
thought to provide an appropriate and reliable marker of 
the endogenous biological horologue under normal con- 
ditions, as well as in constant routine and in other iso- 
lated environments. 
Although melatonin, a lipophilic molecule, easily fil- 
ters through capillary membranes, up to 70% of mela- 
tonin may be weakly bound to albumin [3] which is not 
readily diffusible, and albumin-bound hormones do not 
pass into the surrounding tissues [10]. It is therefore pos- 
sible that a shift in posture may cause a change in plasma 
melatonin levels. Salivary melatonin is thought to closely 
reflect the changes in plasma melatonin levels [9] and 
since saliva is becoming a routine method of determining 
melatonin secretion it is important to consider the effects 
of posture on salivary melatonin levels as well. It is the 
purpose of this investigation to study the possible mask- 
ing influence of posture on melatonin levels. 
Seven healthy volunteers (3M: 4F), aged 24-35 years 
(26.3 ±4 years, mean ± S. D. ), under no medication (ex- 
cept oral contraceptives), one of whom was a smoker, 
were recruited from members of staff and research post- 
graduates of the University of Surrey. All volunteers 
gave informed consent and the study was approved by 
SSD/ 0304-3940(93)E0858-S 
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the University of Surrey Advisory Committee on Ethics. 
They refrained from heavy exercise, drinking alcoholic 
beverages or those containing caffeine, for 12 h prior to, 
and during each stage of the study. On each day of the 
study, the subjects moderated their fluid intake to no 
more than 1.5L daily. 
The 4-day study was divided into two periods (stages 
I and 2) of 2 days, I week apart, and was performed in 
October during the rising phase of the melatonin rhythm, 
between 21: 00 h and 01: 30 h. On all 4 days subjects re- 
mained in a sitting position under domestic lighting 
(150-300 lux) from 21: 00 to 23: 00 h. From 23: 00 to 
01: 30 h, subjects remained sitting (until 24: 00 h) and 
awake under dim light (< 10 lux). After this baseline pe- 
riod, the treatments were applied within each stage as a 
randomised crossover design. From 24: 00 h, the subjects 
assumed a different postural position as follows: 
Stage la: 24: 00 h- standing, 00: 30 h- supine, 01: 00 h 
- standing; Stage 1 b: 24: 00 h- supine, 00; 30 h- standing, 
01: 00 h- supine; Stage 2a: 2400-01: 30 h- supine; Stage 
2b: 2400-01: 30 h- standing. Brief and slow movement 
was allowed throughout each stage. 
Blood samples (5 ml, collected by dim red torch light 
after 23: 00 h; < 10 lux) were taken hourly via an indwell- 
ing forearm cannula, together with hourly saliva samples 
(after chewing on parafilm), from 21: 00 to 24: 00 h and 
then every 10 min from 24: 00 h until 01: 30 h. Only water 
was allowed just after saliva sampling, to reduce any pos- 
sible interference with salivary melatonin estimation. 
Blood samples were collected into lithium heparin tubes 
and centrifuged (2,500 xg for 15 min), the plasma sepa- 
rated within 25 min of collection and stored at -20°C 
until analysed for melatonin using the method of Fraser 
et al. [6]. The interassay coefficients of variation were 
12.4%, 9% and 7.3% at 19.4,36.8 and 191 pg/ml (n = 10). 
The minimum detection limit was 3.8 ± 0.24 pg/ml 
(mean ± S. E. M. ). Saliva samples were collected into 
minivials and stored at -20°C until analysed for mela- 
tonin using the method of English et al. [5]. The interas- 
say coefficients of variation were 16%, 10%, 9% and 6% 
at 8.7,20,36 and 58 pg/ml (n = 8). The minimum level of 
detection was 1.9 ± 0.15 pg/ml (mean ± S. E. M. ). 
All plasma and salivary melatonin values were calcu- 
lated as a percentage change in melatonin levels from the 
initial point of assuming a different postural position 
using the subjects as their own controls. Since each stage 
was of a random crossover design, any differences be- 
tween standing and supine positions were compared be- 
tween stages la and lb and between stages 2a and 2b. 
Area under the curve (AUC) analysis followed by Stu- 
dent's paired t-tests (two-tailed) were used to identify sig- 
nificant differences between postures. Paired compari- 
sons were also made at each 10-min sampling point 
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Fig. 1. Percentage change in A. plasma melatonin and B. salivary mela- 
tonin levels within 30 min in alternate postural positions from 24: 00 h. 
Mean ± S. D., n=7. *P < 0.05, **P < 0.01, ***P < 0.001: significant 
differences between standing and supine positions (stage la (": versus 
stage lb (Q), paired t-test, two-tailed). Mean difference in melatonin 
levels (± S. D. ) between standing and supine: 24: 00-00: 30 h (plasma: 
P<0.05,35.2 ± 21.3%: saliva: P<0.01,42 ± 27%), 00: 30-01: 00 h 
(plasma: P<0.0 1,33.5 ± 16.2%; saliva: 30.9 ± 34.4%) and 01: 00-01: 30 
h (plasma: P<0.01; 36.7 ± 17.5%; saliva: 31.9 ± 44.8%), significance 
levels determined from AUC analysis followed by paired t-test. 
between standing and supine using Student's paired t- 
tests (two-tailed). Correlations between plasma and sali- 
vary melatonin levels were carried out using Pearson's 
correlation. All values lower than the detection limit of 
the assay were excluded from the calculations. This cor- 
responded to 5% of the plasma melatonin data and 6% of 
the salivary melatonin data. All values are quoted as 
mean ± S. D. unless stated otherwise. 
No subject reported any oral lesion and no blood con- 
tamination was observed in the saliva samples. All sub- 
jects completed stage 1. Four subjects completed stage 2 
and one further subject completed stage 2a and 60 min of 
stage 2b. 
Fig. 1 shows the percentage change in melatonin levels 
within 30 min periods in alternate postural positions 
from 24: 00 h. Changing from standing to supine and 
back to standing (stage 1 a), and likewise when the posi- 
tions were reversed (stage 1 b), caused marked differences 
in percentage change of both plasma and salivary mela- 
tonin levels. AUC analysis identified significant differ- 
ences between standing and supine positions with greater 
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Fig. 2. Individual profiles showing percentage change in plasma melatonin levels over a 90 min period from 24: 00 h. Significant difference (P < 0.01) 
over 90 min between supine (A, stage 2a ) and standing (0, stage 2b ) positions for plasma melatonin only (n = 4; AUC analysis, paired t-test). Mean 
difference in melatonin levels ± S. D. -- plasma: 18.6 ± 14.8%, saliva: 25.7 ± 46.3%. The changes in plasma melatonin levels reached significance 
(P < 0.05. paired t-test, n= 4) at 20,40,50,60 and 70 min between stages 2a and b. 
increases associated with the standing position (Fig. 1). 
Significant changes between postures were observed 
within 10 min in all three time periods for plasma mela- 
tonin, Fig. lA. Differences in salivary melatonin levels 
between standing and supine positions were less signifi- 
cant, Fig. 1 B. 
Fig. 2 shows the individual profiles for the percentage 
change in plasma melatonin levels over a 90 min period 
between stages 2a and 2b. Differences between standing 
and supine positions were significant for plasma mela- 
tonin only (P < 0.01) with AUC analysis. The changes in 
salivary melatonin levels were more variable and proved 
not to be significant. 
Good correlation between plasma and salivary mela- 
tonin levels was obtained during hourly sampling 
(r = 0.83, P<0.0001, y=0.59 [± 0.01] x-2 [±1.2]) 
from 21: 00 to 24: 00 h. Although still highly significant, 
the correlation between the two melatonin mediums was 
not as good during short term sampling (r = 0.555, 
P<0.0001, y=0.23 [± 0.02] x+5.7 [± 0.9]). Salivary 
II. I.. 
melatonin levels were estimated to represent 
46.2 ± 18.1% and 40.4 ± 18.7% during hourly and 
10 min sampling, respectively, of the corresponding 
plasma levels. 
When moving from a supine position to a standing 
position, blood volume becomes redistributed from the 
central pool within the chest, to the lower limbs where 
small molecules pass through the capillary membranes 
into the interstitial space by diffusion. The plasma vol- 
ume is reduced, thus increasing the concentration of non- 
filtrable blood constituents such as red cells, and proteins 
together with their bound components [7], including al- 
bumin-bound hormones [10]. 
The results from this study indicate that changing 
from the standing to the supine position caused a marked 
fall in plasma and salivary melatonin levels which was 
reversed on returning to the standing position once 
again. When these positions were reversed over the same 
period of time an opposite effect of similar magnitude 
was seen. These differences were significant for plasma 
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melatonin within 10 min as calculated between stages 1a 
and 2b and within 20 min comparing stages 2a and 2b. 
These changes showed no reliable (P > 0.1) progressive 
change with time indicating that the changes in plasma 
melatonin levels associated with the effects of posture 
were rapid and remained consistent after approximately 
20 min. This agrees well with other posture-related stud- 
ies affecting various blood constituents where little 
change occurred after 20 min (e. g. ref. 7). 
The effects on salivary melatonin levels were more var- 
iable. This may be associated with frequent and forced 
sampling (every 10 min) which probably changes sali- 
vary composition and secretory mechanisms of the gland 
[4], modifying the true melatonin concentration in saliva. 
Although the overall proportion of melatonin levels in 
saliva to plasma, throughout hourly and 10 min sam- 
pling, remained comparable, the correlation fell consid- 
erably throughout 10 min sampling. 
Abalan et al. [1] recently noted a difference of 
32.6% ± 34.3 (mean ± S. D., range: -20% to 94%) in 
total plasma cortisol - another circadian phase marker 
- on standing for 40 min compared to remaining supine, 
during the rising phase of the cortisol rhythm. A similar 
difference in plasma and salivary melatonin levels was 
observed in this study even though sampling was more 
frequent and over different periods of time. 
Although considerable interindividual variation was 
evident, these results indicate that posture has a masking 
effect on plasma and salivary melatonin levels. Changes 
due to posture may prove to be important when inter- 
preting data from subjects in different postural positions, 
for example, comparing bedridden patients and healthy 
controls, and may have implications in situations where 
the body is exposed to other environments where body 
fluid shifts are also experienced, such as spaceflights, 
water immersion and exercise. Changes in melatonin and 
cortisol levels due to posture may alter circadian parame- 
ters such as daily means and amplitudes and influence- 
acrophase values. In fact Samel et al. [11] studied the 
effects on the circadian system of 7 days of bed rest with 
a constant sleep-wake cycle and a regular photoperiod. 
Although neither melatonin or cortisol were measured, 
small changes in rhythm acrophases were evident for 
noradrenalin, adrenalin, potassium, heart rate and urine 
volume and significant changes in rhythm amplitudes 
were observed. These changes may be attributable to in- 
activity and posture. 
This study indicates the necessity for standardising the 
timing of blood sampling and indeed saliva sampling 
with prior knowledge of the postural position and the 
time in that position. Care should also be taken in the 
interpretation of results from high frequency saliva sam- 
pling. 
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